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"The true remedy for all diseases is Nature's remedy. 
Nature and Science are at one, believe me; though we 
are taught differently. Nature has provided, in the white 
corpuscles as you call them · in the phagocytes as we 
call them · a natural means of devouring and 
destroying all disease germs. There is at bottom only 
one genuinely scientific treatment for all diseases, and 
that is to stimulate the phagocytes. Stimulate the 
phagocytes. Drugs are a delusion. Find the germ of the 
diseqse; prepare from it a suitable antitoxin; inject it 
three times a day quarter of an hour before meals; and 
what is the result? The phagocytes are stimulated; they 
devour the dùease; and the patient recovers - unless, of 
course he's too far gone." 
Sir Ralph Bloomfield Bonington in 
'The Doctor's Dilemma" by Bernard Shaw, 1906 
Ter nagedachtenis van mijn grootmoeder 
Aan mijn ouders en grootvader 
Voor Jacqueline 

CHAPTERI 
GENERAL INTRODUCTION 
Based on: 
The use of animal models in diagnosis and 
treatment of renal cell carcinoma: 
an overview 
R.J.A. van Moorselaar 
J.A. Schalken 
G.O.N. Oosterhof 
F.M.J. Debruyne 
World J. Urol., in press 

1 ANIMAL MODELS FOR UROLOGICAL CANCERS 
The ultimate evaluation of any new therapeutic modality requires careful 
randomized and controlled clinical studies. Clearly, to define all therapeutic 
parameters and principles in human studies would be expensive, time consuming, 
and could involve ethical limitations (1). On the other hand, no single animal model 
can mimic the human situation or give final answers; it can only provide 
approximations. Animal models representative for human cancer, however, have 
proven to be useful to test new therapeutic concepts. In this section an overview will 
be given of the available animal model systems for urologica! cancers. 
Animal models offer many advantages, e.g. an unlimited number of cells and 
tumors is available to perform multiple and duplo experiments. Tumor lines can be 
exchanged among several laboratories, thereby allowing the study of identical 
material (2). 
In general, animal model studies should comply with the following factors: 
1) uniformity of genetic strain and age of host, 2) controlled onset of tumor growth, 
3) uniformity of tumor type, 4) precise knowledge of tumor load and growth rates, 
5) regulation of dietary elements and physical stress, 6) total compliance to drug 
intake and timing, 7) complete follow-up, 8) uniform control over onset and 
termination of the study and subject, with all subjects available for autopsy, 9) large 
numbers in each study group, all monitored at the same time, and 10) one observer 
making all evaluations (1). 
More specifically, an ideal model for renal cell carcinoma should arise 
spontaneously, and have the histologic characteristics of a pure adenocarcinoma, a 
predictable growth rate, the capacity to metastasize and the ability to grow without 
hormonal dependence (3). 
Coffey and Isaacs have defined the requirements for an idealized animal 
model of prostatic cancer (1,4): it should be 1) spontaneous in origin, 2) developed 
in aged animals, 3) of proven prostatic origin, 4) a slow-growing adenocarcinoma, 5) 
histologically similar to human prostatic cancer, 6) having a biochemical profile 
similar to prostate, 7) a malignant phenotype with metastatic pattern to bone and 
lymph nodes, 8) capable of elevating serum tumor markers, 9) hormone-sensitive, 
10) capable of responding to hormonal therapy followed by relapse to hormone-
insensitive state, 11) developed and transplantable or easily inducible in syngeneic 
animals, 12) available in large number of animals for statistical considerations, 13) 
responsive similar to known human prostatic cancer therapies, 14) available in a 
wide diversity of tumor types (differentiation, hormonal response, etc.) corresponding 
to human tumor variability. 
Specific requirements for an animal model for bladder cancer include that it 
should be spontaneously arisen, consist of a pure transitional cell carcinoma, and 
transplantable in syngeneic animals, subcutaneously as well as intravesically. 
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In general, animal model systems can be divided into different categories: 
drug induced tumors, virus-induced tumors and spontaneous tumors (5). 
Heterotransplanted human tumors in immune-deprived animals form a fourth 
category. 
1.1 Drug-induced tumors 
1.1.1 Renal tumors 
Both steroid and stilbene estrogens are potent carcinogenic agents in the 
Syrian golden hamster, malignant renal neoplasms develop after chronic hormone 
treatment (6,7). These tumors display hormone-dependent growth, and hormonal 
treatment reduces tumor growth; this degree of hormonal dependence, however, is 
not found in human renal cancer. Renal adenocarcinomas have been induced by 
chemical agents including, dimethylnitrosamine (DMN), Formic acid 2-[4-(5-Nitro-2-
furyl)-2-thiazolyl]-hydrazide (FNT), and 4'-fluoro-4-biphenylacetamide (FBPA) in 
different rat strains (8,9,10). Mice show a strain-related susceptibility to renal 
carcinogenesis by DMN, which relates to the ability of renal microsomes to generate 
mutagenic metabolites from DMN (11). Heavy metals, like lead, will induce renal 
tumors in rats and mice, also radiation can induce renal tumors, and the 
combination of radiation and dietary lead increases the tumor incidence (12,13). A 
review of chemicals inducing kidney tumors is provided in references 6 and 13. 
1.1.2 Prostatic tumors 
Prostatic adenocarcinomas can be hormonally induced in Noble (Nb) rats. 
The Nb rat is an inbred strain developed by R.L. Noble of the Cancer Research 
Center in Vancouver (14,15). The origin of this strain is not entirely clear, but it 
probably arose from a Long-Evans rat. The Nb rats have a low incidence of 
spontaneous prostatic adenocarcinomas, 2 tumors were found in 409 rats older than 
13 months (incidence of 0.48%). After prolonged treatment (> 6 months) with s.c. 
testosterone implants, in approximately 20% of the rats prostatic tumors appear. If 
testosterone is combined with estrone implants, carcinomas of the prostate occur 
after a shorter interval, 43 weeks in stead of 59-64 weeks (16). Furthermore, 
metastatic disease develops in more than 40% of the animals, in which a tumor was 
induced. All tumors and metastases are readily transplantable in syngeneic animals. 
In this way the Noble series of prostatic cancers were established (17,18). The 
different transplantable tumors can be classified as androgen-dependent, autonomous 
or estrogen-dependent (14). From the more than 200 rat prostatic adenocarcinomas 
described by Dr. Noble, Dr. Drago choose to study eight tumors (14). These 
autonomous and androgen-stimulated tumors have been used for extensive 
chemotherapeutic studies in Nb rats as well as xenografts in nude mice (15,19,20). 
Hormonal inducibility of prostatic cancer may be affected by the strain of 
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rats used. In a direct comparison of two rat strains it was shown that s.c. 
implantation of silastic tubes with testosterone increases the incidence of microscopic 
prostate tumors from 10 to 40% in Lobund-Wistar rats (21). In contrast, 
testosterone did not increase the incidence of these tumors in Sprague-Dawley rats 
(21). Hildebrand et al. demonstrated differences in decrease of ventral prostate 
weight between Lewis and Sprague-Dawley rats by the combination of 
dihydrotestosterone and estradiol (22). Furthermore, age of the rats and absence or 
presence of testes were important factors that influenced the response of rat 
prostates to hormonal manipulation (22). 
Intravenous administration of the chemical carcinogen 7,12-dimethylbenz(a)-
anthracene (DMBA), induces prostatic tumors in castrated rats, mice and hamsters 
(23). 32% of F344 rats exposed to 3,2"-dimethyl-4-amino-biphenyl (DMABP) 
develop microscopic prostatic carcinoma, among tumors in several other organs (24). 
The number of rats with prostatic carcinoma in situ increased to 86%, when the rats 
were subjected to an intermittent ethinyl estradiol-supplemented diet prior to an 
injection of DMABP (25). More than 50% of Lobund-Wistar rats develop large, 
palpable prostatic adenocarcinomas after one i.v. inoculation of N-nitroso-methylurea 
(MNU), followed 7 days later by a s.c. depot of testosterone (26). Most of the 
tumor-bearing rats manifested metastases (26). Pour and Stepan were able to 
produce prostatic tumors in Wistar derived MRC rats with N-nitroso(2-
oxopropyl)amine (BOP) in intact and castrated rats during androgen-enhanced cell 
proliferation in the prostate (27). Testosterone given for life following BOP 
administration induced prostatic cancer in over 60% of all rats, whereas tumor 
incidence was significantly lower in rats treated with testosterone for only a short 
period of time. Simultaneously papillomas and carcinomas of the urinary bladder 
were induced (27). 
Bosland et al. applied temporary chemical castration to Wistar rats, by 
administration of cyproterone acetate (CA) for 18 days. After three daily 
testosterone injections following cessation of the chemical castration, a single dose of 
a carcinogen was given to the rats (28,29). This protocol ensured an intact status of 
the animals during promotion and progression of the tumors. MNU induced a 30% 
incidence of carcinomas of the dorsolateral prostate, 63 weeks after MNU injection. 
The incidence after DMBA administration was lower, only 5%. No carcinomas were 
found in animals that received MNU or DMBA directly after pretreatment with CA 
only. In the case of DMABP, however, tumors were not found in rats pretreated 
with CA and testosterone, but only in animals given CA alone. This effect has been 
related to the slow metabolization of DMABP to its active form. The transient 
phase of maximally stimulated cell proliferation in the dorsolateral prostate occurs 
later in the group receiving CA alone, when compared to the group receiving CA 
plus testosterone, and can therefore possibly coincide with the delayed formation of 
activated DAMBP. 
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The etiology of prostatic cancer is essentially unknown (30). Animal models 
of induced prostatic tumors can greatly contribute to the identification of agents or 
factors that modify or induce the carcinogenic process. For immunotherapeutical 
studies, however, spontaneous tumor models are more useful (see section 1.5). 
1.1.3 Bladder tumors 
In a number of animal species, like mice, rats, hamsters, guinea pigs, dogs 
and cows different carcinogens have shown to induce bladder tumors (31-35). 
Butyl-(4-hydroxybutyl)nitrosamine (BBN) is potent carcinogen which has 
been found to induce bladder tumors in mice and dogs (36,37). Rats fed BBN 
containing drinking water develop, after a latency period of 20 weeks, bladder 
tumors. Kunze and Schauer added BBN at a dose of 20 mg/kg/day in the drinking 
water of Wistar rats for a period of 40 to 150 days (38). 88.8% of the rats 
developed transitional cell carcinoma, whereas 7.9% had squamous cell carcinoma. 
In a study of Herman et al. 300 ACI rats received 0.05% BBN in the drinking water 
for 12 weeks, starting at the 7th post natal week (39). Using monoclonal antibodies 
against cytokeratin 10, they showed development of squamous metaplasia 20 weeks 
after termination of BBN administration. These lesions progressed to tumors 
predominantly composed of squamous elements (39). Several permanent cell lines 
have been established from BBN induced tumors, such as the rat cell lines, NBT-II 
and BC-50 (40,41). BBN3 is a cell line established in C57BL/6J mice and FCB is 
derived from a dibutylnitrosamine (DBN) induced anaplastic transitional cell tumor 
in IFxC57Fl hybrid mice (42,43). Biochemical analyses showed an increase of ras 
and myc oncogene expression in BBN induced rat bladder tumors, which has been 
suggested as an early genetic event during bladder carcinogenesis (44,45). Further 
alteration of these two genes or mutation of additional genes may be required for 
completion of the malignant transformation (45). 
The nitrosamide, N-methyl-N-nitrosurea (MNU), produces tumors in a wide 
variety of organs, except bladder, if given orally, intravenously or intraperitoneally 
(46). Hicks and Wakefield induced bladder carcinomas in female Wistar rats by 4 
biweekly intravesically applied doses of 1.5 mg MNU. In most animals transitional 
cell carcinoma developed along with squamous cell carcinoma of the bladder (46). A 
subcarcinogenic MNU dose had synergistic effects on bladder carcinogenesis in 
combination with saccharin- or cyclamate containing diets (47). MNU also induced 
morphological changes in vitro, on normal rat bladder cells and MNU-induced rat 
bladder tumor cells (48,49). Steinberg et al. used the same MNU treatment schedule 
as Hicks and Wakefield (46) in female F344 and Copenhagen rats (50). F344 rats 
developed TCC, no squamous cell or mixed squamous cell/transitional cell 
carcinomas of the bladder were found, while 50% of the Copenhagen rats 
developed either squamous cell carcinoma alone or in combination with transitional 
cell carcinoma. Cytogenetic analyses of the six F344 rat tumors revealed normal 
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karyotypes in 3 tumors, while karyotypes of the 3 other tumors contained one or 
more structural markers (50). Biochemically no increase in ras-oncogene expression 
was detected (50). 
Rats, mice and dogs are susceptible to the highly specific carcinogenic action 
of N-[4-(5-nitro-2-furyl)-2-thiazolyl]fonnamide (FANFT) on the urothelium (51-56). 
Sprague-Dawley and F344 rats received 0.188% FANFT mixed with the diet (51-53). 
After three weeks the rats developed hyperplasia of the bladder mucosa, which 
progresses to carcinomas. After 8 weeks, however, concurrent squamous metaplasia 
was found and after 11 weeks mixed transitional and squamous cell carcinomas are 
found (53). Hyperplasia induced by FANFT feeding is reversible up to 6 weeks, but 
after 8 weeks the changes are irreversible and will result in formation of carcinomas 
in all animals (57). Furthermore, a dose-dependent relation between FANFT-dose 
and tumor formation could be demonstrated (58). Some FANFT-induced tumors are 
transplantable in syngeneic rats by orthotopic transplantation, i.e. injection of single-
cell suspension in bladder wall of recipient rats (59). Biochemical analyses of 
FANFT induced tumors revealed an increased expression of ras and myc oncogenes 
(45,60). 
Soloway et al. established five cell lines from FANFT-induced tumors arisen 
in the urinary bladders of adult СЗН/Ые mice. All cell lines are transplantable into 
syngeneic mice. One of these cell lines, the MBT-2, is widely used for 
immunotherapeutical and chemotherapeutical studies (62). The MBT-2 tumor is 
growing Sx., but more importantly also intravesically (63,64). From the original 
tumor different metastatic sublines have been derived with an implantation site-
dependent difference in metastatic ability (65). 
Some other chemicals, such as N-2-fluorenylacetamide (FAA), DMBA, 
methylcholantrene (MCA), and Bracken Fern (Pteris aquilina) are able to induce 
bladder tumors (34,66-68). After 4 months of FAA feeding, hyperplasia occurred 
and after 6-8 months squamous and transitional cell carcinoma appeared. Three cell 
lines of the squamous cell carcinoma have been established (69). Normal bladder 
epithelium of С57В171сг-а' mice undergoes neoplastic formation in vitro after a brief 
exposure to DMBA (68). From these cells, cell lines have been derived, which can 
be transplanted in bladders of syngeneic mice (70). Implantation of MCA pellets in 
bladders of F344 rats can induce tumor formation. Three of these induced tumors 
have been serially transplanted (67). 
Oyasu et al. developed the "heterotopically transplanted rat urinary bladder" 
model (НТВ) (71-73). This model consists of an urinary bladder from male F344 
rats transplanted into the gluteal muscles of syngeneic recipients with an attached 
s.c. placed reservoir. HTBs which were exposed to a low dose of MNU developed 
only low-grade, low-stage carcinomas, whereas bladders exposed to a higher dose of 
MNU or another carcinogen frequently developed high-grade, high-stage carcinomas 
(72). Normal urine may contain tumor promoting substances, since HTBs receiving 
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normal urine had a higher incidence of carcinomas than those receiving normal 
saline (71). 
Most induced tumors consist of both poorly differentiated transitional cell 
carcinoma and squamous cell carcinoma. In human bladder cancer in the western 
world, however, pure squamous cell carcinoma is relatively infrequent (3-6% of all 
bladder cancers) (74). Also from a clinical perspective squamous cell carcinoma 
differs significantly from transitional cell carcinoma. At time of initial presentation, 
86-100% of squamous cell carcinomas demonstrate invasion of the bladder wall and 
5-year survival rate is low (7-20%) (75). 
1.2 Virus-induced tumors 
Polyoma virus, simian virus (SV40), and adeno virus 7 have been shown to 
produce renal tumors in hamsters and other rodents (6,76). A herpes virus induces 
renal tumors in the leopard frog (Rana Pipiens). These tumors are generally 
multicentric, bilateral and metastasize to lung, liver and other viscera. This so called 
Lucke tumor provides an opportunity to study the natural history of a prevalent, 
naturally occurring, virally induced neoplasm (76). Claude found spontaneous renal 
adenocarcinoma in 40% to 60% of BALB/c mice. These tumors are serially 
transplantable; unfortunately, intratumoral virus-like particles were identified (77). 
From this tumor two other models were developed, the MKT-CD1 and the RAG 
model (78). 
1.3 Spontaneous tumors 
Spontaneous tumors are tumors that arise in animals which have not been 
deliberately exposed to any carcinogenic agent and which are of strains not known 
to harbor any vertically or horizontally transmitted oncogenic virus (5). 
1.3.1 Renal tumors 
Spontaneously occurring renal tumors are rare in laboratory animals, the 
incidence ranges from 0.0004% to 0.2% (13). Fortner found one spontaneous kidney 
tumor among 246 Syrian hamsters (79). In two studies no kidney tumors occurred 
during the life-span of 86 and 352 F344 rats, respectively (80,81). Thompson et al. 
reported 1 kidney tumor, a nephroblastoma, in 125 Sprague-Dawley rats (82). In a 
study with the aim to find spontaneous prostatic tumors, 4 renal cancers were found 
in 300 normally aged ACI rats (chapter VII, this thesis). In contrast to these low 
tumor occurrences, Eker and Mossige reported a line of Wistar rats in which 37 out 
of 89 rats (41.6%) developed a renal adenocarcinoma (83). They propose the 
involvement of a dominant genetic element in the etiology of these lesions. 
Spontaneous murine tumors have been reported also, e.g. Vandendris described the 
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RC-tumor, a spontaneously arisen low-immunogenic tumor in CDF1 mice, which 
microscopically appears as an anaplastic tumor (84). In a review. Murphy reports on 
the occurrence of spontaneous primary renal tumor in domestic animals, rabbits, 
cattle and horses and other wild animals like birds and snakes (12). 
The two best characterized spontaneous kidney tumors are the Renca 
adenocarcinoma of Balb/C mice (85) and the rat renal cell tumor in the Wistar-
Lewis rat (3). The Renca tumor is an anaplastic tumor of renal origin, it is 
transplantable by different routes, intramuscularly, intraperitoneally, intravenously, 
and subcutaneously, but most effectively intrarenally. The tumor metastasizes from 
an intrarenal implant to the regional lymph nodes, lungs, liver, and spleen, as well 
as to some other organs. The immunogenicity is relatively low. Tumor-bearing mice 
routinely die between 35 and 45 days; tumor doubling time is approximately 7 days. 
The rat renal cell tumor arose spontaneously in the kidney of a male Wistar-Lewis 
rat and has been maintained by serial transplantation (chapters II and IV, this 
thesis). Further characterization revealed a histological appearance of a clear cell 
renal cell carcinoma, with ultrastructural presence of desmosomes (86). Intermediate 
filament expression pattern studies showed, like most human renal cell tumors, 
coexpression of vimentin and cytokeratins (86). 
1.3.2. Prostatic tumors 
Spontaneous prostatic carcinomas are rare in non-human mammals. 
Rivenson and Silverman, in their bibliographic survey of reports of prostatic 
carcinomas among laboratory animals published between 1900 and 1977, found no 
reports of cases in mice (87). In 1983, Waymouth et al. described two spontaneous 
prostatic tumors in old (>700 days) mice (88). In a group of 55 untreated virgin 
female Mastomys (Rattus Natalensis) 1 prostatic adenocarcinoma and 4 proliferative 
hyperplasias were described (89). Furthermore, spontaneous tumors in hamsters and 
a monkey were found (4,34,79). Leav and Ling studied twenty cases of prostatic 
cancer in dogs and found clinical, morphological and pathogenetic similarities with 
the disease in man (90). The cancers, for example, occurred among dogs of 6 years 
and older and bone metastases were not rare. 
In a histological study of grossly normal prostates of 1775 F344 rats, 64 
adenomas and 7 adenocarcinomas were found (3.6% and 0.4% respectively) (91). 
The three best characterized models of prostatic adenocarcinoma among laboratory 
rats are the Pollard tumors, the tumors of the ACI/seg rat and the Dunning tumors. 
Spontaneous, metastasizing, prostatic adenocarcinomas develop in 10% of germ free 
Wistar rats, at 32-40 months of age (92). Further characterization of the Pollard 
tumors have yielded four cell lines (PA I, PA II, PA III and PA IV). All cell lines 
can be cultivated in vitro with retention of tumorigenic and metastatic capacities 
(93-96). 
In 1975, Shain and coworkers identified spontaneous adenocarcinomas of 
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the ventral prostate in 7 of 41 aged (34 to 37 months old) ACI rats (97). To 
confirm these data and to study the pathology of the disease, Ward et al. examined 
the prostates of 201 ACI rats, at 24 to 40 months of age (98). They found an age-
related increase in the incidence of prostatic tumors. At the age of 33 months 95 to 
100% of the rats have intraalveolar prostatic atypical hyperplasias, and 35 to 40% 
exhibit invasive carcinomas. In vitro cell lines have been established from an ACI 
prostatic tumor (99,100). However, the tumor from which the cell lines were derived 
was obtained after 4 months treatment with testosterone containing silastic capsules. 
Surprisingly, we did not find prostatic tumors in a cohort of 300 normally aged ACI-
rats, as described in chapter VII of this thesis. 
In untreated Copenhagen rats the incidence of microscopic prostate cancer 
is 10%, the incidence of grossly manifest prostatic cancer is < 1 % even at 36 months 
of age (101). In 1961, W.F. Dunning discovered a prostatic tumor in a 22 months 
old inbred Copenhagen rat (102). Following serial in vivo passaging of the original 
R3327 tumor, different sublines were obtained. Isaacs and Hukku described the 
complete genealogy of all these R3327 sublines, which widely differ in their 
histology, growth rate, androgen sensitivity and metastatic abilities (103). From most 
in vivo lines, in vitro cell lines have been established, that retain their phenotypic 
characteristics (104). All lines are transplantable in Copenhagen rats and the Fl 
generation of Fisher χ Copenhagen rats. 
1.3.3 Bladder tumors 
Few spontaneous bladder tumor models are available up to now. The 
Brown Norway rat has a high incidence of spontaneously occurring urothelial tumors 
of the bladder and ureter, 35% of the male and 3% of the female rats developed 
bladder tumors, which are transplantable in syngeneic rats (105,106). The invasive 
tumors consisted of transitional epithelium, but also areas of squamous metaplasia 
were observed, squamous cell carcinoma, however, was not common. In the Nb rat 
a single transplantable transitional cell tumor has been described (107). In DA/Han 
rats 54% of male and 14.4% of female rats develop spontaneous urinary bladder 
tumors, the incidence increases with age of the rats (108). The most frequent 
tumors found in the DA/Han rats were solid type transitional cell carcinomas; 0.3% 
of the male and 9.6% of the female rats had SCC (108). 
1.4 Xenografts in nude mice 
In vivo models using human tumors offer an important tool in the study of 
tumor biology, such as patterns of growth and differentiation and responses to 
treatment. However, heterotransplantation of human tumors generally results in 
rejection of the graft because of histoincompatibility between donor and host. 
Exception of this occurs in cases in which the animal host has been rendered 
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immunologically unresponsive, as by thymectomy, sublethal irradiation or use of 
antisera against recipient lymphocytes, or when tumors are transplanted in 
immunologically privileged sites, such as the hamster cheek pouch (109). 
In 1962, Isaacson and Cattanach first described a hairless mouse mutant 
(110,111). Flanagan studied the genetics of the mutation and confirmed that the lack 
of hair was determined by a recessive autosomal gene, for which the mutant mice 
were homozygous (112). Pantelouris demonstrated the absence of a thymus and 
consequently an impairment of cell-mediated immune functions (113). However, 
humoral antibody formation (B-cell mediated) is only slightly impaired, whereas the 
activity of other T-cell-independent defense mechanisms, such as NK cells and 
macrophages are even increased in comparison to normal mice of the same strain 
(114-116). 
Following the demonstration of Rygaard and Povlsen in 1969 that human 
tumors grow in athymic mice, a large number of serially transplantable xenografts of 
different human tumors have been established (117). The implantation site of the 
primary tumor appeared to be of critically importance (118). The xenograft model 
has the advantage of providing large quantities of tumor tissue in a reproducible 
manner and a 'physiological' milieu as compared to tissue culture (35). The 
limitations of this model, however, include differences between host and human 
metabolism, risks of contamination by transformed host cells or viruses, risks of 
cross-species immunological interactions, low metastatic range and of course the 
abnormal host immune functions (35). The xenograft model has shown to have 
limited value in the selection of the optimal chemotherapy for the individual patient, 
due to the low take rate and slow tumor growth (119). However, drug tests against 
a panel of human tumor lines can predict clinical effectivity of these drugs (120). 
1.4.1. Renal tumors 
A great number of renal xenografts has been described (2,121-130). 
Clayman et al. could successfully transplant 7 out of 29 primary human renal cell 
carcinomas into nude mice. It appeared that only tumors with a nuclear grade of 3 
or 4 could grow after implantation (129). The authors, therefore, suggest that the 
nude mice may act as an effective filter to distinguish between aggressive and non-
aggressive high grade renal cancers and that tumor take is indicative of impending 
metastatic disease and death. Similarly, Ebert et al. established 63 in vitro cell lines 
out of 498 successive attempts. They found that these cell lines, which were able to 
survive 10 passages and 1 year in continuous culture, were derived from tumors 
which exhibited clinically aggressive features, e.g. metastases or main renal vein 
invasion (2). Conversely, only 14.2% of the metastatic tumors could be established 
in vitro, which implies that biological aggressiveness is necessary but not always 
sufficient for establishment of a cell line. Twenty-six of 33 (79%) cell lines formed 
tumors in nude mice (2). In contrast to the take rates of Ebert and Clayman, 
17 
Knöfel et al. showed a hundred percent take rate of 30 human renal cell carcinomas 
implanted into nude mice (130). The "bioassay" indicated by Clayman, therefore, 
appears not useful in general. The discrepancy between these studies could be 
secondary to the use of different mouse strains (NIH Swiss versus NMRI) or to 
differences in the age of the mice at time of implantation (4 to 6 weeks versus 6 to 
8 weeks) (130). 
Naito et al. established RCC tumor lines with different phenotypic 
characteristics, including differences in invasion and metastasis in nude mice (131). 
The various sublines have been isolated from a single surgical specimen by different 
procedures. Hashimura et al. also described two cell lines growing in vitro and in 
nude mice which were established from the same patient, either from the primary 
tumor or from the renal vein effluent of the perfused tumorous kidney (132). 
1.4.2. Prostatic tumors 
Due to the low take rate after heterotransplantation in nude mice, the 
number of prostatic cell lines and xenografts is limited. For example, van 
Steenbrugge et al. established 3 permanently growing tumor lines out of 150 
transplantation attempts (133). Likewise, Reid showed that none of 63 surgical 
specimens of prostatic adenocarcinomas transplanted into 145 nude mice developed 
into a growing neoplasm (134). However, when mice were treated with anti-mouse-
interferon serum, implantation of two primary prostatic cancers gave rise to 
transplantable tumor lines. This effect has been advocated to the complete blocking 
of the augmentation of NK cell activity in the nude mice (134). Wagner et al. could 
increase the take rate of prostatic cancer and BPH specimens by implanting 
dihydrotestosterone containing silastic implants in the nude mice (135). 
Upto now 16 different prostatic xenografts have been described (Table I). 
Eight lines originated from primary tumors, whereas the remaining lines are derived 
from metastatic lesions. In vitro cell lines have been established from half of the 
xenografts. Seven xenografts grow androgen dependently (LNCaP, PC82, HONDA, 
PC-EW, TEN/12, PC-EG, JCA-1), which indicates that these lines have a 
preferential growth in intact male nude mice, as compared to female or castrated 
nude mice (133,136-149). 
The original EB33 line grows hormone independently (136). However, after 
in vitro cloning, 23 out of 111 clonal cell lines revealed a suppression of growth of 
more than 50% in androgen-free media (150,151). The androgen-dependent clones 
can be stimulated in vivo with DHT to significantly faster growth. 
The DU145 tumor line is derived from a brain metastasis (137,152). After 
heterotransplantation in nude mice no metastases were found. Kozlowski et al. 
report that implantation of silastic tubes of beta-estradiol into nude mice prior to 
tumor implantation increases the incidence of spontaneous metastasis from 0 to 3 
out of 10 mice (153). 
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TABLE I. Prostatic tumor xenografts 
Cell line· Origin 
Growth capacity 
in vitro hormone-dependency
0 
EB33 (136) 
DU145 (137) 
PC3 (138) 
LNCaP (139) 
PC82 (140) 
PC93 (141) 
HONDA (142) 
PC-EW(143) 
9479 (144) 
TEN/12 (145) 
TSU-Prl (146) 
PC133 (133) 
PC135 (133) 
PC-EG (147) 
PPC-1 (148) 
JCA-1 (149) 
primary tumor 
metastasis 
to brain 
metastasis 
to bone 
metastasis 
to lymph node 
primary tumor 
primary tumor 
metastasis 
to testis 
metastasis 
to lymph node 
metastasis 
to bone 
primary tumor 
metastasis 
to lymph node 
metastasis 
to bone 
primary tumor 
primary tumor 
primary tumor 
primary tumor 
+ 
+ 
+ 
+ 
-
+ 
-
-
-
-
+ 
-
-
-
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
* references, in brackets 
ь
 implantation in nude mice 
c
 androgen dependent means a preferential growth in intact male nude mice, as compared to 
female or castrated nude mice 
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In 1979, Kaighn et al. characterized the PC3 line, which is derived from a 
metastatic bone lesion (138). S.c. injection of PC3 cells results in spontaneous 
metastases to the draining lymph nodes and lungs in more than 50% and 13% of 
mice, respectively (154-156). Metastases to other organs, including the skeleton, were 
not observed (156). Different metastatic sublines have been isolated (155). The 1-
LN-PC-3-1A (1-LN) subline was derived from a spontaneous lymph node metastasis. 
The 1-LN spontaneously metastasizes to both regional and distant lymph nodes, and 
pulmonary micrometastases are observed in 30-50% of mice from which the primary 
tumor is excised (155,157). Kozlowski et al. also described aggressive in vivo derived 
variant cell lines (153,158). Investigations comparing the aggressive variants with the 
parental line showed a significantly greater plasminogen activator activity in the 
aggressive variants (159). 
The LNCaP cell line is developed by Horoszewicz from a metastatic lesion 
and is androgen-dependently growing in vitro (139). By using the technique of 
limiting dilution different sublines have been developed (160). Cytogenetic 
comparison of androgen responsive and unresponsive sublines showed preservation 
of the original parental karyotype and additional, subline specific, marker 
chromosomes (161). In vivo propagation of the tumor is possible in 62% of intact 
male nude mice and in 22% of castrated mice (139). In our own experience 2 out 
of 10 mice developed tumors after s.c. injection of 4 χ IO6 cells of the LNCaP.FGC 
subline. Transplantation of these tumors resulted in a tumor take in 15 of 40 mice. 
1.5.3. Bladder tumors 
After heterotransplantation of human bladder cancer tissue into immune-
deprived and nude mice some short term and serially transplantable xenograft lines 
have been established (35). Sufrin et al. implanted 9 low-grade and 11 high-grade 
transitional cell carcinomas in a total of 104 nude mice (162). Successful takes were 
observed in 40% of the tumors. The stage of the tumor, histological grade, 
multicentricity, recurrence rate and clinical prognosis were not related to the success 
or failure of graft takes in the nude host (162). Naito et al. confirmed these data, 
they implanted 30 transitional cell carcinomas and one squamous cell carcinoma in 
nude mice and obtained s.c. growth in 8 of 31 tumors (163). Serially transplantation 
was only possible with the squamous cell carcinoma. Furthermore, Matthews et al. 
showed an 39% successful xenograft growth (7/18), four of these tumors have been 
passaged successfully (164). Huland could transplant and passage 5 out of 16 
bladder cancers (165). Moreover, Naito et al. successfully transplanted 3 out of 8 
transitional cell tumors of the upper urinary tract (166). 
In immune deprived mice Kovnat could generate progressively growing 
xenografts from 20 out of 53 tumors (38%) (167). Also in these studies no evident 
correlation between success of xenografting and stage, grade, or clinical course of 
the disease was found. 
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Russell et al. found growth of primary implants in 11 of 20 specimens, from 
these tumors serially transplantable xenografts have been established (168,169). Each 
xenograft reflects the histological and ultrastructural features of its tumor of origin. 
Substantial heterogeneity, however, is present within the morphologically similar 
tumors. Studies with these lines may help to explain the diverse natural history of 
bladder cancer. 
A great number of immortal cell lines for bladder cancer have been 
described (170,171). Some of these lines are tumorigenic in nude mice after s.c. 
inoculation. Two different sublines of the T24 cell line, originally described by 
Bubenik (172), differed highly in their tumorigenicity (173). One subline was non-
tumorigenic, whereas the other subline produced tumors in 100% of the mice. The 
latter line contained fewer chromosomes and the authors suggest that tumorigenicity 
may be related to the loss of a regulatory gene (tumor-suppressor gene?) (173). We 
have also injected T24 cells, obtained from two different sources, in nude mice. 
Seven months after s.c. injection of 107 cells in 1/10 or 2/10 mice tumors developed. 
Further transplantation of these tumors was successful in all mice (18/18 and 20/20 
respectively). 
Bladder tumor cell lines have been successfully transplanted in the urinary 
bladder of nude mice. Comparison of tumors from the invasive EJ and the non­
invasive RT4 cell line revealed that the invasive cells contained an endogenous 
mutated Η-ras oncogene (174). Furthermore, the invasive cells have an enhanced 
Cathepsin В production (175). Cathepsin В is a proteinase with the ability to 
degrade laminin, a basement membrane component, and thereby facilitating the 
invasion of tumor cells into the surrounding tissues. Transfection of normal or 
mutated ras-oncogene into RT4 cell converted these cells into an invasive phenotype 
(176). Therefore overexpression of normal or mutated ras genes can be implicated 
in bladder tumor progression. 
15 Immunogenicity of animal tumors 
Human tumors fall, with rare exceptions, into the category 'spontaneous' as 
defined here (5). Syngeneically transplanted tumors of strictly spontaneous origin 
usually are non-immunogenic, and are therefore, according to Hewitt, by definition 
the only appropriate models for clinical cancers (5,177). The current consensus is 
that tumor specific antigens do not exist, and that all "neoantigens" are shared to 
some extent with normal tissues (178). In 1953, Foley et al. tested the antigenicity of 
spontaneous mammary tumors and obtained a negative result, whereas 
methylcholantrene induced tumors were immunogenic (179,180). Hewitt et al. also 
found no induction of immunity against 27 spontaneous murine tumors (181). 
Middle and Embleton obtained similar results in 28 naturally arisen tumors (182). In 
a previous paper, however, they found that a proportion of spontaneous tumors was 
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clearly immunogenic (183). Virus-induced tumors express common virus-coded 
antigens and are usually strongly immunogenic (177). Chemically induced tumors 
also tend to express individually distinct antigens. Depending upon the carcinogen 
the degree of immunogenicity is variable, but a large proportion of chemically 
induced tumors are immunogenic (177). Spontaneous arisen tumors, therefore, seem 
to provide the best tumor model for immunotherapeutical studies (5,184). Care must 
be taken for the possibility of incompatibility reactions due to genetic deviations 
between host and tumor in the course of time (185). Freezing of tumors and 
returning to the original tumors after a certain number of transplant generations can 
prevent this genetic drift (186). 
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2 CYTOKINES USED IN THIS STUDY 
2.1 Interferon 
Interferon (IFN) was discovered in 1957, when Isaacs and Lindenmann 
observed the phenomenon of viral interference (187). Viruses could trigger IFN-
secretion by infected cells, whereas IFN rendered cells resistant to infection caused 
by the offending virus as well as from a variety of other viruses. In 1980 a 
committee devised a system for the nomenclature of IFN and accepted a definition 
for IFN: "to qualify as an interferon, a factor must be a protein which exerts virus 
nonspecific, antiviral activity at least in homologous cells through cellular metabolic 
processes involving synthesis of both RNA and protein" (188). 
Up to now three major classes of IFN are defined on basis of chemical, 
antigenic and biologic differences: alpha-, beta-, and gamma-IFN. These three 
classes of IFN seem to be present in all mammalian species (189,190). 
Natural IFN-alpha ("leukocyte-IFN" or "lymphoblastoid interferon") is 
produced by leukocytes and macrophages (191). Multiple genes code for two 
families of more than 20 structurally related IFN-alpha proteins (192-194). In 
general, human alpha-IFNs are polypeptides of 165-166 amino acids, with at least 
70% sequence homology between individual molecules (189,195). The human IFN-
alpha genes are all clustered on chromosome 9 (196,197). Natural IFN products 
obtained from white blood cells of buffy coats are indicated by the symbol (Le), 
while the designation (Ly) is reserved for IFN-alpha derived from cultured 
lymphoblastoid cells. Recombinant DNA technology has led to cloning and 
expression of individual IFN genes in bacteria and eukaryotic cells (198,199). Three 
human recombinant IFN-alpha preparations are currently in use, IFN-alpha2a, -2b, 
and -2c. 
Natural IFN-beta ("fibroblast interferon") is produced by fibroblasts, and is 
encoded by a single gene, which is structurally similar to the IFN-alpha genes and 
also located on chromosome 9 (189,1%). There is 29% homology between IFN-
alpha and -beta amino acid sequences (200). Upon induction of IFN with poly(I:C) 
in diploid fibroblasts another human IFN, IFN-beta2, has been reported (189). This 
IFN appeared to be structurally distinct from the major form of IFN-beta or other 
known IFN species and has been renamed to interleukin 6 (IL-6) (190). 
Natural IFN-gamma ("immune interferon") is secreted by activated 
lymphocytes following exposure to antigens or mitogens (189). NK cells are also 
powerful producers of IFN-gamma when stimulated with IL-2 or ^ О ^ . Human 
IFN-gamma is a homodimer of 166 amino acids, including a 20 amino acid secretory 
peptide. IFN-gamma is encoded by a single gene, located on chromosome 12 (201). 
The isolation, characterization and expression of the genes encoding rat and mouse 
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IFN-gamma have also been reported. Both cytokines share approximately 40% 
amino acid sequence homology with human IFN-gamma (202-204). This low 
homology is probably responsible for the species-specificity. 
Next to their antiviral effects, IFNs have the ability to inhibit cell 
multiplication, i.e. antiproliferative activity. This activity was first described by 
Paucker et al. in 1962 (205). Two fundamental mechanisms are associated with the 
antitumor properties of IFN: direct effects on tumor-cells and immunomodulation. 
2.1.1 Direct effects 
IFN exerts its action through cell surface-specific receptors. IFN-alpha and -
beta share a common receptor, as demonstrated by the ability of IFN-beta to 
compete for the binding of labeled IFN-alpha, and vice versa (189). The gene 
encoding for the IFN-alpha/beta receptor has been assigned to chromosome 21 
(189). Zhang et al. compared IFN activity against two trisomic-21 (T-21), three 
diploid (D-21) and one monosomic-21 (M-21) fibroblast cell lines, and found that T-
21 cells were more sensitive to the antiviral activities of IFN-beta than of IFN-
gamma. This difference, however, was not found for the antiproliferative activities of 
both IFNs (206). The receptor for IFN-gamma has also been cloned and sequenced, 
and is located on chromosome 6 (207,208). Following IFN binding to cells the 
complex is rapidly internalized (189). 
The intracellular events induced by IFN are largely unknown (209). A new 
family of proteins, the immunophillins, might be important in the intracellular signal 
transduction (210). IFNs act intracellularly by transiently inducing or up- and down-
regulating genes. IFN-induced proteins include, 2'-5' oligoadenylate synthetase (2'-5' 
synthetase), Pl/eIF 2 alpha protein kinase, Mx protein, indoleamine deoxygenase 
(IDO), guanylate binding proteins, metallothionein II, thymosin B4, and xanthine 
oxidase (189,211). 2'-5' synthetase (212,213) and Pl-eIF 2 alpha protein kinase are 
implicated in the antiviral and cell multiplication effects of IFN. In the mouse the 
antiviral state is controlled by a host gene Mx, unlike the nuclear mouse protein, the 
human Mx-like protein is localized in the cytoplasm (189,214). 
IDO is ubiquitously distributed in normal and malignant tissues. IDO 
initiates the metabolism of tryptophan, which is an essential amino acid and is 
necessary for a variety of metabolic processes (215). Addition of tryptophan to 
tissue culture medium of cell lines blocks the antiproliferative activity of IFN-gamma 
(216). These observations make it possible to postulate that tryptophan depletion by 
IDO induction might be one of the mechanisms of action of the in vivo antitumor 
activity of IFN (215,217,218). 
Among the proteins induced by IFNs are the proteins of the Major 
Histocompatibility Complex (MHC) class I and II proteins (219-227). MHC proteins 
are essential for the recognition of aberrant cells by the immune system. Class I 
antigens are cell surface glycoproteins with a polymorphic heavy chain linked to 
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beta2-microglobulin and are expressed on all nucleated cells (228). Under normal 
conditions, class II antigen expression is limited to selected cell types, such as B-
lymphocytes, macrophages, and activated T-lymphocytes, however virtually every cell 
type can be induced by IFN-gamma to express MHC class II antigens. Class II 
antigen expression has also been shown on renal tubular cells and some renal cell 
carcinomas (229), although the last observation could not be confirmed by others 
(230). Cytotoxic Τ lymphocytes kill target cells which express foreign proteins (e.g 
"tumor" or viral antigen) only if this protein is associated with syngeneic MHC class 
I antigens. This phenomenon is referred to as MHC restriction, in contrast to the 
non-МНС restricted cell killing by natural killer cells (231). A decrease in MHC 
class I expression can contribute to tumor progression and metastasis (232,233). 
Experiments with transfection of genes encoding class I antigens in MHC-deficient 
tumors have demonstrated that augmentation of class I expression can reduce 
tumorigenicity and metastatic potential and increase immunogenicity (233,234). T-
helper cells recognize antigen in association with MHC class II molecules after this 
antigen has been processed in antigen-presenting cells, such as macrophages, 
monocytes and dendritic cells (226). Τ helper cells promote the proliferation and 
maturation of antibody-producing B-cells. Class I antigens are induced by all three 
types of IFN, but only IFN-gamma induces class II. Induction or increase of MHC 
expression may increase the hosts ability of immune-mediated tumor destruction. 
In addition to the MHC molecules, antigen-independent interactions 
between adhesion molecules are required for initiation of a specific immune 
response. Lymphocyte function associated antigen-1 (LFA-1), a member of the 
integrin family found on most leukocytes, participates in cell-cell interactions during 
Τ lymphocyte help, during killing by both cytotoxic Τ lymphocytes and NK cells, and 
in adhesion of leukocytes to endothelium (235). Intercellular adhesion molecule-1 
(ICAM-1) is a member of the immunoglobulin superfamily (236), and is expressed 
not only on hematopoietic cells, but also on endothelial cells, fibroblasts and 
malignant cells (237,238). ICAM-1 is a counter-receptor for LFA-1; its importance in 
Τ cell functioning has been demonstrated by blocking T-cell killing with antibody to 
ICAM-1 (236,239,240). IFN-gamma and TNF cause strong induction of ICAM-1 on 
a wide variety of tissues including renal cell carcinoma, and greatly increase binding 
of lymphocytes and monocytes through their cell surface LFA-1 (236,240-242). This 
mechanism might be favorable for an increased anti-tumor host response. 
Furthermore, IFNs are associated with other cell differentiating effects 
(244). The synthesis of hormone receptors is considered a function of more 
differentiated tumors. Alpha-IFN treatment increased the expression of estrogen-
receptors on two human breast tumor cell lines, and sensitized these to the 
antiproliferative effects of the anti-estrogen Tamoxifen (245). Likewise, IFN-beta 
increased estrogen and progesterone receptors on another human breast cancer cell 
line (246). Glucocorticoid receptors are induced on a human myelogenous cell line 
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(247) by IFN-alpha and -beta, and IFN-beta enhanced the production of estrogen 
and progesterone receptors on human endometrial cancer (248). Induction of 
androgen receptors on prostate cancers cells could also make these cells more 
susceptible for hormonal therapy. Immunocytochemical analyses revealed relatively 
high levels of androgen receptors in the androgen-responsive Dunning R3327H-
tumor (249). The androgen receptor mRNA level was about 75% compared to the 
normal rat dorsal prostate (100%). Androgen independently growing tumors, like the 
Dunning R3327MatLyLu, had very low levels of androgen receptor mRNA (<5%). 
In the experiments presented in chapter V of this thesis, we treated rats carrying 
the Η-tumor with rat-gamma-IFN and/or TNF. Castration of these rats, after 
cessation of cytokine therapy, did not produce a greater tumor regression in 
comparison to the control group, indicating that in this tumor the cytokines did not 
induce androgen receptors. 
IFN treatment of cells can also lead to decreased expression of genes. 
Gamma-IFN inhibits the expression of c-erbB-2 gene in ovarian carcinoma cell lines 
(250). IFN modulates the expression of several other oncogenes, such as c-myc, c-
fos, c-Ha-ras, v- or c-src (189). Recently it has been shown that IFN-alpha/beta can 
selectively down-regulate the expression of mitochondrial genes in both human and 
murine cultured cell lines, which is a new pathway for IFN-mediated responses 
(251). 
2.1.2 Indirect, immunomodulatory effects of IFN 
IFNs efficiently enhance the cytotoxic activity of natural killer (NK) cells. 
This effect can be demonstrated and quantitated by preincubating lymphocytes in 
the presence of IFN and then testing their cytotoxic ability against target cells 
unable to induce IFN production (231). All three types of IFN are able to induce 
NK cell activity, IFN-gamma, however, enhances NK cytotoxicity to a lower extent 
and with slower kinetics than IFN-alpha or IFN-beta (231). Although almost all 
IFN-alpha species induce NK cells, IFN-alphaJ, with potent antiviral and 
antiproliferative activities, fails to do so. IFN-alphaJ can block the NK stimulatory 
activity of other IFN-alpha species, and compete with these IFNs for attachment to 
the IFN-receptor on NK cells (252). In this comparison of multiple alpha-IFNs 
which differed in only a few amino acids, it has been suggested that the tertiary 
structure of the protein regulates the ability to stimulate NK cells. 
Furthermore IFNs, especially IFN-gamma, activate the tumoricidal activities 
of monocytes and macrophages (253). The IFNs are part of the cytokine network 
and are able to induce the production of other cytokines, such as TNF-alpha and 
interleukin-1, by macrophages (254). 
Neopterin, a compound derived from guanosine triphosphate (GTP), 
represents a precursor molecule of biopterin, an essential cofactor in 
neurotransmitter synthesis. In monocytes and macrophages neopterin-release is 
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activated by IFN (255,256). By measuring parameters that are induced by IFN 
treatment, such as neopterin and ß2-microglobulin, it is possible to compare 
activities of different IFNs and to assess the optimal biologically active dose in a 
clinical setting (257-259). For example, Aulitzky and coworkers showed that a 
relatively low dose of gamma-IFN, 100 ßg (2 χ IO6 lU) once weekly was biologically 
more active than higher doses (260). The low dose resulted in a nearly maximum 
rise of neopterin and ß2-microglobulin levels in the serum with minimal side effects, 
whereby the increments in these markers were predictive for response. Similarly 
immunological parameters were optimally elevated not at the highest dose level for 
IFN treatment in patients suffering from melanoma or hairy cell leukemia (261-263). 
2.2 Tumor Necrosis Factor 
The induction of hemorrhagic necrosis by bacterial products has already 
been described in the early 30's (see for review ref. 264). The substances 
responsible for these effects are the endotoxins. These are the lipopolysaccharides 
(LPS) that are found on the outer surface of gram negative bacteria (265). 
Endotoxin induces "hemorrhagic necrosis" in transplanted tumors, but does not kill 
tumor cells in culture, which indicates an indirect mechanism of action (265,266). 
In 1975, Carswell and Old found that serum of mice treated with endotoxin, 
14-21 days after BCG-infection, contained a substance which caused hemorrhagic 
necrosis of transplanted meth A sarcomas in these mice; this substance was 
designated tumor necrosis factor (TNF) and is a product of macrophages (266-269). 
Best effects were found on well-established (7-day) transplants, whereas virtually no 
effect on 5-day transplants was found. Coiynebacteria and Zymosan were as 
effective as BCG as priming agents for TNF release by endotoxin (266). Human 
TNF has been purifíed and characterized by Aggarwal et al. (270) and its gene has 
been cloned and brought to expression in E. Coli. (271-273). 
Other investigators were interested in the mechanism underlying the severe 
cachectic state accompanying chronic parasitic infections in animals. They observed a 
marked elevation of plasma very low density lipoproteins (VLDL), which resulted 
from a clearing defect, caused by a loss of peripheral tissue lipoprotein lipase (LPL) 
activity (274). Endotoxin treated macrophages and a macrophage cell line produced 
a monokine that could inhibit LPL activity. This factor was purified to homogeneity 
by Beutler et al. and named cachectin (274). After cloning of the cDNA for 
cachectin it was shown that TNF and cachectin are identical (275). 
TNF is a protein of 157 amino acids that is synthesized as a 223 amino acid 
precursor from which a 76 residue signal peptide is cleaved off (271). Mature 
murine TNF consists of 156 amino acids, the 235 amino acids pre-TNF is 79% 
homologous to human TNF (276,277). This may be an explanation for the low 
species specificity of TNF. TNF is encoded by a single gene, located on 
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chromosome 6 (278-280). The TNF-gene is closely linked to the gene coding for 
lymphotoxin (LT) or TNF-beta. LT is produced by activated lymphocytes and has 
anti-neoplastic properties similar to TNF (281,282). About 30% of the amino acids 
of both molecules are identical. The genes for TNF and LT are located within 8 kB 
of genomic DNA, between the genes for MHC class I and II antigenes, i.e. located 
in the region of the so-called Class III MHC genes (280). The close linkage and 
amino acid sequence homology suggests a common ancestral gene for TNF and LT. 
TNF and LT interact with the same membrane receptors. Structural 
analyses of these receptors by ligand cross-linking and affinity purification revealed a 
TNF receptor molecule of about 85 kD (283-286). Recently, a molecule of 60 kD 
was found which represents the biologically relevant TNF receptor, since a 
monoclonal antibody against this protein uniformly blocked various gene regulatory 
as well as cytostatic and cytotoxic activities of TNF (287). It is conceivable that p85 
may cooperate with p60, e.g. by modulation of ligand binding activity (287). The cell 
membrane expression of the TNF receptor is enhanced by IFN-a!pha (288) or IFN-
gamma (284,289,290) and decreased by protein kinase С activating agents (291,292), 
inhibitors of protein synthesis (293) or drugs that depolymerize microtubules (293). 
Several mechanisms serve to decrease the number of receptors, such as 
internalization or reduced synthesis and/or translocation to the plasma membrane 
(2086). Another mechanism is shedding of receptors, e.g. neutrophils shed TNF 
receptors to rapidly decrease the number of receptors on their surface (294). 
After binding to its receptor, the receptor-TNF complex is internalized and 
degraded (283). The nature of the intracellular mediators of TNF action have to be 
identified. Arachidonic acid might play a role in TNF signal transduction, because its 
release and metabolism is an early event stimulated by TNF (295). Arachidonic acid 
induces the c-fos oncogene expression in a dose-dependent manner, but did not 
induce c-jun oncogene expression. Inhibition of the degradation of arachidonic acid 
by an lipoxygenase inhibitor abolished the induction of c-fos by TNF, but not of c-
jun. These data suggest that at least two second messenger pathways are activated 
by TNF (295). TNF-sensitivity is not solely dependent on the number of functional 
receptors present on the cell surface or on the ability to internalize TNF, since 
TNF-resistant cell lines can express equal amounts of receptors as TNF-sensitive cell 
lines (283,296). 
In addition to endotoxin, other compounds are capable of inducing TNF 
production by monocytes, such as IFN-gamma (297,298), IL·! (298), ІЬ2 (299) and 
TNF itself in an autocrine manner (298,300). Moreover, prostaglandin E2 (301,302), 
vitamin D3 (303), activated complement protein C5a (304), urinary colony-
stimulating factor-l (CSF-1) (305), granulocyte-macrophage colony-stimulating-factor 
(GM-CSF) (306) have been shown to induce TNF production. Under certain 
circumstances hyperthermia can induce TNF synthesis (307). Cellular cyclic AMP 
and IL-4 act antagonistically on TNF production (299,308). 
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TNF is predominantly produced by monocytes/macrophages, but several 
other cell types have also been shown to produce TNF. These include T- and B-
lymphocytes and NK-cells, but the quantity of TNF released is minute compared to 
that produced by macrophages (231,309,310). Recently it has been shown that 
keratinocytes, after stimulation with endotoxin or UV-light, can release TNF (311). 
Some tumor cells also have been shown to produce TNF; interestingly some tumor 
cell lines inherently resistant to TNF express TNF mRNA (312-314). Himeno et al. 
transfected the TNF-sensitive L-M cell line with a human TNF gene and these cells 
acquired resistance to TNF (315). Conversely, inhibition of endogenous TNF 
production by introducing antisense TNF gene into TNF-less sensitive HeLa cells, 
enhanced TNF sensitivity (315). 
2.2.1 Direct antitumor effects of TNF 
TNF has potent antitumor effects against tumor cells in vitro (316-319). 
However, TNF is not equally cytotoxic to all tumor cells and some tumor cells are 
even resistant (316,319,320). Evenmore, the antitumor activity is dependent on the 
in vitro test used (321). In vitro antitumor activity of TNF can be enhanced in 
combination with chemotherapeutic agents directed against DNA topoisomerase II 
(322-326). In contrast, TNF augmented the growth of diploid fibroblasts (316,327), 
and has potent fibroblast chemotactic activity (328). 
Cell death can occur by two distinct mechanisms, necrosis and apoptosis. 
Necrosis is the classical form of cell death; flocculation of nuclear chromatin 
together with non-specific cleavage of the cell's DNA is a feature of cells 
undergoing necrosis (329). During apoptosis, a series of well defined degeneration 
changes occur within the cell, which result in the degradation of DNA into 
oligonucleosome chains. This form of cell death is also termed "programmed cell 
death" (329,330). TNF induces apoptosis in TNF-sensitive cells (331-333). 
TNF has been shown to induce hydroxyl radical production in TNF-sensitive 
cells, resulting in oxidative damage (334,335). Intracellular hydroxyl scavengers, such 
as glutathione, exert a protective function against this cytocidal effect of TNF (336). 
TNF induces expression of the genes for collagenase and the oncogenes fos, 
jun, and myc (295,337,338). In another study no correlation between TNF sensitivity 
and ras and myc oncogene expression was observed (339). Furthermore, TNF has 
been shown to induce EGF-receptors and HLA class I and II expression on tumor 
cells (340,341). 
2.2.2 Indirect, immunomodulatory effects of TNF 
TNF augments the activities of cells of the immune system, such as Τ 
lymphocytes (342-344), macrophages (344-347) and NK cells (348). In an clinical 
trial, however, Kist et al. could not confirm the NK cell augmenting activity of TNF 
(349). Furthermore, TNF has been shown to enhance В cell proliferation and 
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differentiation (350,351). 
Several animal model studies illustrated the immunomodulatory effects of 
TNF and the need for an intact immune system. TNF causes regression of SAI 
sarcomas in normal mice, but not in thymectomized, T-cell deficient, mice (352). 
Haranaka et al. showed inferior antitumor effects of TNF against meth A sarcoma 
in nude mice, compared to the antitumor effects in nu/+ mice (353). Furthermore, 
TNF induces a specific immune response against meth A sarcoma in intact mice 
(354). Asher et al. observed tumor necrosis in immunogenic and non-immunogenic 
murine sarcomas, complete regressions, however, were only seen with immunogenic 
tumors (355). Manda et al. showed no direct, in vitro, cytotoxicity of TNF against 
several murine tumors, in vivo treatment, however, showed (indirect) antitumor 
activity (356). 
Furthermore, the production of cytokines, such as IL-1 (357), ^ 6 (358), 
GM-CSF (359) and platelet-activating growth factor (360), is enhanced by TNF. 
2.2.3 Vascular effects of TNF 
Direct effects of TNF on vascular cells in vitro have been reported. These 
include, in addition to growth inhibiting and cytotoxic effects (361), the induction of 
cell surface adhesion molecules (LFA-1, ICAM-I) (362), MHC class I antigens (362-
364), platelet-activating factor (PAF) (365), monocyte chemoattractant MCP-l/JE 
(366) and the enhancement of a procoagulant effect on endothelial cells (367). The 
direct effects favor the accretion of thrombus and the adhesion of neutrophils, 
monocytes and lymphocytes on the endothelial surface. The induction of fibrin 
formation also leads to occlusive thrombosis and is associated with an 80% 
reduction of tumor perfusion (368). In vivo studies confirmed that thrombus 
formation is an important effect of TNF (369-371). The effects were more extensive 
in 6 to 15 days old Meth A sarcomas in comparison to 3 days old tumors. Van de 
Wiel et al. showed that TNF initially induces an active hyperemia that is rapidly 
converted to a passive hyperemia (372). Furthermore, TNF increases the 
permeability of endothelial cell monolayers and stimulates formation of inter-
endothelial cell spaces in vitro (373). In vivo studies revealed a breakdown of 
laminin which can cause loss of vascular integrity (372). Mcintosh et al. 
demonstrated that the neovasculature of transplanted and spontaneous tumors in 
mice is specifically affected by a single dose of TNF (5-20 jig/mouse), but found no 
effect on the vascularization of normal tissue transplants (374). This difference might 
be explained by differences in the neovascularization of normal and tumor grafts, 
but their exact mechanism remains to be elucidated (374). 
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2.3 Model systems for measuring antiprohferative effects 
In vitro experiments enable us to measure the direct antitumor effects of 
cytokines. In the studies presented m this thesis a modified double layer soft agar 
model system has been used as originally described by Hamburger and Salmon (375-
377). In the upper layer a single cell suspension of tumor cells is plated. These cells 
form colonies which can be counted with an automated colony counter (378). The 
number of colonies formed during drug treatment is compared to the colony 
number of the untreated control and is a measure for the antiproliferative activity of 
that drug. Assessable growth of primary tumors remains a problem due to the low 
plating efficiencies and clumping artefacts (379,380). To correct for initial cell 
clumps a cytotoxic control is added, the number of "colonies" counted in these 
dishes are deducted from the control or treatment groups (381). There is little 
opportunity to determine the indirect drug activity using the basic clonogenic assay. 
Inclusion of macrophages in the underlayer could be a possibility to optimize the 
assay, since addition of macrophages inhibited colony formation more than IFN-
gamma treatment alone, due to the secretion of soluble substances by these 
macrophages, which consist in part of TNF (382). In a small study, Strayer et al. 
suggest that the soft-agar assay can identify responders for IFN treatment (383). 
Clinical correlations between in vitro sensitivity and in vivo response to HuIFN-
alpha were possible in 7 renal cell carcinoma patients. 4 out of 4 patients with 
>60% decrease of colony formation responded clinically (2 PR, 2 minor responses), 
while all three patients showing less than 60% decrease m colony formation had 
progressive disease (383) 
Another in vitro model is the MIT away In this assay the conversion by 
viable cells of soluble yellow l-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazohum 
bromide into purple colored MTT-formozan is measured (384-386) This assay is 
usually used for chemosensitivity testing of cell lines. Mickisch et al attempted to 
adapt the assay to pnmary tumors by purifying the single suspension by Ficoll 
density centnfugation (387). However, also in this study the admixture of fibroblasts 
and measuring growing fibroblasts in stead of tumor cells cannot be excluded. The 
soft agar assay has a major advantage in this respect, only tumor cells will grow in 
soft agar and not the fibroblasts 
The multicellular spheroid model is of intermediate complexity between 
monolayer cultures in vitro and tumors in vivo. Spheroids are three-dimensional cell 
aggregates that simulate micrometastases or intervascular microregions of larger 
tumors (388). Spheroids from cell lines or from pnmary tumor specimens, show 
growth kinetics similar to those of tumors in vivo (388,389). The degree of structural 
or functional differentiation m the pnmary tumor may be retained in spheroids 
(388,389). Within a spheroid there is a large spatial vanation in cellular 
proliferation. Generally, most of the proliferating cells are located in the outer three 
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to five cell layers. With increasing depth into the spheroid cell cycle times prolong 
and cells become quiescent, i.e. cells arrested in Gö-phase but remaining clonogenic 
(389). In the central area of spheroids with diameters larger than 300-500 μηι there 
are often large massive necrotic areas. In the studies presented in Chapter III 
spheroids are cultured with the liquid overlay technique; spheroids are cultured in 
dishes coated with a agarose gel to prevent attachment to the bottom of the dishes. 
Spheroids have been widely used in chemotherapy and radiotherapy research (390). 
Furthermore, spheroids have been used to analyze the interaction between immune 
cells and solid tumors (391-393). 
Treatment of nude mice carrying human tumor xenografts give the 
opportunity to assess the antitumor effects of cytokines in vivo. However, both the 
antiproliferative and immunomodulatory effects of IFN are species-specific. Human 
IFN-alpha or IFN-gamma have no effect on the mouse immune system as measured 
by NK cell or macrophage activity and therefore only direct effects of IFNs on 
human tumor cells can be assessed (394-396). 
In vivo testing of tumors implanted in rats or mice offer the major advantage 
that direct as well as indirect, immune-mediated effects, can be measured. The best 
tumor models for immunotherapeutical studies are spontaneously arisen, non-
immunogenic, autochthonous or implanted tumors in syngeneic mice (5,177). 
Inoculation of in vitro cell lines in rats or mice gives the possibility of comparing in 
vitro and in vivo effects of drugs. Disadvantages of syngeneic animal models are 
obviously the use of non-human tumors, and differences in metabolism and 
pharmacokinetics between rodents and man of the drugs tested. 
2.4. Antitumor effects of IFN against urological tumors 
2.4.1 Antitumor effects of IFN against renal cell carcinoma 
Fleischmann et al. developed a human renal xenograft, JDF-1, which has 
been maintained in nude mice. IFN-alpha has a dose-dependent growth-inhibiting 
effect on colony formation in soft-agar and in nude mice of this tumor (397,398). 
HuIFN-alpha(Ly) had dose-dependent antitumor effects after daily, for 2-4 weeks, 
s.c. or i.t. administration against the KU-2 and RCC-1 xenografts (399). RecIFN-
alpha and -beta showed modest inhibition of cell growth of the ACHN cell line 
after a 24 hour treatment period. Cell growth was recovered to normal rate and 
doubling time 24 hours after removal of the IFNs (400). Borden et al. showed dose-
dependent antiproliferative effects after 72-120 hours of treatment with HuIFN-
alpha and -beta. In these studies HuIFN-beta was more potent then HuIFN-alpha 
(401). RecIFN-gamma, however, produced a complete growth inhibition of cell 
growth, and the cell doubling time was increased after removal of this IFN (400). 
Gohji et al. showed similar effects; recIFN-gamma had a stronger growth-inhibiting 
effect in comparison to recIFN-alpha and -beta on the KO-RCC-1 cell line 
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(402,403). The RCC-nu-1 cell line was more resistant, the IFNs only slightly 
inhibited cell growth. Higher doses of IFN-gamma significantly enhanced the effects 
of different chemotherapeutic agents (403). In vitro studies against the SN 12 cell 
lines revealed a more effective inhibition of IFN-alpha hybrids against the parental 
SN12C cell line, whereas recIFN-gamma was more effective against the metastatic 
subline SN12L1 (404). In contrast, HuIFN-alpha(Ly) or HuIFN-gamma given daily 
for 17 successive days could not inhibit JRC-11 xenograft growth (405). 
RecMuIFN-alpha and -beta have significant antiproliferative effects in the 
MTT assay against the murine Renca tumor (406). RecMuIFN-gamma, however, 
exhibited only minimal and inconsistent direct growth inhibition. Recombinant hybrid 
IFN-alphaA/D is the only human IFN with antiproliferative effects against cells of 
other species, and therefore this IFN showed antiproliferative effects against the 
Renca cells in vitro. Very low levels of IFN-gamma potentiated the inhibitory effects 
of IFN-alpha and -beta. In vivo studies showed potent antitumor effects of IFN-
alphaA/D alone or in combination with IFN-gamma. In contrast, the combination of 
IFN-alpha and -gamma only slightly increased survival of nude mice implanted with 
Renca cells. This implies that long-term survival of mice probably depends on a T-
cell mediated response against the Renca tumor. Cured euthymic mice showed 
immunity against Renca rechallenge (406). 
Nanus et al. tested the antitumor effects of IFN-alpha against 16 RCC cell 
lines and correlated these effects with the expression of six kidney-associated 
differentiation antigens (407). The expression of one antigen, gpl60, correlated with 
resistance to IFN-alpha, and, conversely, lack of expression of gpl60 correlated with 
sensitivity to IFN-alpha. This correlation was also observed in vivo using nude mice. 
The authors conclude that the absence of gpl60 expression by RCCs may be 
predictive for sensitivity to IFN-alpha, and, thus, provide a basis for identifying IFN-
responsive patients (407). 
Although the number of preclinical studies of renal cell carcinoma is rather 
limited, clinical studies have been performed. The need for new treatment strategies 
and the promising effects of IFN in tumor models have provided a rationale for 
these trials. Cumulative results reviewed in several papers show an overall response 
rate for IFN-alpha of 16% (191,408,409). 
Clinical experience with IFN-beta or -gamma is less extensive. The number 
of patients treated with IFN-beta is too low to draw firm conclusions. Objective 
response rates are in the range of 10-20% (191,409-411). 
A wide range of response rates has been reported in patients treated with 
IFN-gamma (191,409,411-413). Rinehart et al., for example, reported no responses 
in 13 patients during a phase I trial (414). In contrast, low dose IFN-gamma has 
been associated with an overall response rate of 30% (260). However, Goepel et al. 
have treated 13 patients with the doses used by Aulitzky et al. and found only 8% 
responders (415). 
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Different studies have assessed the effects of combinations of IFNs. In three 
phase II studies S3 patients received either IFN-alpha and -gamma at equal dosages 
(2 χ ΙΟ0 Ό/τη2) от at equal protein weights (2 χ IO6 U/m2 IFN-alpha and 0.2 χ ICf5 
Ό/τη2 IFN-gamma) or an alternating treatment regimen was used: IFN-gamma 5 χ 
lOfym2, week 1, IFN-alpha 10 χ itf/m2, week 2; 2 weeks out of 3. The response 
rates of these studies are 0/10 (0%), 4/25 (16%) and 1/13 (8%) (416). Foon et al. 
did not find differences in response rates in randomized three-arm study comparing 
IFN-alpha alone (2 χ Vfi/m2, three times a week), IFN-gamma alone (1 χ lOfym2, 
three times a week), or the combination of both cytokines (1/21, 1/21 and 2/47 
objective responses, respectively) (417). Ernstoff et al., however, found objective 
responses in 8 out of 30 assessable patients (27%), sequentially treated with IFN-
alpha and -gamma (418). 
At the departments of Urology and Medical Oncology at the University of 
Nijmegen two subsequent phase I/II trials were conducted (419,420). An initial 
group of patients was treated with an escalating dose alpha-IFN and a fixed dose of 
gamma-IFN. Based on the experience in the first group, a follow-up study was 
started with a four times higher alpha-IFN dose and the same low gamma-IFN dose. 
32 patients were included in the first study with a starting dose of alpha-IFN 6 
Mg/m2 = 2 χ 106 IU/m2 and a fixed low dose of gamma-IFN (0.1 mg/m2 = 2 χ 
lOfym2) s.c. two times weekly. After 4 or 8 weeks of treatment, the alpha-IFN dose 
was escalated with 6 Mg/m2 until the maximum tolerated dose (MTD); which was 30 
Mg/m2 (range 6-36 Mg/m2). In 2 patients a CR (7%) and in 6 a PR (21%) was seen 
resulting in an overall response of 28% (419). In a subsequent study 25 patients 
were treated with a starting dose alpha-IFN of 24 Mg/m2 and a low dose of gamma-
IFN (0.1 mg/m2); alpha-IFN dose was escalated every two weeks with 6 Mg/m2 until 
MTD. The overall response rate of this second group was 22% (420). 
More comparative studies are needed to establish exactly the role of IFNs 
in the management of metastatic RCC. All published results so far are gathered 
from phase I/II studies. Overall response rates, therefore, have to be evaluated and 
interpreted with great caution. A comparative EORTC phase III trial is ongoing, 
comparing IFN-alpha monotherapy to alpha- and gamma-IFN combination therapy. 
2.4.2 Antitumor effects of IFN against prostatic carcinoma 
The androgen-dependent LNCaP cell line is resistant to HuIFN-beta in vitro 
(139). In contrast, studies using recIFN-alpha and HuIFN-beta showed 
antiproliferative activity against the androgen-independently growing PC3 and 
DU145 cell lines, IFN-beta being more effective then IFN -alpha (404,421). HuIFN-
alpha also inhibited PC3 cells in a dose-dependent manner, this direct 
antiproliferative effect is at least partly mediated by cyclic AMP (422). 
A limited number of clinical trials have been conducted in prostatic cancer. 
Complete and partial responses have been reported, but the number of treated 
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patients is too small to draw firm conclusions about effectivity of IFNs in prostatic 
cancer (Table II) (423-426). One case report of a complete response has been 
described in a patient with prostatic cancer receiving 7 - 9 χ 10o U HuIFN-gamma 
per day for 12 weeks (427). 
Clinical research with cytokines could be hampered by the fact that prostate 
cancer is primarily and predominantly a disease of metastases to bone. Experience 
with the use of IFNs in renal cell carcinoma showed that lung metastases are 
especially susceptible for IFN treatment (428). The primary tumor, bone and central 
nervous system metastases rarely respond to this type of treatment. However, 
clinical responses with IFN-alpha and -beta treatment have already been obtained in 
prostatic cancer patients with osseous metastases (Table III). 
Another consideration regarding the clinical applicability of cytokines is the 
fact that prostate cancer is a very slow-growing tumor. In vivo labelling studies with 
the thymidine analogue bromodeoxyuridine, BrdU, revealed an extremely low 
fraction of cells in S-phase (3.5%, range 1.0 - 10.7%) in a series of 46 patients with 
prostatic cancer (429). Bladder tumors, for example, have a S-phase fraction of 
12.3% (range 2.0 - 30.0%) (429). The low mitotic activity could probably be a 
reason that chemotherapy has had such poor success in prostate cancer therapy. In 
contrast, for IFN-alpha and -beta it has been shown that resting tumor cells are 
more sensitive targets for its antiproliferative activity than rapidly multiplying cells in 
vitro (430). IFNs can inhibit cell proliferation by blocking cells in the G0/G1 phase 
of the cell cycle. 
Table II. Antitumor effects of IFN against prostatic carcinoma, clinical trials 
IFN type 
HuIFN-alpha 
HuIFN-alpha 
rIFN-alpha 
HuIFN-beta 
administration 
route 
? 
i.m. 
s.c 
i.V. 
no. 
10 
14 
9 
16 
patients regimen 
3 or 9 χ 106 
U/day 
6 χ 106 U/m2 
3 days/month 
5-10 χ 106 
U/m2 3x/wk 
6 χ 106 3x/Wk 
12 weeks 
responses 
1 CR, 3 PR 
5 CR, 6 PR 
-
-
ref. 
423 
424 
425 
426 
2.4.3 Antitumor effects of IFN against transitional cell carcinoma of the bladder 
HuIFN-beta produced >20% growth inhibition in 2 out of 3 cell lines after 
120 hr. of continuous exposure, whereas HuIFN-alpha was not effective in these cell 
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lines (401). In a further study the number of cell lines was extended to five and in 
addition to the naturally produced IFNs, recIFNs were used (431). All cell lines, 
except the 647V cell line, were sensitive to IFN. No significant difference was seen 
between natural and recombinant IFN-alpha. Although recIFN-beta was not 
equivalent in effectiveness to naturally produced IFN-beta, its antiproliferative 
activity was greater than IFN-alpha (431). In contrast to IFN-alpha and -beta, 
recIFN-gamma significantly inhibited in vitro growth of the 647V cell line (432). 
RT4 cells were sensitive to the antiproliferative effects of both recIFN-alpha and -
gamma, combinations of these IFNs gave synergistic effects (433). The growth of the 
RT4 cell line grown as xenograft in nude mice, was inhibited by HuIFN-beta, when 
treatment was started at time of tumor inoculation (434). 
Table III. Antitumor effects of IFN against TCC, clinical trials 
IFN type 
HuIFN-alpha 
HUIFN-alpha 
HuIFN-alpha 
HuIFN-alpha 
recIFN-alpha 
recIFN-alpha 
recIFN-alpha 
recIFN-alpha 
recIFN-gamma 
administration 
route 
i.m. 
i.t. 
i.m. 
intravesical 
intravesical 
intravesical 
intravesical 
intravesical 
intravesical 
No. patients 
TCC· CISb 
3 
8 
8 
8 
10 
8 
16 
-
13 
-
-
-
8 
-
4 
19 
38 
47 
-
regimen responses 
CR PR 
4 χ 10* U/day, 
8 weeks, then 3x/wk 
2 χ 106 U/day, 
3 weeks 
1 χ 106 U/2 days, 
6 months 
50 χ 106 U/day, 
8 weeks 
5 χ 107 U 2x/wk 
6 weeks 
54 χ 106 U/week, 
8 weeks 
50-1000 χ 106 U 
/week, 8 weeks 
107 U/week or, 
10 χ 107 U/week, 
12 weeks, 
then lx/month 
1 mg 3x/week 
8 weeks 
6 
1 
3 
-
1 
4 
6 
2 
20 
1 
3 
-
2 
3 
4 
2 
5 
13 
9 
-
ref. 
443 
444 
445 
446 
447 
448 
449 
450 
451 
1
 transitional cell carcinoma, 
b carcinoma in situ 
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Grups and Frohmüller evaluated the effects of recIFN-alpha against 17 
bladder carcinoma cell lines, and were able to divide these cell lines in sensitive 
(>50% growth inhibition), semisensitive (25-50% growth inhibition) and resistant 
(<25% growth inhibition) cell lines (435). The combination of recIFN-alpha, 
HuIFN-beta and recIFN-gamma effectively inhibited growth of the 639V cell line 
(435). Encapsulation within multilamellar liposomes augments the antiproliferative 
effects of recIFN-alpha against the 253J cell line and could overcome the resistance 
to IFN-alpha of a 253J subline (436). More than 50% of the cells contained 
intracytoplasmatic liposomes (436). 
Differences in IFN sensitivity of different cell lines could not be attributed 
to the number of IFN receptors per cell or IFN affinity for these receptors 
(432,437). 
Mouse IFN-alpha/beta demonstrated antiproliferative activity in vitro but did 
not affect MBT-2 tumor growth in vivo (438). Combination treatment with 
Adriamycin or DFMO did not increase the effect of IFN in vivo (438,439). 
Several clinical trials have been conducted with different IFNs (Table III) 
(440-451). Intravesical instillations were used without any apparent side effects. The 
studies presented here have shown activity of IFN against superficial bladder cancer 
as well as against carcinoma in situ. 
2.5 Antitumor effects of TNF against urological tumors 
The number of studies using TNF as single agent is limited. Heicapell et al. 
used the tumor lines described by Naito et al. (131,452). They found significant 
differences among the different cell lines, demonstrating the heterogeneity of 
cytotoxic effectivity of TNF within a single renal tumor (452). Shibayama found in 
vitro antitumor activity against the KU-2 cell line (453). Burgers and Donaldson, 
using different RCC xenografts, both showed in vivo antitumor effects in nude mice, 
and demonstrated synergistic antiproliferative effects in combination with the 
chemotherapeutic agent VP16 (454,455). 
Shaw et al. treated rats bearing the Dunning R3327 MatLyLu prostatic 
tumor by intraperitoneal or intratumoral TNF injections (456). Intratumoral 
administration was most effective in both reducing tumor growth and in prolongation 
of survival (456). Sherwood et al reported cytotoxicity of TNF against the PC3, 
DU145 and LNCaP cell lines in vitro (457). Intravenous treatment of nude mice 
bearing the PC3 tumor resulted in significant tumor growth inhibition (457). 
Fruehauf et al., however, found that the PC3 cell line was almost completely 
resistant in vitro to the action of TNF, whereas LNCaP cells were sensitive targets 
for TNF (458). 
Most studies using TNF in TCC have been performed in the murine MBT-2 
model. Studies with TNF derived from supematants of the endotoxin stimulated 
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J774.1 macrophage cell line showed in vitro cytotoxicity, this crude TNF also 
significantly suppressed growth of subcutaneous tumors (459). Recombinant TNF 
alone, or in combination with a low dose Actinomycin D had no cytotoxic effects in 
vitro, furthermore, intravesical treatment with 10 μg TNF did not reduce the 
outgrowth of bladder tumors in vivo (460). In contrast to these results, Lee et al. 
observed a significant reduction in МВТ-2 tumor weight with intravesical crude and 
recombinant TNF treatment in a dose-dependent fashion (461). The tumor 
incidence was lower with crude TNF, which was not the case with the recombinant 
TNF. The differences in antitumor activity may be explained by admixture of other 
cytokines or endotoxins in the crude TNF preparations or by differences between 
human and murine TNF. In the KK-47 bladder tumor xenograft model, 
intravenously or intratumorally administered recombinant TNF did not inhibit the 
growth of subcutaneously implanted tumors (462). Das et al. used the DU-4284 
xenograft, implanted under the renal capsule, and found that intravenously 
administered TNF (50-100 Mg/kg 2 or 3 times) significantly inhibited tumor growth 
(463). In contrast to adriamycin, cisplatin and dactinomycin, VP16 synergistically 
potentiated the cytotoxic effects of TNF (463). 
Several phase I trials with s.c, i.m or i.v. TNF administration have been 
conducted. The maximum tolerated dose is approximately 150 μ%Ιτα2 (464-470). 
Figlin et al. treated 14 RCC and 11 melanoma patients with an escalating dose of 
TNF (25-75 μg/m2/day), daily for 8 weeks and found no objective responses (471). 
Eisenhauer et al. treated 22 RCC patients with 150 μg TNF/m2 for 5 days every 
other week and observed 1 PR and 1 CR (472). 
2.6 Combination treatment with IFN and TNF 
2.6.1 In vitro studies 
Different in vitro and in vivo studies revealed synergistic antiproliferative 
effects of the combination of IFN and TNF against different tumors. For example, 
IFN-gamma in combination with TNF has synergistic effects against colon carcinoma 
(473), cervical carcinoma (474), mastocytoma (475) and lung cancer cell lines (476). 
Fransen et al. investigated the effects of IFN-gamma and TNF against more than 30 
normal and tumor cell lines (477). IFN-gamma and TNF had remarkable synergism 
against a large number of tumor cell lines. Some cell lines, not sensitive to TNF 
alone, became highly sensitive when IFN-gamma was present as well. All normal, 
non-transformed diploid cell lines were insensitive to TNF even in the presence of 
IFN-gamma (477). 
Salmon et al. used the soft-agar assay to test the growth-inhibiting effects of 
IFN-gamma, TNF and their combination against 102 primary tumors (478). In 68 
instances the tumor specimens were tested against IFN, TNF as well as the 
combination. Exposure to the combination often resulted in a greater antitumor 
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effect than observed with either agent alone, with at least subadditive effects in 62% 
of the specimens tested (especially in colorectal and lung cancer). Exposure to the 
combination reduced the dose of TNF required for significant antitumor activity by 
about threefold (478). Price et al. studied the cytotoxic effects of IFN-gamma and 
TNF on primary cultures of leukemia cells, and found additive and synergistic 
effects in cells from all 17 patients (479). IFN-alpha and -beta also showed 
synergistic effects in combination with TNF against different cell lines (480-482). 
Kavoussi et al. demonstrated synergistic in vitro effects of IFN-gamma and 
TNF against four different RCC cell lines (483). Pretreatment of tumor cells with 
IFN enhanced or induced sensitivity of tujmor cells to TNF. In vitro studies using 
five different RCC xenografts were performed in our laboratory (484,485). After 
original subcutaneous transplantation of small tumor pieces (2 mm^) in both flanks 
of Balb-C nu/nu mice, the tumors were passaged every four weeks. Single cell 
suspensions were used for in vitro tests using a soft agar assay. Drugs were 
administered as a single application on day 1, colony formation was followed during 
four weeks in which growth was measured using temporal growth curves (377). A 
dose-dependent inhibition in colony formation was evident for all five tumor lines in 
single drug tests. In combination tests 1,500 IU IFN/ml and 3,000 IU TNF/ml were 
used. All combinations showed synergistic effects, except for the combination of 
alpha- and gamma-IFN in the NC-65 tumor which had sub-additive effects. The 
combinations of IFN and TNF showed the best in vitro antiproliferative effects. A 
heterogeneity towards the direct antiproliferative effects of cytokines in RCC was 
shown. 
Liu et al. performed in vitro studies using the PC3 prostatic cancer cell line 
and demonstrated antitumor effects of IFN-gamma and TNF monotherapy (486). 
TNF has synergistic effects in combination with the growth factor inhibitor suramin. 
The authors, however, did not test the effects of the combination of IFN-gamma 
and TNF. Up to now, no studies have been performed with the combination of IFN 
and TNF in prostatic cancer. 
Bahnson and Ratliff showed, in an in vitro study, that murine bladder tumor 
cells (MBT-2), 4 hours pretreated with IFN-gamma were more sensitive to TNF 
(460). Longer pre-incubation times (24 hours, 48 hours) did not enhance TNF 
mediated cytotoxic activity. IFN-gamma alone exhibited no antiproliferative activity 
toward these cells (460). 
2.6.2 In vivo studies 
IFN-gamma and TNF have synergistic effects in different syngeneic model 
systems; e.g. for melanoma (487,488), colon cancer (489), methylcholanthrene 
(MCA) induced sarcoma (490) and breast cancer (491). IFN-alpha induced 
synergistic effects in combination with TNF against a weakly immunogenic sarcoma 
model, MCA-106 (492). No improved antitumor effects, however, resulted from 
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therapy with any cytokine alone or in combination against the non-immunogenic 
MCA-102 sarcoma (492). 
Combination of IFN and TNF also revealed enhancement of their respective 
activities in nude mice. Human tumor xenografts of breast and bowel tumors (493), 
ovarian tumors (494) and melanoma (495) were sensitive targets for cytokine 
combination therapy. 
We have performed studies with eight human renal tumor xenografts, which 
were transplanted subcutaneously (s.c.) into nude mice (496). Of three tested routes 
of administration, intravenous, intraperitoneal and s.c, only the s.c. route was 
effective against tumor growth. IFN was given 3 times per week and TNF 3 or 5 
times per week in different concentrations. From initial results with the NC-65 
tumor 10 treatment regimens were chosen, alpha-IFN 0.5 and 5 ng/gram mouse, 
gamma-IFN 8 and 80 ng/gram and TNF 500 ng/gram were used and combinations 
of these cytokines in order to evaluate the effects in the other xenografts. 
Combinations of both alpha- and gamma-IFN with TNF resulted in a complete 
growth inhibition of most tumors. All tested RCC xenografts showed different 
sensitivities towards the cytokines, which may represent the heterogeneity of RCC. 
The IFN's showed to have optimum doses, which was sometimes a low dose, TNF 
antitumor effects were dose-dependent. The best antiproliferative effects were found 
when treatment was started 24 hours after tumor implantation, treatment starting at 
a tumor volume of 50 mnr showed no or slight growth inhibiting effects. 
Baisch et al. also showed that the combined treatment of IFN-alpha and 
TNF was more effective against a RCC xenograft than the single treatments (497). 
In contrast to the enhanced antiproliferative effects in vitro against the 
murine bladder tumor MBT-2, in vivo treatment with IFN-gamma and TNF did not 
provide additional benefit in comparison to TNF monotherapy (498). 
The mechanism of action of the synergism between IFN and TNF remains 
to be elucidated. Several studies showed that IFN-gamma can induce the number of 
TNF-receptors on the tumorcell surface (284,289,290). Aggarwall et al., found that 
IFN-alpha, -beta, and -gamma had synergistic cytotoxic effects in combination with 
TNF against the ME-180 cervical carcinoma cell line; TNF-receptor-induction, 
however, occurred only with IFN-gamma treatment and the authors therefore 
conclude that the induction of TNF-receptors by IFN is not a major mechanism for 
their synergistic cytotoxic effects (499). Furthermore, IFN-gamma induces the 
expression of the TNF-gene and the release of TNF (227,500). The DNA-
fragmenting activity of TNF is enhanced by IFN-gamma (501). Another mechanism 
of action could be the induction of IL-6, which was observed during IFN-gamma 
and TNF combination therapy, but not during treatment with either cytokine alone 
(502). 
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2.6.3. Clmìcal trials 
The number of clinical trials performed with IFN and TNF combination 
therapy is limited. Abbruzzesse et al. performed a phase I trial in patients with 
advanced gastro-intestmal cancer and observed suggestive antineoplastic activity in 
biliary and pancreatic cancer (503). 
In a phase II study, the efficacy and side effects of TNF 50 μg/πr i.m. and 
gamma-IFN 0.1 mg/m2 s.c, 3 times per week, in advanced, progressive RCC was 
studied (411). 21 patients have been included in this study, 13 males and 8 females. 
In 14 patients évaluable for response 1 CR and 3 MR have been found, 10 patients 
had progressive disease. Side effects included high fever, rigors, flu-like symptoms 
and anorexia in all patients. These preliminary data show a modest activity and a 
considerable toxicity for the combination of TNF and gamma-IFN in the treatment 
of RCC. 
Otto et al. evaluated in an phase I/II trial the toxicity and efficacy of TNF 
monotherapy and combination treatment with IFN-alpha2a in RCC (504) Patients 
received either TNF alone (n=7) with dose escalation from 20 to 300 /ig/m" iv , 5 
times per week, or IFN-dlpha2a alone 12 χ IO6 lU ι m. 3 times per week, every 
week (n=4), or the combination of both regimens (n=5). No objective responses 
were found in any schedule. Toxicity included fever, chills, flu-like symptoms, nausea, 
vomiting, malaise, anorexia, hepato- and myelotoxicity The MTD was between 120 
and 300 /ig/m2 for TNF. In a phase II study with the combination of TNF 160 
μg/m2, 5 times per week, every third week and IFN-alpha2a, 18 χ 10o lU, 3 times 
per week every week, 18 patients were included. 14 of these patients are évaluable 
for response up to now. 2 CR, 4 PR (43% objective responses) and 6 SD were 
found They conclude that combination treatment of alpha-IFN and TNF is a 
tolerable treatment for RCC patients. The follow-up in this study is relatively short, 
and these positive effects need to be confirmed by others. 
41 
3. SCOPE OF THE THESIS 
In the studies presented in this thesis we have investigated the antitumor 
effects of IFN and/or TNF against renal, bladder or prostatic tumors in different in 
vitro and in vivo model systems. 
The treatment of choice for localized RCC is surgery. However, nearly 40 to 
50% of patients have metastatic disease at time of presentation and will die from 
their cancer. The median survival of patients with metastatic RCC is approximately 
12 months; survival at 2 years is less than 10% (505). As in other types of advanced 
cancers, therapy of disseminated RCC has been based on the three traditional 
approaches: surgery, chemotherapy and radiotherapy. None of these have 
significantly improved patient survival. The observation that spontaneous remissions 
occur in approximately 0.8% of patients with RCC has led to the concept that the 
disappearance of distant metastases without therapy may be due to rejection by the 
immune system (506). This generated interest in the use of immunotherapeutic 
modalities such as cytokines. IFN is the agent most widely used in the treatment of 
RCC (section 2.4.1), however, many questions regarding the route of administration, 
treatment schedules and dosages remain unanswered. The number of (pre)clinical 
studies using TNF in RCC is limited. Some studies using nude mice showed 
promising results with IFN/TNF combination treatment (496,497). In chapter Π we 
describe the antiproliferative effects of IFN and TNF mono- and combination 
therapy and the importance of tumor volume at start of therapy on tumor growth of 
a rat renal cell tumor. Next to cytokine combination therapy, we have tested the 
growth-inhibiting effects of TNF in combination with radiotherapy on rat renal cell 
tumor spheroids (chapter III). The antitumor effects of the combination of TNF 
with chemotherapeutical agents directed against DNA-topoisomerase II on in vitro 
and in vivo growth of this rat renal cell tumor, are described in chapter IV. 
Hormonal therapy is for almost 50 years, since the pioneering efforts of 
Huggins and Hodges, the major treatment modality for prostatic cancer (507). 
Unfortunately, almost all of these patients will relapse to a state unresponsive for 
further anti-androgenic therapy or chemotherapy. Therefore, new treatment 
modalities are urgently needed. In chapter V we describe the antitumor effects of 
IFN and TNF mono- and combination therapy against in vitro and in vivo tumor 
growth of androgen-dependent and -independently growing rat prostatic tumors. 
Since IFN and TNF combination therapy has not been tested against human tumors 
we have also performed studies in the nude mouse model system against two human 
androgen-independently growing xenografts (chapter VI). 
In chapters II-V we have used spontaneously arisen serially transplantable 
rat renal- or prostatic tumors. For TCC few spontaneous tumor models are available 
(section 1.3.3). In chapter П we describe the establishment and characterization of 
two independently arisen rat bladder tumor (RBT) lines, representing the 
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progression of bladder cancer from slow growing, non-metastasizing tumors to 
rapidly growing, metastasizing tumors. This model system may be helpful in the 
identification of specific markers associated with the progression of bladder cancer. 
TCC has already been shown to be effectively treated by non-specific 
immunotherapeutical agents such as BCG. This treatment, however, has been 
associated with local and/or systemic side effects. Intravesical treatment with IFN 
also showed clinical effectivity, but without side effects (section 2.4.3, Table II). The 
number of experimental studies using TNF is limited (section 2.5). We, therefore, 
used the RBT model to test the antitumor effects of IFN and TNF mono- or 
combination therapy against TCC (chapter VIII). 
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ABSTRACT 
We have investigated the antiproliferative activities of recombinant rat-
gamma-Interferon and recombinant human Tumor Necrosis Factor alpha in a rat 
renal cell carcinoma model system. The tumor was transplanted subcutaneously, the 
drugs were administered peritumorally. Gamma-Interferon treatment starting two 
days after tumor implantation resulted in a dose-dependent growth inhibiting effect. 
Tumor Necrosis Factor alpha was only effective at the highest concentration. 
Different combinations of the drugs have additive or synergistic antiproliferative 
effects. The combination of both highest doses completely inhibited tumor growth 
without any obvious toxic effects on the rats. Rechallenge of the cured rats with a 
tumor piece in the contralateral flank did not result in a tumor specific immune 
response. Shortening of the treatment period to two weeks resulted in an increased 
lag-period, but finally all tumors started to grow. Furthermore, the anti-tumor effect 
was dependent on tumor volume at start of therapy. Monotherapy could not inhibit 
tumor growth of an established tumor. The combination with both highest doses, 
however, inhibited tumor growth even when treatment was started at a tumor 
volume of two to five cnv*. 
Treatment with gamma-Interferon and Tumor Necrosis Factor is most 
effective at low tumor burden. These studies suggest that clinical application of 
these drugs is most effective in an adjuvant setting. 
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INTRODUCTION 
Advanced carcinoma of the kidney is refractory to nearly all forms of 
systemic therapy. Hormonal therapy can result in a small proportion (0-10%) of 
objective responses, but these are incomplete and of short duration. Single or 
combination chemotherapy also gives no clearly definable improvement in patient 
survival. 
Immunotherapy is a relatively new approach in cancer therapy. Biological 
Response Modifiers (BRMs) like interferons, tumor necrosis factor and interleukins 
show promising results in experimental model systems and in Phase I and II clinical 
trials7'2"5. The efficacy of interferon (IFN) monotherapy in renal cell carcinoma 
(RCC) has recently been reviewed4 and is associated with clinical responses in 
approximately 15% of patients. Combination therapy with alpha- and gamma-IFN 
can result in even higher response rates5. Lymphocyte activated killer cells combined 
with interleukin 26 and tumor infiltrating lymphocytes7 also appear to be very 
promising immunotherapeutic options. 
Gamma-IFN is a product of activated T-lymphocytes and has pleiotropic 
effects*. For example, it can directly inhibit the growth of tumor cells in vitro, alter 
the expression of surface antigens and stimulate NK-cells and macrophages. 
Tumor necrosis factor alpha (TNF), originally identified as a substance 
produced by macrophages exposed to endotoxin, possesses a number of biological 
activities, particularly anti-tumor activity. TNF causes cytostasis or cytolysis of in 
vitro cell cultures from a variety of animal and human malignant tumors . However, 
TNF can stimulate the in vitro growth of normal cells and induce procoagulant 
activity in endothelial cells and thrombus formation70, which has been suggested as 
an indirect tumoricidal effect. In vitro studies on human renal cell xenografts showed 
that TNF has direct antiproliferative effects on RCC . Furthermore, in vivo studies 
using murine models, showed that TNF had anti-tumor effects at high doses12·13. 
Combinations of gamma-IFN and TNF can result in the enhancement of 
their respective anti-tumor activities thus providing an even more promising 
therapeutic approach, that up to now has not been tested for RCC in syngeneic 
model systems in vivo. Even though phase I and II trials indicate that TNF or 
gamma-IFN treatment is feasible2"5, many questions regarding the mode of action 
(i.e. direct cytotoxic effect vs. indirect immune system mediated effects), the route of 
administration, treatment schedules and dosages remain hitherto unanswered. 
Therefore, more basic studies in experimental animals may provide guidelines for 
the optimal use of BRMs in humans. 
In the studies described here, we tested the antiproliferative effects of 
gamma-IFN and TNF in a syngeneic tumor model system, a spontaneously arisen 
rat renal cell carcinoma. Histologically and biochemically the tumor closely 
resembles human RCC16·17. 
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Both the direct antiproliferative and immunomodulatory activities of gamma-
IFN are species specific. Human gamma-IFN is active in human and not in 
syngeneic mouse systems and vice versai8. Therefore we have used rat-gamma-IFN 
in our rat renal cell tumor model system, this rat-gamma-IFN showed no antiviral 
activity with mouse or human cells, both sensitive to their homologous interferon, 
but rat cells could be protected against both vesicular stomatitis virus and vaccinia 
v i i W . In contrast to gamma-IFN, TNF shows little species specificity. Murine and 
human TNF are 79% homologous at the amino acid level and only the murine 
natural TNF is a glycoprotein20. The in vitro activities of murine and human TNF 
were compared, and only a very limited degree of species specificity was found20. 
Also in vivo the species preference is not as pronounced as in the case with the 
interferons27. Both murine and human TNF showed synergistic antiproliferative 
effects with murine gamma-IFN in a mouse model system^. 
The importance of tumor volume at start of therapy was evaluated, and the 
implications of these findings for clinical use of these BRMs are discussed. 
MATERIALS AND METHODS 
Animals 
Adult male Lewis rats (Charles River Wiga GmbH, Sulzfeld, FRG) were 
kept 3 rats per cage with a regimen of 12 hours light per day. The animals were 
allowed access to RMH-TM food (Hope Farms BV., Woerden, The Netherlands) 
and water ad libitum. 
Tumor Line 
The rat renal cell tumor line was kindly provided by Dr. R. Babayan, 
Boston, MA. The tumor was maintained by serial subcutaneous transplantation. For 
our experiments, the tumor was excised from a tumor-bearing animal, and after 
removal of normal and necrotic tissue, the tumor tissue was cut into pieces of 50 
mg (46-53 mg). The precise weight of each tumor piece was measured on 
preweighed sterile gauzes on a laboratory scale (Mettler). An 0.5 cm incision was 
made in the right flank of recipient animals, and after separating the subcutaneous 
tissue by blunt dissection, the tumor fragment was placed subcutaneously (s.c). The 
incision was closed using skin clips (7.5 χ 1.75 mm, Aesculap, Germany). In this way 
a tumor take of 100% was achieved. The tumor did not metastasize from this site. 
After complete removal of subcutaneous tumors of 2-3 cm together with 
overlying skin and subcutaneous fat, no tumors recurred. A direct rechallenge with 
50 mg tumor pieces in the contralateral flank did not cause any changes in tumor 
take or growth rate in 14 untreated rats, suggesting that this tumor is not 
immunogenic. 
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Drugs 
Recombinant human TNF alpha was kindly provided by Boehringer 
Ingelheim (Alkmaar, The Netherlands). The specific activity of TNF determined in 
the presence of Actinomycin D was 6 χ 10 Units/mg protein as determined in the 
L·929 cytotoxicity assay. The purity was >99% as determmed by SDS 
Polyacrylamide gel electrophoresis and it contained less than 1.0 ng endotoxin per 
mg protein based on the limulus amoebocyte assay. The original TNF solution was 
diluted with RPMI 1640 culture medium (Gibco, Paisley, UK) to a final 
concentration of two, 20, or 200 μg per ml, divided in aliquots and stored at -20* C. 
Recombinant rat gamma-IFN was produced by a chinese hamster ovary 
(CHO) cell line transformed with a plasitìid carrying the chromosomal gene for rat 
gamma-IFN and purified as described previously22. The cytopathic effect reduction 
assay was used for estimating gamma-IFN activity. Ratee cells^ (a continuous rat 
embryonic cell line) were incubated with gamma-IFN for 18 hours before they were 
challenged with vesicular stomatitis virus to determine the cytopathic effect. Because 
no internationally accepted reference standard for rat interferon is available, all 
titers were determined by comparison with a laboratory standard preparation of 
gamma-IFN (one mg pure rat gamma-IFN corresponds with 7 χ IO6 Units). After 
purification by monoclonal antibody affinity chromatography gamma-IFN was freeze-
dried for longtime storage. It was reconstituted with Milli-Q to a final concentration 
of 16,000 or 160,000 Units per ml, divided in aliquots and stored at -80° С until use. 
Treatments and monitoring 
Gamma-IFN and TNF were administered s.c, peritumorally, 3 and 5 times 
per week respectively, in a 0.5 ml injection volume. Phosphate buffered saline (PBS) 
was used for the control group. Treatment started two days after tumor implantation 
or at a tumor volume of 0.2-0.5, one or two to five cm^ and was continued until the 
tumors in the control group reached a volume of 10 cm . However, in the 
experiments with shorter treatment periods, two weeks of treatment or a single 
administration was given. All experiments were carried out in duplicate. 
Tumor growth was followed by measurements of tumor size according to the 
method of Janik et a\.23 by the same measurer throughout each experiment. Three 
times per week length (I), width (w) and height (h) were measured using a slide 
caliper. No correction was made for skin thickness. The tumor volume (V) was 
calculated from the formula 
V = 0.5236 χ 1 χ w χ h. 
Statistical analysis 
For each rat, the tumor volume was estimated 6 weeks after tumor 
implantation (i.e. time when control group reaches volume of 10 enr*) by log linear 
regression on the tumor volumes throughout this period. Two-sided t-tests were used 
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to compare the final volumes of the treatment versus the control groups and to test 
for additive effects in the combination treatments. Ρ < 0.05 is considered as 
statistically significant. 6 animals were included in each group. 
The effect of treatment A is defined as EA = Vcon(ro//V4 and the effect of 
treatment В as EB = V^^/V^, where V^, Vg, and УсоШп^ are the estimates for 
the tumor volumes of treatment A, В or control group respectively. Additivity is 
defined2* as Έ.
Α+Β = Έ.Α χ E B (i.e. log E.A+B = log EA + log EB). A combination 
of two treatments is synergistic when the effect of the combination (EA+B) is 
greater than the product of the effects of the separate treatments. 
RESULTS 
To study the in vivo anti-tumor effects of gamma-IFN and TNF, we used a 
spontaneously arisen, syngeneic transplantable rat renal cell tumor l i n e ^ 7 . 
Single agent therapy. 
Pilot-studies in which we evaluated the influence of administration route on 
anti-tumor effect showed that i.p. and i.v. injected BRMs were less effective than s.c. 
injections. Similar observations were made in other rodent model systems25. 
Therefore, we injected gamma-IFN and TNF s.c, peritumorally, in the experiments 
described. 
Gamma-IFN monotherapy (fig. 1A) was started 2 days after tumor 
implantation. Under these conditions gamma-IFN has an antiproliferative effect 
whereby the highest dose results in the strongest growth inhibiting effect, suggesting 
a dose-dependent response (40,000 U gamma-IFN, s.c, 3 times per week gave 
intermediate effects, data not shown). 
When TNF was used as single agent only the highest dose (i.e. 100 μg TNF 
per rat per day) produces a significant anti-tumor effect (fig. IB). 
In both series of experiments using single agent therapy it appeared that 
after termination of therapy, the tumor regained its original growth potential (i.e. 
same volume doubling time, data not shown). 
Combination therapy 
Reasoning that gamma-IFN and TNF can have additive or synergistic 
effects, we combined 8,000 or 80,000 U gamma-IFN with 10 or 100 Mg TNF (fig. 2). 
The combination of 8,000 U gamma-IFN and 10 Mg TNF had an additive growth 
inhibiting effect. A tenfold increase of the TNF dose did not improve the anti-tumor 
effect. 
Combinations with the highest dose of gamma-IFN produced the best 
effects. In the group treated with the combination 80,000 U gamma-IFN and 10 Mg 
TNF, only 2 out of 6 rats developed a tumor (Table I). Moreover, tumor growth 
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Figure 1. Effect of single agent therapy started 48 hours after tumor implantation. 
A: Gamma-IFN monotherapy administered s.c, peritumorally, 3 times per week. 4—4 control, Q-Q 
8,000 U gamma-IFN (p = 0.05) and · - · 80,000 U gamma-IFN (p < 0.001). 
B: TNF monotherapy, s.c, peritumorally, S times per week. 4—4 control, Q—Q 1 μg TNF (n.s.), t - t 
10 μ£ TNF (n.s.) and 0 — 0 100 μg TNF (ρ = 0.02), ns. = not significant 
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Figure 2. Combination therapy with gamma-IFN and TNF, 3 times and S times per week 
respectively. Treatment started 48 hours after tumor implantation. •—• control, Q-Q 8,000 U 
gamma-IFN and 10 μg TNF (ρ = 0.002), · - · 8,000 U gamma-IFN and 100 pg TNF (ρ = 0.03), 
φ—О 80,000 U gamma-IFN and 10 μg TNF (ρ < 0.001). With the combination 80,000 U gamma-
IFN and 100 Mg TNF no tumors developed at all. 
Table I 
IFNa 
0 
8,000 
80,000 
0 
0 
0 
8,000 
8,000 
80,000 
80,000 
Treatment 
TNF* 
0 
0 
0 
1 
10 
100 
10 
100 
10 
100 
Bodyweightc 
day 0 
365 (28) 
359 (26) 
373 (20) 
375 (12) 
359 (14) 
356 (14) 
373 (27) 
352 (22) 
364 (21) 
352 (21) 
Bodyweight 
day 42 
431 (33) 
414 (13) 
ND 
431 (17) 
415 (17) 
415 (25) 
424 (34) 
420 (38) 
422 (24) 
414 (18) 
Increase'' 
6 5 ( 8 ) 
5 5 ( 7 ) 
5 6 ( 7 ) 
5 6 ( 7 ) 
59 (15) 
5 1 ( 8 ) 
68(18) 
57 (12) 
58 (11) 
Cure/ 
0/6 
0/6 
0/6 
0/6 
0/6 
0/6 
0/6 
0/6 
4/6 
6/6 
units rat-gamma-IFN per rat, 3 times per week 
micrograms TNF per rat, 5 times per week 
weight in grains, standard deviation in parentheses 
weight increase in grams, standard deviation in parentheses 
not determined 
number of rats tumor free for more than 200 days/total number of rats per group 
Table I. Effect of s.c. peritumoral administration of recombinant rat-gamma-IFN and recombinant human 
TNF on bodyweight and number of cured male Lewis rats. Data of a representative experiment. 
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started 35 days later than the control group (lag-period of 35 days). Significantly, at this 
dose of 80,000 U gamma-IFN with a tenfold increase of the TNF concentration to 100 
ßg no tumors developed at all. Both combinations have synergistic effects (p < 0.001). 
Because 200 days after tumor implantation no tumors were found, these rats were 
considered cured. 
Effect of duration of therapy 
Having found a drug combination that could prevent tumor formation 
completely, we sought to gain more insight regarding the administration scheme. Since in 
clinical trials^"* treatment is usually given intermittently for 1 or 2 weeks for reasons of 
toxicity, we tested the effectiveness on tumor growth of shorter periods of treatment. 
We, therefore, treated the animals with the optimal drug combination 80,000 U gamma-
IFN and 100 μg TNF for one day or for two weeks starting 48 hours after tumor 
implantation (fig. 3). A single administration of the combination already gave a clear 
growth inhibition. When treatment was continued for two weeks, tumors started to grow 
21-58 days later than the control group (lag-period). However, all rats developed a 
tumor. 
Figure 3 
DAYS 
Figure 3. Effects of shorter duration of therapy with the optimal drug combination 80,000 U gamma-IFN 
and 100 μg TNF. Treatment started 48 hours after tumor implantation. 4—4 control, Q—Q a single 
administration (p = 0.001) and · - · two weeks treatment (p = 0.002). 
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Treatment does not induce immunity 
To determine whether BRM therapy using the combination 80,000 U gamma-
IFN and 100 μg TNF can induce specific immunity, as observed by Palladino et al26, we 
rechallenged 6 cured rats with a subcutaneous tumor. 200 days after tumor implantation 
and subsequent treatment a new tumor piece of SO mg was implanted in the 
contralateral (left) flank. All rats developed a tumor which started to grow without a 
lag-period and with a normal growth rate. 
The influence of tumor volume at start of therapy 
The first series of experiments revealed that gamma-IFN and TNF therapy can 
inhibit tumor growth completely. Whether this therapy is effective in provoking the 
regression of larger tumors was studied by starting therapy at different tumor volumes. 
Monotherapy started at a tumor volume of 0.2-0.5 cm3 had no effect on tumor 
growth (fig. 4A). 
The most effective BRM combinations as established in the low tumor load 
studies, were tested for their antiproliferative efficacy when treatment was started at 
higher tumor loads. The combination with 10 ng TNF had no antiproliferative effects 
(fig. 4B). The combination with 100 /ig TNF, however, slowed down tumor growth 
significantly (fig. 4C). Even when tumors reached a size of two to five cm , growth rate 
could be inhibited almost completely. However, no regression of tumor size could be 
provoked. After completion of therapy all tumors started to grow again with the same 
volume doubling time. 
Figure 4 
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Figure 4. The influence of tumor volume at start of therapy. Gamma-IFN 3 times and TNF 5 times per 
week, s.c, peritumorally. 
A: Monotherapy started at tumor volume of 0.2-0.5 cm3. •—• control, Q—Q 8,000 U gamma-IFN (n.s.), 
*-* 80,000 U gamma-IFN (n.s.), O-O 10 μg TNF (n.s.) and | - | 100 μg TNF (n.s.). 
B: Combination therapy with combination of 80,000 U gamma-IFN and 100 Mg TNF. •—• control, Q—Q 
start treatment at 0.2-0.5 cm3 (n.s.) and · - · start treatment at 1 cm3 (n.s.). 
C: Combination therapy with combination of 80,000 U gamma-IFN and 100 μ в TNF. •--• control, 
О—О sun treatment at 0.2-0.5 cm3 (p = 0.005), »-4 start treatment at 1 cm* (p= 0.003) and Q-Q Stan 
at 2-5 cm3 (p = 0.001). 
n.s. = not significant 
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Side effects of therapy 
No obvious side effects were seen at any dose of gamma-IFN or TNF alone or 
in combination. No rats showed any signs of lethargy or wasting. At the end of the 
treatment period all rats were weighed and all groups had gained weight within the 
same range as shown in Table I. 
DISCUSSION 
Chemotherapy and radiotherapy have limited therapeutic efficacy in advanced 
renal cell carcinoma. Therefore, new treatment modalities must be developed. Previous 
in vitro studies have shown that Biological Response Modifiers such as gamma-IFN and 
TNF have antiproliferative effects on renal cell carcinoma^. In the studies presented 
here, we investigated the antiproliferative effects of these BRMs in a non-immunogenic 
animal model system. 
Gamma-IFN monotherapy showed a better effect with increasing doses. These 
results suggest a dose-dependent relationship between gamma-IFN dose and tumor 
growth inhibition. Similar observations were made by Gresser27 with mouse alpha/beta-
IFN in a syngeneic Friend Leukemia tumor model system. Talmadge^5, however, showed 
that 50,000 U of mouse gamma-IFN 3 times per week was highly effective, whereas 
100,000 U of this IFN had no therapeutic effectivity, suggesting a bell-shaped dose-
response curve, i.e. a dose-optimum. It cannot be excluded that higher doses of gamma-
IFN in our model system will also have less efficacy on tumor growth. TNF 
monotherapy was only effective with the highest dose of 100 дg. This indicates that TNF 
monotherapy will have very limited clinical potential, which is already apparent from 
phase I trials^. 
The combination of 8,000 U gamma-IFN and 10 or 100 μg TNF has additive 
effects, whereas combinations of 80,000 U gamma-IFN with 10 or 100 μg TNF have 
clearly synergistic antiproliferative effects (p<0.001). Animals in which no tumor growth 
was evident after 6 weeks of treatment, remained more than 200 days tumor free and 
were considered cured. In different rodent model systems, this combination has also 
been shown to be effective against other solid tumors, such as breast, bowel and lung 
carcinomas and melanomas*2"^. 
Having found a drug combination that can prevent tumor formation completely 
after 6 weeks of treatment, we shortened the treatment period in a separate experiment. 
A single administration of a combination of 80,000 U gamma-IFN and 100 ng TNF 
resulted in a significant growth inhibition, but no lag-period was observed. Two weeks of 
treatment, however, prolonged the lag-period by at least 21 days. It is, therefore, 
conceivable that intermittent therapy, i.e. two weeks treatment, two weeks no treatment, 
can be sufficient for anti-tumor therapy. 
Palladino et al.2 6 found that TNF treatment of Meth A sarcoma bearing mice 
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resulted in the establishment of a tumor specific immunity. Mice which had rejected a 
s.c. Meth A sarcoma were immune to rechallenge with a lethal dose of this tumor 35 
days after initial challenge. In contrast, specific immunity did not develop after alpha-
IFN treatment of the intraperitoneally growing L1210 tumor2*. Similarly, no specific 
immunity was found in our model system. Rechallenge 200 days after initial tumor 
implantation had no influence on tumor take or growth rate. Under these experimental 
conditions no specific immune response was induced by gamma-IFN and TNF treatment 
which suggests that a direct anti-tumor mechanism and/or macrophage and NK cell 
mediated tumor cell lysis are responsible for the growth inhibition. However, it cannot 
be excluded that the cytokines can induce tumor associated antigens necessary for a 
specific immune response. Further studies are needed to elucidate the working 
mechanisms of these BRMs. 
In most clinical trials BRM treatment is started when the patient has proven 
(progressive) metastatic disease. The patient has a high tumor load even when a tumor 
nephrectomy has been performed. Therefore, we investigated the effect of gamma-IFN 
and TNF on higher tumor loads. Starting therapy 15 days after tumor implantation at a 
tumor volume of 0.2-0.5 cc, gamma-IFN or TNF monotherapies were not effective on 
even the smallest tumors. This is in good agreement with the limited efficacy of IFN 
monotherapy observed in clinical trials^. 
The combination of 80,000 U gamma-IFN and 10 μg TNF, which was very 
effective when treatment was started 48 hours after tumor implantation did not inhibit 
tumor growth when started at higher tumor volumes, however the combination of the 
highest doses of gamma-IFN and TNF significantly slowed down tumor growth, but did 
not provoke tumor regressions. Similar observations of the influence of tumor volume at 
start of therapy were elegantly shown for experimental prostatic carcinoma29. These 
experiments clearly demonstrated the need to carry out tumor debulking and adjuvant 
chemotherapy as early as possible in order to minimize the total tumor load and to 
maximize the possibility of cure. 
Pilot studies showed that peritumoral injections were more effective than i.p. or 
i.v. treatment in our model system. In clinical trials, however, treatment is usually given 
systemically unequivocally resulting in lower local drug levels. Reasoning that the 
smallest tumors were most sensitive to low BRM doses (fig. 2 compared with figs. 4A 
and 4B), we might argue that patients with RCC should be treated as early as possible, 
as in the case of localized disease, starting with therapy immediately after nephrectomy. 
Due to the unpredictable clinical course of this disease a significant number of patients 
with stage I RCC would be overtreated which is clearly unacceptable. In addition to this 
therapy it is, therefore, of major importance that new diagnostic tools are developed that 
help us to find patients with a poor prognosis (i.e. patients at risk). Awaiting these new 
diagnostic tools a randomized clinical trial could be started comparing surgery alone vs. 
surgery plus adjuvant IFN and TNF in patients with locally advanced RCC and/or with 
micrometastases in the regional lymphnodes (stage II and III). 
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ABSTRACT 
We have investigated the antiproliferative effects of Tumor Necrosis Factor 
Alpha (TNF) and radiation on a recently described rat renal cell tumor line grown 
as multicellular tumor spheroids (MTS). Treatment commenced when the spheroids 
had reached a diameter of 250 μτη. TNF was diluted in the tissue culture medium in 
different concentrations, ranging from 250-1000 ng/ml. TNF monotherapy had a 
dose-dependent inhibiting effect on spheroid growth. Single-dose irradiation with 2, 4 
or 6 Gy also retarded spheroids signififcantly in their growth. In the combination 
treatment the highest dose of TNF (1000 ng/ml) was added 4 hours prior to 
radiation. TNF could not induce a potentiation of the radiation injury at 2 Gy. The 
combination with 4 Gy, however, had additive-, and the combination with 6 Gy 
synergistic antiproliferative effects; in these treatment regimens respectively 2 and 5 
out of 24 spheroids were controlled, i.e. cured. These experiments suggest that TNF 
in combination with radiotherapy may be beneficial for the treatment of renal cell 
carcinoma or cancer in general. 
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INTRODUCTION 
There are currently no effective standard treatments for renal cell carcinoma 
(RCC). Hormonal therapy can result in a small proportion (0-10%) of objective 
responses, but these are incomplete and of short duration. Single or combination 
chemotherapy also gives no clearly definable improvement in patient survival (1). 
Immunotherapy is a relatively new approach in cancer therapy. Today, 
interferons (IFN) are the most extensively studied Biological Response Modifiers 
(BRMs) in metastatic RCC. Numerous studies with natural and recombinant IFN-
alpha have been conducted with an overall objective response of 15% (2). 
Tumor Necrosis Factor Alpha (TNF), first described by Carswell and 
associates as an antitumor substance in the serum of mice treated sequentially with 
BCG and endotoxin (3), is a cytokine with a number of biological activities (4), 
particularly anti-tumor activity. In vitro and in vivo studies using RCC xenografts 
showed antiproliferative effects of TNF monotherapy and synergistic growth-
inhibitory effects when combined with IFN (5,6,7). In a rat renal cell tumor model 
system TNF had a dose-dependent anti-tumor effect when treatment started 48 
hours after tumor implantation, combination treatment with gamma-IFN inhibited 
tumor growth completely. TNF monotherapy, however, was not effective against an 
established tumor, i.e. when treatment started 15 days after tumorimplantation (8). 
Studies using BRMs in combination with radiotherapy are rare. The 
combination of Interleukin-2 with Tumor Infiltrating Lymphocytes and radiotherapy 
produced synergistic effects against murine sarcomas (9). TNF augmented the 
radioresponse of a murine mammary carcinoma in vivo but not in vitro (10,11). 
These studies indicate that combination of immunotherapy and external beam 
irradiation can be useful in cancer treatment. 
Multicellular tumor spheroids (MTS) are an in vitro model of intermediate 
complexity between tumors in vivo and conventional in vitro culture systems. MTS 
represent small avascular tumors or metastases (12,13,14). MTS in tissue culture 
have almost spherical geometry, with an outer layer mainly consisting of dividing 
cells and an intermediate layer of resting cells. After a certain diameter, different in 
each type of spheroids, has been reached, necrotic regions develop in the centre. In 
the present study we report on the responses to treatment of rat renal tumor 
spheroids with TNF or radiotherapy and their combinations. 
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MATERIAL AND METHODS 
Tumor cells 
The HM carcinoma cell line is derived from a spontaneously arisen rat renal 
cell tumor (15,16). Cells were maintained in complete medium consisting of RPMI 
1640 culture medium supplemented with 10% foetal calf serum, 2mM L-glutamine, 
100 lU/ml penicillin, 100 ßg/ml streptomycin (GIBCO Ltd, Paisley, Scotland), 250 
nM dexamethasone and 20 mM HEPES (N-2-Hydroxyethylpiperazine-N'-2-
ethanesulfonic acid) (Sigma, St. Louis, MO, USA). Stock cultures of the cells were 
maintained in monolayer culture at 37 С in 6% COj in air with 100% humidity. 
Spheroids 
The methods of producing spheroids have been described elsewhere (17). In 
short: single cell suspensions were obtained by trypsinizing exponential monolayer 
cultures and inoculating 1 χ IO5 cells into 60 mm Petri-dishes (Nunc AS, Kastrup, 
Denmark) coated with 1% agarose (BDH Chemicals Ltd, Poole, England) to 
prevent attachment to the dishes. After four days of incubation, small spheroids (200 
μνη) could be harvested and were transferred to individual wells of 24-wells test 
plates (Costar, Cambridge, MA, USA) coated with 1% agarose. Plates were 
incubated as above with weekly changes of medium. 
TNF-treatment 
Recombinant human TNF was generously supplied by Boehringer Ingelheim 
(Alkmaar, The Netherlands). The specific activity of TNF determined in the 
presence of Actinomycin D was 6 χ IO7 Units/mg protein as determined in the L-
929 cytotoxicity assay. The purity was >99% as determined by SDS Polyacrylamide 
gel electrophoresis and it contained less than 1.0 ng endotoxin per mg. protein 
based on the limulus amoebocyte assay. The original TNF solution was diluted with 
RPMI 1640 culture medium to a final concentration of 50.000 ng/ml, divided in 
aliquots and stored at -80 C. Treatment started when spheroids reached a diameter 
of 250 μιη. Immediately prior to use the TNF solution was further diluted with 
complete RPMI 1640 culture to final concentrations of 250, 500 and 1000 ng/ml. 
Each well contained 1 ml medium and was changed biweekly. Control spheroids 
received complete medium only. 
Irradiation 
Spheroids were irradiated at a diameter of 250 μιη using a 18 MV photon 
beam from a Saturne linear accelerator (CGR, Bue, France) at a dose-rate of 2 
Gy/min, with a wax build-up to ensure homogeneous energy deposition within each 
well. Radiation was applied as a single dose. Control plates were removed from the 
incubator for the same period of time (20-40 min). In the combined treatment 
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modality studies, the TNF containing medium was given 4 hours before irradiation. 
Spheroids were irradiated with the drug in the medium. 
Treatment responses 
The growth of spheroids on test plates was determined by measurement of 
diameters of individual spheroids using a calibrated scale in the eye-piece of an 
inverted microscope two times per week. Assuming spherical geometry, volumes 
were calculated and growth curves constructed by plotting the ratio log 
(volume/initial volume) as a function of time after treatment. Growth delay (GD) 
was estimated from the difference in time required for non-treated and treated 
spheroids to reach a volume of five times the original volume. To correct for 
possible differences in growth rate, the specific growth delay (SGD) was calculated 
as: SGD = GD/V^ where V ,^ is the volume doubling time of untreated control 
spheroids. 
RESULTS 
Spheroids of a rat renal cell tumor line grown in vitro, were used to test the 
direct antitumor effects of TNF and/or radiation. 
Antitumor activity of TNF monotherapy 
Spheroids of 250 μπι diameter were incubated with increasing doses of TNF 
(250-1000 ng/ml culture medium). Freshly diluted TNF in complete medium was 
changed twice weekly. TNF monotherapy was started at day 0. To evaluate the 
effectiveness of different treatments the difference in time to reach a size 5 times 
the initial volume was measured, i.e. growth delay (GD). To compare results 
between different experiments the specific growth delay (SGD) was calculated by 
dividing GD with the volume doubling time of the respective untreated growth 
control. Under the experimental conditions described, TNF has an antiproliferative 
effect with the highest dose resulting in the strongest growth inhibition, indicating a 
dose-dependent response (figure 1). SGD increased from 1.4 with the lowest dose to 
3.5 with the highest dose of TNF (table I). 
Effects of radiation alone 
To see whether radiation alone could inhibit spheroid growth, we exposed 
spheroids to graded doses (2-6 Gy) of radiation (fig. 2). Irradiation produced 
retardation of growth, for varying time periods, depending on the radiation dose. 
The curves for the 2 and 4 Gy treated groups showed identical effects on day 4. 
The effect for 4 Gy treated spheroids increased until day 7, after which growth was 
resumed at a doubling time comparable to the 2 Gy treated and the control group. 
The growth inhibitoiy effect after 6 Gy was significantly higher than in the 2 and 4 
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Gy treated groups. This effect was already evident at day 4, and persisted until day 
12, when growth was resumed at approximately control rate. The lateral 
displacement (growth delay) of the growth curves after irradiation is not linear 
proportional to the dose, suggestive of a non-linear dose-response relationship. 
Figure 1 
too 
Relative volume 
Time (day) 
Figure 1. Effect of TNF monotherapy on spheroid growth. The Y-axis represents the relative volume 
plotted on a logarithmic scale as log (volume/initial volume). Each point represents the average 
volumes of at least ten spheroids. Bars represent standard errors. · - · , control, 0-0, 250 ng/ml TNF, 
500 ng/ml, Q-Q, 1000 ng/ml. 
Table I. Specific growth delay (SGD) in HM spheroids induced by different 
treatments 
Treatment 
TNF 
TNF 
TNF 
radiation 
radiation 
radiation 
combination 
combination 
combination 
Dose 
250 ng/ml 
500 ng/ml 
1000 ng/ml 
2Gy 
4Gy 
6Gy 
TNF 1000 
TNF 1000 
TNF 1000 
ng/ml 
ng/ml 
ng/ml 
+ 2 
+ 4 
+ 6 
Gy 
Gy 
Gy 
S.G.D. ± SD / 
1.4 
1.9 
3.5 
1.3 
1.8 
5.2 
3.4 
5.2 
12.4 
± 0.3 
± 0.5 
± 0.5 
± 0.2 
± 0.4 
± 0.5 
± 0.3 
± 0.5 
± 0.7 
'SD means standard deviation 
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Figure 3 
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Figure 3. Growth curves for spheroids treated with the combination of 1000 ng/ml TNF and 
radiation. Spheroids that regressed completely following treatment were not included in the curves. 
The Y- axis represents the relative volume plotted on a logarithmic scale as log (volume/initial 
volume). Each point represents the average volumes of at least 19 spheroids. Bars represent standard 
errors. ·-·, control, | - | , 1000 ng/ml TNF monotherapy, Q-fl, TNF + 2 Gy, 0-0, TNF + 4 Gy, 
<>-0, TNF + 6 Gy. 
DISCUSSION 
Advanced RCC is generally resistant to medical treatment. Neither chemo-
nor hormonal therapy have improved patient survival, therefore new treatment 
modalities must be developed. BRMs, like IFNs and interleukins, showed promising 
results in phase I and II studies (19,20). Phase I studies indicated that TNF 
treatment is feasible (21). If TNF will be used in cancer treatment, it is likely to be 
used in combination treatments, e.g. in combination with IFNs (22). In the present 
study we tested whether TNF might improve tumor radioresponse. 
We used multicellular tumor spheroids (MTS), a three-dimensional in vitro 
tumor model, that resembles the in vivo tumor situation more closely than 
conventional monolayers do. Mueller-Klieser already suggested that TNF should be 
tested in the spheroid system (13), but to our best knowledge this has not been 
done so far. 
TNF monotherapy showed a dose-dependent antiproliferative effect. This is 
in accordance with other in vitro studies which showed the direct antiproliferative 
effects of TNF against numerous tumor cell lines (23). Radiation alone also 
produced a dose-dependent growth retardation. Combination treatments using the 
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Figure 2 
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Figure 2. Effect of single doses of 18 MV X rays The Y-axis represents the relative volume plotted 
on a logarithmic scale as log (volume/initial volume) Each point represents the average volumes of 
at least 20 spheroids Bars represent standard errors · - · , control, Q—Q, 2 Gy, 0-0, 4 Gy, 
C-O, 6 Gy. 
TNF combined with radiation 
The highest dose of TNF was used to assess the effects of combining both 
therapies. Spheroids were irradiated with different doses in the presence of 1000 
ng/ml TNF. At day 0, 4 hours prior to irradiation TNF was added by changing 
media. The combination of TNF with 6 Gy showed the largest effect; after an initial 
regression of volume, finally most spheroids started to regrow with the same growth 
rate as the untreated controls. 2 and 5 out of 24 spheroids, however, failed to 
regrow and were considered controlled or 'cured' in the combination treatments with 
4 and 6 Gy, respectively. 
A combination of two treatments is considered additive when the effect of 
the combination is equal to the sum of the two separate treatments, and considered 
synergistic when the effect of the combination is greater than the sum of the two 
separate treatments (18). Table 1 summarizes the growth delay values derived from 
the growth curves. 2 Gy showed no potentiating effect on TNF-therapy. 4 Gy, 
however, has an additive effect when combined with TNF, and the combination of 
TNF with a radiation dose of 6 Gy clearly showed synergistic effects, since the SGD 
of the combination, 12.4, is greater than 8.7, the addition of the two single 
treatments (3.5 for TNF 1000 Mg/ml plus 5.2 for 6 Gy). 
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most effective TNF-dose plus radiation produced a greater effect than the respective 
monotherapies, as manifested by an increased growth delay. The combination with 4 
Gy has additive, while that with 6 Gy has synergistic antiproliferative effects. 
Whereas neither TNF nor irradiation alone produced permanent spheroid control, 2 
and 5 out of 24 spheroids were controlled, i.e. cured, in the groups that received 
TNF plus 4 and 6 Gy, respectively. 
Spheroids serve as an in vitro model for the early avascular stage of tumor 
growth, where the degree of structural and functional differentiation in the primary 
tumor may be retained. In vivo studies using the original rat renal cell tumor of our 
HM cell line revealed that TNF treatment was not effective when treatment started 
15 days after tumor implantation, i.e. a very small palpable tumor (8). Our data 
suggest that inclusion of radiation in our therapeutic regimens can enhance the anti-
tumor effects of TNF. Studies with a murine mammary carcinoma revealed a 
significant increase of tumor radioresponse when TNF was combined with local 
radiotherapy (10). 
Several other BRMs, like IFN, interleukm-2 (IL-2) and BCG, have been 
investigated for their ability to improve radiation response. In vitro studies showed 
that IFNs potentiated radiation cytotoxicity (24), this phenomenon is associated with 
an increased blockage at G2-M phase in the cell cycle (25). IL-2 alone could not 
increase mean survival time of mice with experimental hepatic metastases (11). 
Addition of local liver radiation prolonged survival time significantly, best results 
were obtained with triple treatment of radiation, IL-2, and Tumor Infiltrating 
Lymphocytes. Total body irradiation, however, completely abrogated the effects of 
IL-2 due to immunosuppression. Bacillus Calmette Guerin (BCG) also induced a 
significant decrease in tumor growth in association with local tumor irradiation 
(26,27). The timing of BCG administration appeared to be an important factor, 
BCG therapy begun either before or immediately after irradiation was effective, 
whereas delay of BCG treatment to 4 days after irradiation showed no significant 
difference with the control group, which received radiotherapy alone. 
TNF has pleiotropic effects, e.g. it can induce procoagulant formation by 
endothelial cells and stimulate increased levels of fibrinogen in circulation, which will 
promote the formation of microthrombi in tumor vasculature (4). The hypoxic 
conditions created in such an environment protect tumor cells from radiation 
damage. TNF also prompts endothelial cell to production of IL·!. IL-1 is considered 
a radioprotector since pretreatment with IL-1 protects mice in a dose-dependent 
manner from the lethal effects of radiation (28). The best timing for TNF 
administration seems to be immediately after radiotherapy. Sersa et al. (10) and 
Nishiguchi et al. (11) gave TNF 3 hours after irradiation and showed synergistic 
effects. General conclusions about the administration scheme cannot be drawn from 
these studies since they did not include a treatment group with TNF therapy prior 
to radiotherapy in their protocols. 
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In conclusion, administration of TNF as an anti-tumor agent is capable of 
augmenting radioresponse of a rat renal cell carcinoma grown as spheroids. More 
studies are needed to assess the therapeutic scope and potency of TNF when 
combined with radiotherapy in the treatment of RCC and cancer in general. 
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ABSTRACT 
The antiproliferative effects of two DNA topoisomerase-II targeted drugs, 
Adriamycin and VP16, in combination with recombinant human tumor necrosis 
factor alpha (TNF), were investigated in a rat renal cell tumor model system. In 
vitro studies using the double layer soft agar system were performed with the HM 
cell line, derived from the original rat renal cell tumor. TNF monotherapy had dose-
dependent growth inhibiting effects in the dose-range tested (1 to 1000 ng/dish). 
Adriamycin, in doses of 200 to 20,000 ng/dish, completely suppressed colony 
formation. VP 16, however, was less effective and could not completely inhibit colony 
formation (dose range 1 to 10,000 ng/dish). Different combinations of VP16 and 
Adriamycin with TNF had significant antiproliferative effects. Adriamycin 2 ng/dish 
in combination with TNF 1000 ng/dish was the only combination which resulted in 
synergistic effects. 
For in vivo studies TNF was administered subcutaneously, peritumorally, 5 
times per week. Adriamycin and VP16 were administered intraperitoneally in 
different treatment schedules. Treatment started 48 hours after tumor implantation. 
Adriamycin 1 mg/kg for three consecutive days every two weeks had significant 
antitumor effects, and induced synergistic antitumor effects in combination with 10 
or 100 μg TNF per rat. TNF and Adriamycin mono- or combination therapy were 
not effective when treatment started at a tumor volume of 0.2-0.5 спт*. VP16 
monotherapy did not produce significant antitumor effects, and combination with 
TNF did not show substantial augmentation of the therapeutic efficacy. 
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INTRODUCTION 
Renal cell carcinoma (RCC) is the most common kidney tumor in adults. 
Approximately 25-30% of patients with RCC have metastases at time of diagnosis 
(deKemion and Mukamel, 1987). Furthermore, metastases will develop in a majority 
of untreated patients within one year after discovery. Systemic therapy with 
hormonal therapy or chemotherapy has not significantly improved the prognosis of 
patients with disseminated disease (Harris, 1983; Yagoda, 1989). Objective responses 
using hormonal therapy range from 0 to 10 %, with nearly all responses being 
partial and of short duration. Numerous chemotherapeutic agents in mono- or 
combination therapy have been administered in clinical trials, the overall response 
rate in 2,120 patients was 8.77%. Vinblastin monotherapy is the most effective 
agent, however, efforts to improve its response rate by adding other 
chemotherapeutic agents have been unsuccessful. 
Immunotherapy with cytokines is a relative new approach to the treatment 
of cancer (Foon, 1987; Borden and Sondel, 1990). Interferon (IFN) is the most 
extensively studied cytokine in RCC and is associated with approximately 16% 
objective responses (Horoszewicz and Murphy, 1989; Heicappell and Ackermann, 
1990). Tumor necrosis factor alpha (TNF) is another cytokine with in vitro 
antitumor effects against experimental renal tumors (Beniers et αϊ, 1989; Kavoussi et 
al, 1989). TNF is synthesized by various activated phagocytic and non-phagocytic 
cells, including macrophages and monocytes. Furthermore, TNF can mediate the 
necrosis of subcutaneously implanted tumors (Carswell et al, 1975; Mcintosh et al, 
1990). The neovasculature of transplanted and spontaneous tumors in mice is 
specifically affected by a single dose of TNF (5-20 μg/mouse), but there is no effect 
on the vascularization of normal tissue transplants. Growth of various tumors can be 
inhibited in syngeneic tumor models and in human tumor xenografts in nude mice 
(Haranaka et αϊ, 1984; Krosnick et al., 1989; Baisch et al, 1990;Van Moorselaar et 
al., 1990). Although combinations of IFN and TNF can result in the enhancement of 
their respective antitumor activities in experimental models (van Moorselaar et al., 
1990; Beniers et al., 1991), clinical trials are not conclusive yet. One complete 
remission was found in 14 patients évaluable for response in a phase II trial with 
IFN-gamma and TNF (de Mulder et al., 1991), whereas preliminary results of a 
study with IFN-alpha and TNF showed 43% objective responses among 14 patients 
(Otto et aL, 1990). 
The combination of chemotherapy with immunotherapy seems very 
promising (Mitchell, 1988; Wadler and Schwartz, 1990). Clinical trials with IFN-
alpha and vinblastin produced objective responses in 31% and 34% of patients with 
RCC (Fossa et aL, 1986; Bollack et aL, 1991). Another study, however, could not 
confirm these results with 16% objective responses (Schornagel et al., 1989). Marked 
enhancement of in vitro cytotoxicity has been demonstrated when TNF is added to 
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cultures of murine L929 fibrosarcoma and MBT-2 transitional cell carcinoma cells 
coincident to or following the addition of topoisomerase-II-targeted drugs (Alexander 
et αϊ, 1987a; Baloch et α/., 1990; Utsugi et al., 1990). Human lung cancer cells, 
however, were resistant to these combinations (Giaccone et aL, 1990). DNA 
topoisomerase II is a homodimeric enzyme which catalyzes transient breakage and 
reunion of single and double strand DNA, thereby allowing strand passage of 
another DNA segment (Liu, 1989). This activity is required for DNA synthesis, 
chromosome condensation during mitosis and for gene transcription. Topoisomerase 
II has been identified as the site of action for some clinically used chemotherapeutic 
drugs, including Adriamycin, Actinomycin D, VP16 and VM26. These drugs can be 
broadly categorized into DNA intercalating drugs, such as Adriamycin, and non-
intercalating drugs such as VP 16. Both categories of drugs stabilize the transient 
cleavable complex of the enzyme which becomes covalently bound to the 5' 
terminus of DNA during the breaking-reunion reaction, resulting in increased DNA 
excision. This is easily detectable by alkaline eluation as DNA single or double 
strand-breaks and DNA-protein cross-links (Liu, 1989; Binaschi et al., 1990; 
Branellec et al, 1990). In vivo studies with a weakly immunogenic 3-methyl 
cholanthrene-induced sarcoma (MCA-106) showed synergistic effects of Adriamycin 
in combination with TNF (Krosnick et al, 1989). VP16 also produced synergistic 
effects in concert with TNF against two RCC xenografts and in the syngeneic 
murine bladder tumor MBT-2 model (Alexander et ai, 1987b; Burgers et ai, 1989; 
Donaldson et al., 1990). 
In the study presented here we have tested the in vitro and in vivo 
antiproliferative effects of Adriamycin and VP16 in combination with TNF in a 
syngeneic rat renal cell tumor model system which histologically and biochemically 
closely resembles human RCC (deVere White and Olsson, 1980). Adriamycin could 
induce synergistic effects, whereas VP 16 was not effective in this respect. 
MATERIAL AND METHODS 
Animals 
Adult male Lewis rats, weighing 330-350 gram (Charles River Wiga GmbH, 
Sulzfeld, FRG), were kept 3 rats per cage with a regimen of 12 hours light per day. 
The animals were allowed access to RMH-TM food (Hope Farms BV., Woerden, 
The Netherlands) and water ad libitum. 
Tumor Line 
The rat renal cell tumor line was kindly provided by Dr. R. Babayan, 
Boston, USA. The tumor was maintained by serial subcutaneous transplantation. For 
in vivo experiments, the tumor was excised from a tumor-bearing animal, and after 
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removal of normal and necrotic tissue, the tumor tissue was cut into pieces of 40 
mg (38-43 mg). The precise weight of each tumor piece was measured on 
preweighed sterile gauzes on a laboratory scale (Mettler). An 0.5 cm incision was 
made in the right flank of recipient animals, and after separating the subcutaneous 
tissue by blunt dissection, the tumor fragment was placed subcutaneously (s.c.) . The 
incision was closed using skin clips (7.5 χ 1.75 mm, Aesculap, Germany). In this way 
a tumor take of 100% was achieved. 
The HM carcinoma cell line is derived from the rat renal cell tumor (van 
Moorselaar 1991, complete characterization will be described elsewhere). Cells were 
maintained in complete medium consisting of RPMI 1640 culture medium 
supplemented with 10% foetal calf serunl, 2mM L-glutamine, 100 lU/ml penicillin, 
100 ßg/ml streptomycin (GIBCO Ltd, Paisley, Scotland), 250 nM dexamethasone and 
20 mM HEPES (N-2-Hydroxyethylpiperazine-N'-2-ethanesulfonic acid) (Sigma, St. 
Louis, MO, USA). Stock cultures of the cells were maintained in monolayer culture 
at 37 С in 6% C 0 2 in air with 100% humidity. The HM cell line is tumorigenic in 
Lewis rats and has a growth rate similar to that of the original tumor. 
In vitro testing with the double layer soft-agar assay. 
Single cell suspensions were obtained after quick trypsinization of 
subconfluent monolayer cultures. Cell density and viability were determined by 
adding 15 μΐ trypan blue solution (25 mg in 5 ml 3% acetic acid) to 15 μΐ cell 
suspension and simultaneously counting colored and non colored cells using a 
Biirker Turk haemocytometer. Suspensions with a viability of 95% or more were 
used for in vitro testing. For the detection of the in vitro growth potential a 
modified double layer soft agar culture method as originally described by Salmon 
and Hamburger was used. An underlayer of one ml 0.5% agar in double enriched 
(DE) McCoy's 5A medium was plated in 35 mm dishes and allowed to gel at room 
temperature. Tumor cell suspensions were plated in the upper layer consisting of 
DE-CMRL 1066 medium with 0.3% agar. In a pilot study we plated a range of 
10,000 to 100,000 cells of the HM cell line. The optimal starting concentrations 
appeared to be 50,000 cells per dish, resulting in approximately 900 colonies after 
14 days of culture, i.e. plating efficiency of 1.8%. Cells were cultured immediately 
after preparation of the single cell suspension. Dishes were incubated at 37 С in 6% 
CO2 in air with 100% humidity. Growth potential was quantified using an Omnicon 
Fas II automated colony counter (Milton Roy Inc., Rochester, New York). Results 
are presented as the growth potential of cells relative to the untreated control cells. 
Drugs 
Recombinant human TNF alpha was kindly provided by Boehringer 
Ingelheim (Alkmaar, The Netherlands). The specific activity of TNF determined in 
the presence of Actinomycin D was 6 χ IO7 Units/mg protein as determined in the 
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L·929 cytotoxicity assay. The purity was >99% as determined by SDS 
polyaciylamide gel electrophoresis and it contained less than 1.0 ng endotoxin per 
mg protein based on the limulus amoebocyte assay. The original TNF solution was 
diluted with RPMI 1640 culture medium (Gibco, Paisley, UK) to a final 
concentration of 2, 20, or 200 μg per ml, divided in aliquots and stored at -20" C. 
Adriamycin (Adriablastina) was obtained from Farmitalia Carlo Erba 
(Rotterdam, The Netherlands) and reconstituted with sterile water to a final 
concentration of 9, 3, 1 or 0.1 mg/mi. VP 16 (Vepesid) was obtained from Bristol-
Myers B.V. (Weesp, The Netherlands) and diluted with 0.9% sodium chloride to 
final concentrations of 20, 10, 5, or 1 mg/ml. Both drugs were used immediately 
after reconstitution or dilution. 
Treatments and monitoring 
In vitro drug tests were performed by continuous exposure of the drugs to 
the tumor cells. Stock solutions TNF were diluted with DE-CMRL 1066 medium to 
concentrations of 50, 500 or 5,000 U or ng/ml. Adriamycin or VP 16 were diluted 
with sterile water and 0.9% sodium chloride respectively to concentrations of 10 to 
100,000 ng/ml for Adriamycin and 5 to 50,000 ng/ml for VP 16 and layered over the 
gelled upper layer in a volume of 200 μΐ. All agents were used immediately after 
dilution since chemotherapeutic agents can loose their activity by storage (Yang and 
Drewinko, 1985). Dishes in the control group received 200 μΐ DE-CMRL 1066 
medium only. As a cytotoxic control we used 0.37 mM HgClj. In vitro tests were 
performed in triplicate and repeated at least twice. 
For in vivo studies TNF was administered s.c, peritumorally, 5 times per 
week in a 0.5 ml injection volume. Adriamycin and VP 16 were injected 
intraperitoneally in different treatment schedules (see Results), the appropriate 
dilution was chosen in such a way that all rats received an volume of 0.33 - 0.35 ml. 
Phosphate buffered saline (PBS) was used for the control group. Treatment started 
two days after tumor implantation or when the tumor reached a volume of 0.2-0.5 
cm and was continued until the tumors in the control group reached a volume of 
10 c m . All experiments were carried out at least in duplicate. 
Tumor growth was followed by measurements of tumor size according to the 
method of Janik et al. (1975) by the same measurer throughout each experiment. 
Three times per week length (1), width (w) and height (h) were measured using a 
slide caliper. No correction was made for skin thickness. Tumor volume (V) was 
calculated from the formula V = 0.5236 χ 1 χ w χ h. 
Statistical analysis 
Statistical analysis of the in vitro data was done by two-way analysis of 
variance on the logarithms of the colony number at day 14 after seeding. 
Differences between mean colony numbers were tested for significance using the 
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Tukey studentized range test at an experimental O.OS error rate. 
For each rat, the tumor volume was estimated on the last treatment day by 
loglinear regression on the tumor volumes throughout the treatment period. Analysis 
of variance was used to compare the final volumes of the treatment versus the 
control groups and to test for additive effects in the combination treatments. To test 
the significance of differences between groups the Tukey studentized range test was 
used at an experimental 0.05 error rate. 6 animals were included in each group. 
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the tumor volumes of treatment А, В or control group respectively. Additivity is 
defined (van Moorselaar et αϊ, 1990) as
 А+В = EA χ E B (i.e. log E 4 + B = log EA 
+ log EB). A combinatjon of two treatments is synergistic when the effect of the 
combination (EA+B) is significantly greater than the product of the effects of the 
separate treatments. 
RESULTS 
In vitro studies 
50,000 cells of the HM cell line, derived from the rat renal cell tumor, were 
plated in the upper layer of the double-layer soft-agar culture system. Preliminary 
studies with Adriamycin monotherapy revealed that doses of 200 to 20,000 ng/dish 
completely suppressed colony formation. We therefore used in the combination 
treatments the lowest doses of 2 and 20 ng/dish. VP 16 monotherapy gave rise to 
significant growth inhibition with both highest doses of 1,000 and 10,000 ng/dish. 
Complete inhibition of colony formation, however, was not achieved (growth fraction 
0.10 and 0.12 respectively). For combination studies we used the three lower dose 
levels, 1 to 100 ng/dish. Table I demonstrates the effects of Adriamycin, VP16 and 
TNF and their combinations as relative growth potential, i.e. number of colonies in 
treated dishes divided by the number of colonies in control dishes after 14 days of 
culture. TNF 1000 and 100 ng/dish produce significant antiproliferative effects. 
Adriamycin 20 ng/dish also has a significant growth inhibiting effect, whereas none 
of the VP 16 doses produced a significant antitumor effect. Different combinations of 
TNF and Adriamycin 2 ng/dish or VP16 10 or 100 ng/dish show significant 
antiproliferative effects when compared to the untreated growth control. Moreover, 
the combination of Adriamycin 2 ng/dish and TNF 1000 ng/dish resulted in a 
synergistic effect. The combination of 2 ng/dish Adriamycin and 1 ng TNF per dish 
was also significantly better than the respective monotherapies. Adriamycin 20 
ng/dish monotherapy is already too active to show synergism in combination with 
TNF. None of the combinations of VP 16 and TNF produced synergistic effects. 
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Table I 
0 
Adriamycin 20e 
Adríamycin 2 
VP16 100 
VP16 10 
VP16 1 
0 
1.00±0.07b 
0.05±0.02d 
0.73±0.03 
0.78+0.11 
1.23±0.08 
1.07+0.09 
TNF 1000» 
a56±ao2d 
0.07+0.02* 
0.29+0.03d·· 
0.51±0.0#* 
0.64+0.08? 
0.83+0.06 
TNF 100 
0.57+O.Orr1 
0.06+0.02? 
0.43+0.06d 
0.71±0.14d 
0.74±0.06 
0.89±0.04 
TNF 10 
0.63+0.04 
0.05+0.02d 
0.43+0.06d 
0.61±0.04d 
0.93±0.06 
0.99+0.08 
TNF1 
0.79±0.03 
0.06±0.02d 
0.55±0.09d 
0.81±0.Π 
1.14+0.05 
1.09+0.07 
" TNF dose in ng per dish 
ь
 relative growth potential, i.e. number of colonies in treated dishes divided by number of 
colonies in control dishes after 14 days of culture. 
c
 Adriamycin or VP 16 in ng per dish 
d
 significantly different colony number compared to the untreated control (p < 0.05) 
e
 synergistic combination 
Table I. Inhibition of colony formation by Adriamycin, VP 16 or TNF and their combinations. 
TNF monotherapy in vivo 
In previous studies with this rat renal cell tumor model system we evaluated 
the influence of administration route on the antitumor effects of TNF and rat-
gamma-IFN (van Moorselaar et a!., 1990). Comparison of the intravenous, 
intraperitoneal (i.p.) and subcutaneous (s.c.) route showed that s.c. injected cytokines 
were the most effective. We, therefore, administered in the in vivo experiments 
described here TNF s.c, peritumorally. As shown before (van Moorselaar et al., 
1990), TNF 10 μg per rat, 5 times per week, had no significant antitumor effects, 
whereas a ten times higher dose could reduce tumor growth significantly (fig. 1A 
and 5A). 
Antitumor effects of Adriamycin monotherapy or in combination with TNF 
In dose-finding studies we gave Adriamycin every three weeks, either one 
administration of 9 mg/kg or 1 to 3 mg/kg for three consecutive days. All regimens 
started 48 hours after tumor implantation. Rats treated with 9 mg/kg died within 14 
days after start of therapy, likewise rats treated with 3 mg/kg died within 21 days. 1 
mg Adriamycin per kg every three weeks was not lethal, but did not produce 
significant antitumor effects (fig. IB). Combinations of this dosage of Adriamycin 
and TNF 10 or 100 μg per rat also showed neither significant, nor synergistic 
antitumor effects (fig. IB). 
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Figure 1. Antitumor effects of Adriamycin and TNF against the s.c implanted rat renal cell 
carcinoma. Treatment started 48 hours after tumor implantation. A: TNF monotherapy administered 
s.c, peritumorally, S times per week. TNF 100 μg per rat has statistically significant antitumor 
effects. B: Adriamycin monotherapy and in combination with TNF, administered i.p. for three 
consecutive days every three weeks. 
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In order to improve the antitumor effects of Adríamycin the number of 
administrations were increased to three consecutive days every second week, starting 
48 hours after tumor implantation. Adríamycin 1 mg/kg had significant antitumor 
effects, whereas a ten times lower dose was not effective in inhibiting tumor growth 
(fig. 2A). TNF 100 Mg in combination with 0.1 mg Adríamycin per kg substantially 
augmented the antitumor effects, which resulted in a significant growth inhibition 
(fig. 2B). Both doses of TNF in combination with 1 mg Adríamycin per kg also 
significantly inhibited tumor growth, but more importantly these combinations had 
synergistic antitumor effects. Increase of the number of Adríamycin administrations 
to 5 times every week 0.1 mg/kg did not result in improvement of the antitumor 
effects. Monotherapy and combination treatment showed no significant tumor growth 
inhibition (fig. 3). 
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Figure 2. Effects of increase of number of Adnamycin administrations. Treatment started 48 hours 
after tumor implantation. A: Adriamycin monotherapy administered i.p., for three consecutive days 
every two weeks. Adriamycin 1 mg/kg has significant antitumor effects. B: Adriamycin and TNF 
combination therapy. All combinations, except Adriamycin 0.1 mg/kg plus TNF 10 μg, have 
significant antiproliferative effects. Both combinations including Adriamycin 1 mg/kg have synergistic 
effects. 
Figure 3 
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Figure 3. Effect of Adriamycin 0.1 mg/kg, administered i.p., S times per week as monotherapy or in 
combination with s.c, peritumoral TNF. 
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Figure 4 
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Figure 4. Start of treatment at a tumor volume of 0.2-O.S cm3. A: TNF monotherapy administered 
s.c, pentumorally, S times per week. В: Adriamycin 0.1 mg/kg 5 times per week, or 1 mg/kg for 
three consecutive days every two weeks in combination with TNF. 
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Influence of tumor volume at start of therapy 
When treatment started 48 hours after tumor implantation Adriamycin 1 
mg/kg for 3 consecutive days every two weeks has synergistic effects in combination 
with TNF 10 or 100 (ig. In order to study, whether this combination treatment or 
treatment with Adriamycin 0.1 mg/kg 5 times per week, could also provoke 
regression of larger tumors, we started therapy at a tumor volume of 0.2-0.5 cnr*. 
TNF monotherapy had no significant effect on tumor growth (fig. 4A), and also 
Adriamycin monotherapy was ineffective (data not shown). Furthermore, none of 
the combination regimens produced significant or synergistic effects (fig. 4B). 
Antitumor effects of VP 16 monotherapy and in combination with TNF 
Studies in the murine L1210 leukemia model showed a marked schedule 
dependency of VP 16 antitumor activity. Treatment given on day 1, 5 and 9 was 
more effective than treatment on day 1 or day 1 and 9 only (Rozencweig et αϊ, 
1977). We, therefore, administered in our studies 20, 10, 5 or 1 mg VP16 per kg i.p. 
at day 2, 6 and 11 after tumor implantation. The highest dose was lethal for 4 out 
of 6 rats within 5 days after start of therapy, likewise 5 out of 6 rats died within 30 
days when treated with VP 16 10 mg/kg. All rats treated with 5 or 1 mg VP16/kg 
stayed alive, however, these lower doses did not produce significant antitumor 
effects (fig. 5A). In the combined treatment modality, 5 mg VP16 per kg with TNF 
100 /ig had significant antiproliferative effects, however, substantial augmentation of 
the therapeutic efficacy was not found (fig. 5B). 
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Figure 5. Antitumor effects of combination of VP16 and TNF. A:Monotherapies: VP16 5 mg/kg, 
administered i.p., on day 2, 6 and 11 after tumor implantation. TNF administered s.c, peritumorally, 
starting 48 hours after tumor implantation. TNF 100 ßg per rat has significant antitumor effects. B: 
VP16 5 mg/kg and TNF combination therapy. VP16 in combination with TNF 100 μg has significant 
antiproliferative effects. 
DISCUSSION 
The treatment of advanced RCC is an intriguing clinical problem. 25 to 
30% of patients have metastases at time of diagnosis and more than 80% of 
patients with disseminated disease will die within three years. Chemotherapy and 
hormonal therapy give no clearly definable improvement in patient survival (Harris, 
1983; Yagoda, 1989). Immunotherapy with e.g. IFN-alpha is associated with an 
objective response rate of 16% (2% complete and 14% partial responders) in 1,684 
treated patients (Horoszewicz and Murphy, 1989). 
It was found that TNF has in vitro and in vivo antitumor activity against 
rodent and human RCC cell lines (Beniers et al, 1989; Kavoussi et al., 1989; van 
Moorselaar et al, 1990; Otto et al, 1990a). In vitro studies show synergistic effects of 
TNF in combination with other treatment modalities, such as radiotherapy (van 
Moorselaar et al, 1991). The effects of combined treatment of TNF with 
chemotherapy in experimental cancer models are very promising. Two studies in the 
nude mouse model showed synergistic effects of VP 16 and TNF against human 
RCC xenografts (Burgers et al, 1989; Donaldson et al, 1990). We have performed 
in vitro studies in the soft-agar model system to assess the direct growth inhibiting 
effects of TNF and/or chemotherapy against the rat renal tumor. TNF 10 or 100 
ng/dish monotherapy has antitumor effects, whereas VP16 did not significantly 
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inhibit colony formation. None of the TNF/VP16 combinations induced synergistic 
effects. In vitro experiments or studies in nude mice are hampered by an absent or 
abnormal immune system. Despite direct antitumor effects, TNF also has indirect, 
host response mediated, antitumor effects (Havell et al., 1988). To investigate the 
full spectrum of TNF mediated effects, we have implanted the tumor in syngeneic 
Lewis rats. TNF monotherapy has dose-dependent antitumor effects (van 
Moorselaar et al., 1990). VP 16 given singly was lethal in high doses, but lower doses 
had no significant growth inhibiting effects. Unlike in the xenograft studies, 
combinations of VP16 and TNF showed no enhanced antitumor activity. These 
differences in effectivity of VP16 might represent the heterogeneity of RCC, which 
stresses the need to study different human and animal tumors before one can draw 
conclusions on clinical applicability of combinations of these drugs. 
Intrinsic resistance of RCC to chemotherapeutic agents can be explained by 
the overproduction of the protein product of the mdrl gene in a great number of 
human RCCs (Klein, 1989). Normal rat liver showed expression of the mdrl gene as 
described before (Fairchild el αϊ, 1987; Burt and Thorgeirsson, 1988), however, this 
expression could not be detected in normal rat kidney or the rat renal cell tumor 
(data not shown). It is therefore likely that other factors than P-glycoprotein are 
involved in the mechanism of VP 16 resistance in the rat renal cell tumor. 
In contrast to VP16 and TNF, combination of TNF with Adriamycin shows 
synergistic inhibition of colony formation by the HM rat RCC cell line. This 
combination was also effective in vitro against L929, MBT-2 and prostatic cancer 
cells (Alexander et al., 1987a; Utsugi et al., 1989; Fruehauf et al., 1990). However, 5 
lung cancer cell lines appeared to be resistant to TNF/Adriamycin treatment 
(Giaccone et al., 1990). In the Renca murine RCC model, Adriamycin significantly 
inhibited tumor growth and increased the effects of immunotherapy with interleukin-
2 and lymphokine-activated killer cells (Salup et al, 1987). In contrast to these 
results, intraperitoneal administration of Adriamycin, starting one day after s.c. 
tumor implantation every 4 days until day 17, was not effective against another 
murine renal tumor, the RC tumor, in doses of 6, 3 or 1.5 mg/kg (Vandendris et al., 
1983). In our in vivo experiments 1 mg/kg 3 days every 2 weeks showed significant 
growth inhibition as compared to the control group. Moreover combinations with 
both doses of TNF induced synergistic effects, but complete growth inhibition was 
not achieved. Lower doses of Adriamycin or decrease of the number administrations 
produced less antitumor effects, indicating a dose-dependent tumor growth inhibition 
(deVere White and Olsson, 1980). When administered repeatedly, Adriamycin 
appears to accumulate in some tissues, including tumor tissue (Di Marco, 1982). We, 
therefore, administered Adriamycin in a low dose S times per week, but this 
schedule did not increase the antitumor efficacy of Adriamycin alone or in 
combination with TNF. 
When chemotherapy and immunotherapy are used together, it should be 
i n 
avoided that the chemotherapeutic agent negates the stimulation of the immune 
system induced by the immunotherapeutic drugs. Most chemotherapeutic agents are 
immunosuppressive. Adriamycin, on the contrary, has shown to have little or no 
immunosuppressive effects (Cohen et al., 1980; Mitchell, 1988). Adriamycin does not 
interfere with maturation and adherent capacity of human monocytes. However, the 
drug reduces the expression of Fc-receptors and H LA class II antigens on 
monocyte-derived macrophages (van Schie et al, 1990). It has been shown that TNF 
can increase HLA class I and II expression of monocytes and tumor cells (Beutler 
and Cerami, 1988). The antitumor effects and absent or low immunosuppression of 
Adriamycin, in combination with direct antitumor effects and increase of tumor 
immunogenicity by TNF, may partially explain the synergistic effects of the 
combined treatment. 
Furthermore, synergistic effects of Adriamycin and TNF might be due to 
free radical formation and subsequent oxidative tissue damage by both drugs 
(Bachur et al., 1982; Yamauchi et al., 1990). Moreover, both TNF and 
topoisomerase-II-targeted drugs can induce DNA breakage, and TNF pretreatment 
potentiates this breakage and subsequent cell killing by the chemotherapeutic agents 
(Dealtry et al., 1987; Branellec el al., 1990; Utsugi et ai, 1990). 
Adriamycin and/or TNF were not effective in inhibiting growth of an 
established tumor. A similar relation between treatment effectivity and tumor size 
was found for rat-gamma-IFN and TNF in this rat RCC tumor model (van 
Moorselaar et ai, 1990). Within growing tumors anoxia and/or glucose deprivation 
can occur, which will lead to an induction of a subset of stress proteins, the glucose-
regulated proteins (grps). The lysability of tumor cells by Adriamycin, TNF or 
cytotoxic Τ cells decreases due to these grps (Shen et al., 1987; Sugawara et al., 
1990). Furthermore, stressed cells can become drug resistant through the depletion 
of topoisomerase II, which is a consistent characteristic of glucose-regulated stress 
response and not secondary to the movement of stressed cells into a quiescent state 
(Shen et al., 1989). 
In conclusion, Adriamycin and TNF have in vitro and in vivo synergistic 
antiproliferative effects against a rat renal cell carcinoma. There is, however, a 
marked dose and schedule dependency. In contrast to previous studies with RCC 
xenografts, the combination of VP16 and TNF did not produce synergistic effects. 
These studies indicate that the combination of chemotherapeutic agents targeted 
against DNA topoisomerase-II and TNF can have synergistic effects, which might 
give a lead in the development of new treatment strategies for the clinical 
management of RCC. 
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ABSTRACT 
We have examined the antitumor effects of rat Interferon-gamma (IFN-
gamma) and human Tumor Necrosis Factor alpha (TNF) against androgen-
dependent and -independent Dunning rat prostatic tumors. In vitro studies, using the 
double-layer soft-agar assay, showed a very limited antiproliferative activity of the 
drugs in the dose range tested (1-1000 U IFN-gamma and/or 1-1000 ng TNF per 
dish). For in vivo studies IFN-gamma and TNF were administered subcutaneously, 
peritumorally. IFN-gamma was given 3 times per week, 8.000 or 80.000 U per rat, 
and TNF 5 times per week, 10 or 100 μg per rat. IFN-gamma and TNF 
monotherapy were not significantly effective in inhibiting tumor growth, except for 
IFN-gamma against the androgen-independent MatLyLu-tumor. Combinations of 
IFN-gamma and TNF had synergistic antiproliferative effects against all four tumor 
lines tested, however, complete growth inhibitions could not be achieved. Survival 
studies showed significant increase in survival of tumor-bearing rats. 
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INTRODUCTION 
Prostate cancer is the most common malignancy and the second leading 
cause of cancer related deaths in the USA (1) and due to the aging of the 
population the incidence and mortality will most likely increase (2). Hormonal 
therapy is the front-line therapy for patients with advanced or metastatic prostatic 
cancer (3,4). Approximately 60-70% of these patients initially respond to androgen 
ablation, but essentially all of these men eventually relapse to a state unresponsive 
to further antiandrogenic therapy (5). An option for the treatment of relapse and 
hormone-resistant metastases could be the use of chemotherapy. However, there is 
still no firm evidence that chemotherapy prolongs survival as compared to palliative 
therapy. Randomized tjials comparing single vs. combination chemotherapy also 
demonstrated no survival benefit (6,7). 
Therefore, new approaches to the treatment of androgen-independent 
prostatic carcinoma will be required. Immunotherapy with Biological Response 
Modifiers, like Interferons (IFNs) and Tumor Necrosis Factor Alpha (TNF), has 
been adopted effectively in some types of malignancies (8,9). IFN-gamma is a 
product of activated T-lymphocytcs with potent antiviral, antiproliferative and 
immunomodulatory properties such as the activation of natural killer cells and 
macrophages, the increase of expression of tumor associated antigens and the 
modulation of MHC class I and II antigens (10). Interferons showed antiproliferative 
effects against prostatic cancer cell lines in vitro (11). 
In 1975 Carswell et al. noted that post-endotoxin serum derived from mice 
treated with Bacillus Calmette-Guerin (BCG) was able to induce haemorrhagic 
necrosis of experimental tumors. The substance responsible for these effects was 
designated TNF (12). It is synthesized by various activated phagocytic and non-
phagocytic cells, including macrophages/monocytes. TNF has pleiotropic effects, for 
example, it causes cytostasis or cytolysis of a variety of animal and human tumors 
(13). When exposed to TNF endothelial cells produce a procoagulant factor, and 
show decreased expression of thrombomodulin, these effects favor the accretion of 
thrombus on endothelial surfaces, which may be related to the haemorrhagic 
necrosis of tumors (14). TNF showed antitumor effects against the LNCaP, DU 145 
and PC3 prostatic xenografts in vitro and in vivo (15). 
We have examined the antitumor effects of IFN-gamma and TNF in the 
Dunning rat prostatic tumor model. This model consists of a number of sublines 
that differ widely in their histology, growth rate, androgen sensitivity and metastatic 
abilities. An additional advantage of this system is that from a number of in vivo 
tumor lines, in vitro cell lines have been derived that retain their phenotypic 
characteristics (16,17). All sublines are transplantable in immunocompetent rats and 
it is, therefore, possible to study the full spectrum of cytokine mediated effects. We 
show here that IFN-gamma and TNF can have synergistic antitumor effects against 
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rodent androgen-dependent and -independent prostatic tumors. Although it is very 
difficult to extrapolate animal data to the human situation, these studies may give a 
lead to the development of future treatment strategies. 
MATERIAL AND METHODS 
Animals 
Adult male Fj hybrid rats (F344CopFl/OLA/HSD, Copenhagen male and 
Fisher female) were obtained from Harlan OLAC Limited, Bicester, England and 
kept 3 rats per cage with a regimen of 12 hours light per day. The animals were 
allowed access to RMH-TM food (Hope Farms BV., Woerden, The Netherlands) 
and water ad libitum. 
Tumor Lines 
Four well-characterized sublines of the Dunning tumor were kindly provided 
by Dr. J.T. Isaacs (Johns Hopkins Oncology Center, Baltimore, USA). The 
characteristics of the H-, PIF-1-, PAT-2- and MatLyLu-sublines are summarized in 
Table I. 
In vitro cell lines were maintained in RPMI 1640 culture medium 
supplemented with 10% fetal calf serum, 2mM L-glutamine, 100 IU/ml penicillin, 
100 Mg/ml streptomycin (GIBCO Ltd, Paisley, Scotland), 250 nM dexamethasone and 
20 mM HEPES (N-2-Hydroxyethylpiperazine-N,-2-ethanesulfonic acid) (Sigma, St. 
Louis, MO, USA). 
For in vivo studies tumors were excised from tumor-bearing animals, and 
after removal of normal and necrotic tissue, the tumor tissue was cut into pieces of 
20 mg and implanted into the right flank of recipient animals as described before 
(18). 
In vitro testinp with the double laver soft-agar assay. 
Single cell suspensions were obtained after quick trypsinization of 
subconfluent monolayer cultures. Cell density and viability were determined by 
adding 15 μΙ trypan blue solution (25 mg in 5 ml 3% acetic acid) to 15 μΐ cell 
suspension and simultaneously counting colored and non colored cells using a 
Burker Turk hemocytometer. Suspensions with a viability of 95% or more were used 
for in vitro testing. For the detection of the in vitro growth potential a modified 
double layer soft agar culture method as originally described by Salmon and 
Hamburger was used (19). An underlayer of one ml 0.5% agar in double enriched 
(DE) McCoy's 5A medium was plated in 35 mm dishes and allowed to gel at room 
temperature. Tumor cell suspensions were plated at their optimal cell 
concentrations, i.e. concentration of cells that will give rise to formation of 200-500 
120 
colonies after 14 days culture, in the upper layer consisting of DE-CMRL 1066 
medium with 0.3% agar. For the MatLyLu cell line the optimal starting 
concentration is 750 cells per dish (17). In a pilot study we plated a range of 500 to 
100,000 cells of the PIF-1 and PAT-2 cell lines. The optimal starting concentrations 
appeared to be 2,000 and 35,000 cells for the PAT-2 and the PIF-1 cell line 
respectively. Cells were cultured immediately after preparation of the single cell 
suspension. Dishes were incubated at 37*41! in 6% CO2 in air with 100% humidity. 
Growth potential was quantified using an Omnicon Fas II automated colony counter 
(Milton Roy Inc., Rochester, New York) (20). Results are presented as the growth 
potential of cells relative to the untreated control cells. 
Drugs 
Recombinant human TNF-alpha was kindly provided by Boehringer 
Ingelheim (Alkmaar, The Netherlands). The specific activity of TNF determined in 
the presence of Actinomycin D was 6 χ IO7 Units/mg protein as determined in the 
L-929 cytotoxicity assay. The purity was >99% as determined by SDS 
Polyacrylamide gel electrophoresis and it contained less than 1.0 ng endotoxin per 
mg protein based on the limulus amebocyte assay. The original TNF solution was 
diluted with RPMI 1640 culture medium to a final concentration of 20, or 200 /ig 
per ml, divided in aliquots and stored at -20oC. 
Recombinant rat IFN-gamma was produced by a Chinese hamster ovary cell 
line transformed with a plasmid carrying the chromosomal gene for rat IFN-gamma 
and purified as described previously (21). The cytopathic effect reduction assay was 
used for estimating IFN bioactivity. Ratee cells (22) (a continuous rat embryonic cell 
line) were incubated with IFN-gamma for 18 hours before they were challenged with 
vesicular stomatitis virus to determine the cytopathic effect. Because no 
internationally accepted reference standard for rat interferon is available, all titers 
were determined by comparison with a laboratory standard preparation of IFN-
gamma (1 mg pure rat IFN-gamma corresponds with 7 χ 106 units). After 
purification by monoclonal antibody affinity chromatography IFN-gamma was freeze-
dried for longterm storage. It was reconstituted with Milli-Q to a final concentration 
of 16,000 or 160,000 Units per ml, divided in aliquots and stored at -WfC until use. 
Treatments and monitoring 
In vitro drug tests were performed by continuous exposure of the drugs to 
the tumor cells. Stock solutions of IFN-gamma and TNF were diluted with DE-
CMRL 1066 medium to concentrations of 50, 500 or 5,000 U or ng/ml. The BRMs 
were layered over the upper layer in a volume of 200 μΐ, 1 hour after gelling of the 
upper layer. Dishes in the control group received 200 μΐ DE-CMRL 1066 medium 
only. As a cytotoxic control we used 0.37 mM HgC^. In vitro tests were performed 
in triplicate and repeated at least two times. 
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Table I. Biological characteristics of the Dunning R3327 rat prostatic cancer sublines used in this study 
Tumor Histology In vitro cell line Growth rate in vivo* Androgen Sensitivity Metastatic Potential6 
H 
PIF-1 
PAT-2 
MatLyLu 
well differentiated 
moderately differentiated 
anaplastic 
anaplastic 
no 
yes 
yes 
yes 
22 ± 5 days 
3.7 ± 1.1 days 
1.8 ± 0.2 days 
1.5 ± 0.1 days 
yes 
no 
no 
no 
< 5% 
< 5% 
> 90% 
> 90% 
• ref. 17 and own observations 
ь
 number of s.c inoculated rats that develop metastases to lymph nodes and lungs 
For in vivo studies IFN-gamma and TNF were administered s.c., 
peritumorally, 3 and 5 times per week respectively, in a 0.5 ml injection volume. 
Phosphate buffered saline (PBS) was used for the control group. Treatment started 
2 days after tumor implantation and was continued until the tumors in the control 
group reached a volume of 10 cm*. However, in survival experiments treatment was 
continued until death of the animals. 
For the H tumor a different treatment protocol was used. Treatment started 
when the tumor became palpable, this is 8 weeks after implantation. IFN-gamma 
was administered two timesAveek, from day 56 until day 112 after tumor 
implantation. TNF was given 4 times/week, from day 56 until day 205. All 
experiments, except for the H tumor, were carried out in duplicate. 
Tumor growth was followed by measurements of tumor size according to the 
method of Janik et al. (23) by the same measurer throughout each experiment. 
Once weekly for the H tumor, and three times per week for the other three tumors, 
length (1), width (w) and height (h) were measured using a slide caliper. No 
correction was made for skin thickness. Tumor volume (V) was calculated as 
V = 0.5236 χ 1 χ w χ h. 
Statistical analysis 
Statistical analysis of the in vitro data was done by analysis of variance on 
the logarithms of the colony number at day 14 after seeding. Differences between 
mean colony numbers were tested for significance using the Tukey studentized range 
test at an experimental 0.05 error rate (24). 
For each rat, the tumor volume was estimated on the last treatment day by 
loglinear regression on the tumor volumes throughout the treatment period. Analysis 
of variance was used to compare the final volumes of the treatment versus the 
control groups and to test for additive effects in the combination treatments. To test 
the significance of differences between groups the Tukey studentized range test was 
used at an experimental 0.05 error rate (24). 6 animals were included in each group. 
The effect of treatment A is defined as EA = Vconrri)//V4 and the effect of 
treatment В as EB = сопІгоіГ в> where WA, д, and ycontro¡ are the estimates for 
the tumor volumes of treatment A, В or control group respectively. Additivity is 
defined (25) as EA+B = ΈΑ χ E B (i.e. log EA+B = log EA + log EB). A 
combination of two treatments is synergistic when the effect of the combination 
(EA+B) is greater than the product of the effects of the separate treatments. 
123 
RESULTS 
Effect of IFN-pamma and TNF in vitro 
35,000, 2,000 and 750 cells per dish, for the PIF-1, PAT-2 and MatLyLu 
subline, respectively, were plated in the upper layer of the double-layer soft-agar 
culture system. Table II demonstrates the effects of IFN-gamma and TNF as single 
exposure. Treatment started on the day of cell seeding. Combined results of three 
separate experiments are expressed as relative growth potential, i.e. number of 
colonies in treated dishes divided by number of colonies in control dishes after 14 
days of culture. Colony formation, however, was monitored every 3 days after 
seeding and also in the initial colony counting the same relative differences were 
found in treated and untreated groups. The results, therefore, cannot be attributed 
to catch-up growth after a single administration of BRMs. 
IFN-gamma monotherapy has dose-dependent antiproliferative effects 
against the PIF-1 and the PAT-2 cell lines. IFN-gamma showed significant growth 
inhibiting effects in 3 out of 4 dose levels for the PIF-1 cell line and for the highest 
dose against the PAT-2 cell line. Increase of IFN-dose from 1 to 1000 U per dish, 
however, did not increase the effect of IFN-gamma on the MatLyLu cell line. TNF 
monotherapy had no significant effects on colony formation in all three cell lines. 
To determine whether combinations of cytokines might enhance the direct 
antiproliferative effects we combined IFN-gamma in a dose range from 1 to 100 U 
per dish with TNF 1 to 100 ng/dish. Both drugs were added at the same time. The 
combination of 100 U IFN-gamma and 100 ng TNF per dish gave rise to significant 
antiproliferative effects in all three cell lines. According to the definition of 
synergism, whereby the effect of the combination must be greater than the product 
of the two separate treatments, only the combination of 10 U IFN-gamma and 100 
μg TNF per dish has synergistic antiproliferative effects against the MatLyLu cell 
line. All other combinations did not produce synergistic effects. 
Effect of IFN-gamma and TNF against the androgen-dependent H tumor in vivo. 
In previous studies with a rat renal cell carcinoma model system we have 
evaluated the influence of administration route on antitumor effects of the BRMs 
(18). Comparison of the intravenous (i.V.), intraperitoneal (i.p.) and subcutaneous 
(s.c.) route showed that i.p. and i.v. injected BRMs were less effective than s.c. 
injections. Therefore, in the in vivo experiments described here we administered the 
BRMs s.c, peritumorally. 
Tumor pieces of 20 mg of the H tumor were implanted s.c. and treatment 
was started, in contrast to the other three tumors, 8 weeks after tumor implantation. 
IFN-gamma was given 2 times and TNF 4 times/week. As shown in fig 1A IFN-
gamma monotherapy with 8,000 or 80,000 U per rat has no significant antitumor 
effects. TNF monotherapy with 10 or 100 Mg/rat also could not significantly inhibit 
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Table II. Effects of IFN-gamma and TNF in vitro 
treatment 
IFN· 
0 
1000 
100 
10 
1 
0 
0 
0 
0 
100 
100 
100 
10 
10 
10 
1 
1 
1 
TNF* 
0 
0 
0 
0 
0 
1000 
100 
10 
1 
100 
10 
1 
100 
10 
1 
100 
10 
1 
PIF-l 
relative : growth 
potential 
1.00 
0.43 
0.67 
0.77 
0.75 
0.92 
0.95 
1.03 
1.06 
0.71 
0.74 
0.73 
0.93 
0.88 
0.79 
0.97 
0.85 
0.86 
± 
+ 
± 
± 
+ 
± 
± 
± 
± 
+ 
± 
± 
± 
± 
± 
± 
± 
± 
0.10 
0.09e 
0.11e 
0.16 
0.16e 
0.18 
0.14 
0.13 
0.14 
О.И
с 
0.13 
0.10 
0.13 
0.14 
0.14 
0.16 
0.15 
0.13 
PAT-2 
relative : growth 
potential 
1.00 
0.75 
0.80 
0.95 
0.96 
0.73 
0.83 
0.91 
0.90 
0.67 
0.64 
0.80 
0.80 
0.79 
0.81 
0.85 
0.89 
0.96 
± 
+ 
+ 
+ 
+ 
± 
+ 
± 
± 
+ 
+ 
+ 
+ 
+ 
+ 
± 
± 
± 
0.04 
0.08e 
0.06 
0.06 
0.05 
0.03 
0.07 
0.09 
0.05 
0.06e 
0.06e 
0.05 
0.05 
0.04 
0.04 
0.06 
0.04 
0.05 
MatLyLu 
relative growth 
potential 
1.00 
0.82 
0.76 
0.73 
0.71 
0.71 
1.01 
0.84 
1.03 
0.53 
0.72 
0.79 
0.55 
0.65 
0.82 
0.70 
0.95 
0.82 
± 
* 
± 
+ 
+ 
± 
± 
+ 
¿ 
± 
+ 
+ 
+ 
+ 
± 
± 
± 
± 
0.05 
0.07 
0.05 
0.07 
0.07 
0.03 
0.08 
0.11 
0.09 
0.06e 
0.06 
0.08 
0.13<:'d 
0.07e 
0.11 
0.10 
0.12 
0.06 
* IFN-gamma dose in U per dish 
ь
 TNF dose in ng per dish 
e
 significantly different colony numbers compared to untreated control 
d
 synergistic IFN-gamma and TNF combination treatment 
Table IL The PIF-l, PAT-2 and MatLyLu cell lines were plated in the upper layer of the double 
layer soft-agar culture system. IFN-gamma and TNF were added, in a dose range of 1 to 1000 U or 
ng per dish respectively, on the day of cell seeding. Combined results of three separate experiments 
are expressed as relative growth potential, i.e. number of colonies in treated dishes divided by 
number of colonies in control dishes after 14 days of culture. 
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tumor growth of the H tumor (fig IB). 
Reasoning that combination of IFN-gamma and TNF can have synergistic 
effects, we combined 8,000 or 80,000 U IFN-gamma with 10 or 100 ßg TNF (fig 
1С). The combinations of 8,000 U IFN-gamma with 10 ßg or 100 Mg TNF did not 
significantly reduce tumor growth. Substantial augmentation of the therapeutic 
efficacy resulted from combined treatment with the highest dose of IFN-gamma and 
TNF. Tumor regression, however, could not be achieved. 
The highest doses of BRMs produce the best effect, suggesting a dose-
dependent response relationship. According to the definition of synergism only the 
combination of 80.000 U IFN-gamma and 100 μ% TNF has synergistic effects. 
cm 
cm 
b 
3 
5 
4 
3 
2 
1 
в 
-
-
10 «g TNF 
control 
100 дд TNF 
250 
6 r 
cm0 
50 100 150 
control 
8,000/10 
Τ 8,000/100 
80,000/10 
80,000/100 
200 250 
DAYS 
Figure 1. Antitumor effects of IFN-gamma and TNF against the androgen-dependent H-tumor. 
Treatment started 57 days after tumor implantation. A: IFN-gamma monotherapy, administered s.c 
pentumorally, 8,000 or 80,000 U per rat, 2 times per week. B: TNF monotherapy, administered s.c. 
pentumorally, 10 or 100 μg per rat, 4 times per week. C: IFN-gamma and TNF combination therapy, 
the combinations of 80,000 U IFN-gamma plus 10 or 100 μg TNF per rat have statistically 
significant antitumor effects. 
Effects of IFN-gamma and TNF apainst the androgen-independent PIF-1. PAT-2 
and MatLvLu tumors in vivo. 
Having found a drug combination that could synergistically inhibit the slow-
growing, androgen-dependent Η-tumor, we sought to gain insight into the antitumor 
effects against androgen-independent tumors. 
Tumor pieces (20 mg) of the PIF-1, PAT-2 and MatLyLu tumors were 
implanted s.c. IFN-gamma was administered 3 times and TNF 5 times/week. IFN-
gamma or TNF monotherapy could not significantly inhibit tumor growth of the 
moderately differentiated PIF-1 tumor (fig. 2). IFN-gamma and TNF in combination, 
however, mediated a synergistic reduction in tumor growth. 
TNF monotherapy was not effective against the two rapidly growing 
anaplastic tumors, MatLyLu and PAT-2 (figs. 3 and 4). IFN-gamma monotherapy, 
however, was very effective against the MatLyLu tumor. The substantial benefit of 
IFN-gamma alone made it difficult to reach synergism, but combination therapy was 
significantly more effective than TNF or IFN-gamma alone. In the PAT-2 tumor 
combination treatment was also more effective than each of the monotherapies and 
produced synergistic effects. 
In experiments with the androgen-independently growing tumors it appeared 
that, after termination of therapy, after a 10-day lag phase the tumors regained their 
initial growth potential (same volume-doubling time, data not shown). 
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сгтг 
control 
80,000 U FN 
100 MQ TNF 
80,000/100 
30 35 
DAYS 
Figure 2. Effects of 80,000 U IFN-gamma and/or 100 μg TNF per rat, 3 or 5 times per week 
respectively, against the androgen-independently growing PIF-1 tumor. Combination treatment has 
statistically significant antitumor effects. 
enrr control 
100 MQ TNF 
80,000 U IFN 
80,000/100 
Figure 3. Effects of 80,000 U IFN-gamma and/or 100 μg TNF per rat, 3 or 5 times per week 
respectively, against the androgen-independently growing MatLyLu tumor. IFN-gamma monotherapy 
and combination treatment have statistically significant antitumor effects. 
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cm control 
100 дд TNF 
80.000 U IFN 
80,000/100 
12 14 
DAYS 
Figure 4. Effects of 80,000 U IFN-gamraa and/or 100 μg TNF per rat, 3 or 5 times per week 
respectively, against the androgen-independently growing PAT-2 tumor. Combination treatment has 
statistically significant antitumor effects. 
Survival of rats with MAtLyLu-tumors under continuous treatment of IFN-gamma 
and TNF. 
To investigate whether IFN-gamma and TNF combination therapy 
influenced survival of rats we treated MatLyLu-bearing rats with IFN-gamma 3 
times and TNF 5 times/week until death. As shown in fig. 5 all rats finally died, but 
the treated rats had a survival benefit of 11 days when compared to the untreated 
controls (40 days vs. 29 days). This difference is significant with the Wilcoxon test 
(p=0.005). 
DISCUSSION 
Androgen ablation is the front line palliative treatment for advanced or 
metastatic prostatic carcinoma. From 60 to 70% of the patients will respond to 
hormonal therapy. However, following this initial positive response a nearly universal 
relapse will follow to an androgen-insensitive state. The median survival of these 
patients is between 4 and 8 months. To date chemotherapy showed no substantia] 
improvement in the survival of patients with hormone-escaped metastatic prostatic 
cancer. Clearly novel therapeutic interventions must be developed. Medenica et al. 
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Figure 5 
10 20 30 40 50 
DAYS 
Figure 5. Survival of MatLyLu-tumor bearing rats. 0-0 untreated controls, | — | rats treated with 
80,000 U IFN-gamma. 3 times per week and 100 /ig TNF, 5 times per week. The difference is 
statistically significant as evaluated by the Wilcoxon test. 
treated 14 patients with IFN-alpha and observed 5 complete responses and 6 partial 
responses (26). Gutterman and Quesada also found encouraging results with IFN-
alpha (27). They found 1 complete response and 3 partial responses among 10 
treated patients. Other authors (28,29), however, could not confirm objective clinical 
responses with IFN-alpha or -beta. The number of patients treated with these two 
types of IFN is too small to draw firm conclusions about clinical activity of the 
drugs. We have investigated the antiproliferative efficacy of immunotherapy with 
IFN-gamma and TNF, in vitro and in vivo in the Dunning rat prostatic tumor model 
system. The syngeneic Dunning R3327 system of serially transplantable rat prostatic 
cancers mimics many of the most important characteristics of the human disease, 
and serves, therefore, as an appropriate model system. 
In vitro tests were performed to investigate the extent to which the 
antitumor effects of the BRMs in vivo can be contributed to direct growth inhibiting 
effects. For these studies we used the soft agar assay of Hamburger and coworkers, 
which has been suggested as a relevant system for preclinical evaluation of potential 
new agents. We have shown previously that IFNs and TNF can inhibit colony 
formation of renal cell carcinoma cells in this assay (30). The in vitro studies 
presented here revealed a very limited activity of IFN-gamma and TNF alone or in 
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combinations, indicating that both cytokines have a very limited direct cytostatic or 
cytotoxic effect on prostatic cancer cell lines in the dose range tested. 
Horoszewicz et al. could not demonstrate antiproliferative effects of highly 
purified human beta-interferon (HuIFN-beta) against the hormone-sensitive LNCaP 
prostatic cancer cell line in vitro (31). In contrast to these results, Sica et al. showed 
that HuIFN-beta and recombinant human IFN-alpha (rHuIFN-alpha) had growth-
inhibiting effects against the hormone-insensitive PC3 and DU 145 prostatic cancer 
cell lines in vitro (11). Sherwood et al. reported cytotoxicity of TNF towards all 
three cell lines in vitro (15); Fruehauf et al., however, found that the PC-3 cell line 
was almost completely resistant to the action of TNF whereas the LNCaP cells were 
sensitive targets for TNF (32). 
IFN-gamma and TNF can have direct effects but, more importantly, also 
indirect, immune system-mediated effects. There is little opportunity to determine 
this indirect drug activity using the basic clonogenic assay. Inclusion of macrophages 
in the underlayer could be a possibility to optimize the assay, since addition of 
macrophages inhibited colony formation more than IFN-gamma treatment alone, 
due to the secretion of soluble substances by these macrophages, which consist in 
part of TNF (33). 
In vivo studies showed that IFN-gamma or TNF monotherapies, except IFN-
gamma against the MatLyLu tumor, were not significantly effective in inhibiting rat 
prostatic tumor growth. Shaw et al. also used the MatLyLu tumor (34). They 
reported that a single administration of TNF 30 μg i.p. had no antitumor effect, 
whereas intratumoral (i.t.) injection significantly reduced tumor growth. 
Administration of TNF i.v. to nude mice bearing s.c. or intraabdominal PC-3 tumors 
resulted in a significant growth reduction (15). These results indicate that the 
optimal route of administration for cytokines has not been established yet. 
Since both IFN-gamma and TNF monotherapy had limited activity we 
combined these drugs. With the H tumor we performed dose-finding studies and 
found out that the combination of 80,000 U IFN-gamma and 100 jig TNF had 
synergistic antiproliferative effects. This combination was also tested against more 
rapidly growing, androgen-independent tumors. Synergistic effects were apparent in 
the PIF-1 and PAT-2 tumors. Against the MatLyLu tumor the combination was 
more effective than the monotherapies in the dose range tested. IFN-gamma 
monotherapy was already too active to show synergism in the combination. 
In survival studies we showed that combined treatment with IFN-gamma and 
TNF significantly prolonged survival of MatLyLu-bearing animals compared to 
untreated controls. Shaw et al. also showed a survival benefit for i.t. treated rats 
with TNF alone (24 days compared to 31 days) (34). 
The involution following androgen-ablation is an actively initiated process, 
induced by a decrease of prostatic androgens beyond a critical point (35). This 
active energy-dependent process which involves a cascade of biochemical changes, 
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like fragmentation of the genomic DNA into the nucleosomal oligomers (multiples 
of a 180-nucleotide base pair subunit) is referred to as programmed cell death (36). 
Recently it has been shown that androgen dependent prostatic cells retain the ability 
to activate programmed cell death in response to androgen ablation (37). In 
androgen-independent prostatic cancer cells, however, there is a defect such that the 
programmed cell death is no longer activated by androgen removal. TNF exerts its 
anticellular effect in a similar way, by degradation of DNA into nucleosome 
fragments, and this effect can be enhanced by IFN-gamma (38,39). This may in fact 
explain the synergistic effects of combinations of these cytokines. Immunotherapy 
with biological response modifiers could be a method to activate the programmed 
cell death in androgen-independent cancer cells. 
The experimental data presented here indicate that cytokines can have 
antiproliferative effects against hormone-independent cancer cells. This may open a 
way to a new therapeutic modality in the treatment prostatic cancer. 
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ABSTRACT 
We have investigated the antiproliferative effects of recombinant human 
alpha- and gamma-Interferon (IFN) and recombinant human Tumor Necrosis Factor 
alpha (TNF) against the hormone-independently growing PC3 and DU 145 prostatic 
tumor lines. Subcutaneous, peritumoral administration of the drugs was started 24 
hours after subcutaneous implantation of 1-2 mnr* tumor pieces. IFN was given 
three times per week and TNF five times per week. IFN-alpha (dose-range 0.5-5 
ng/gram bodyweight) had significant growth-inhibiting effects against the PC3 tumor, 
but showed no significant antitumor effects against the DU145 tumor. IFN-gamma 
monotherapy (dose-range 8-80 ng/g body weight) was less effective than IFN-alpha. 
500 ng/gram TNF produced growth inhibition of both tumors, whereas the lower 
dose (50 ng/g) was only effective against the PC3 tumor. IFN-alpha and -gamma 
combination treatment had significant antiproliferative effects against the PC3 tumor, 
but not against the DU 145 tumor. Combinations of IFN-alpha and TNF were very 
effective against both xenografts, some combinations resulted in complete growth 
inhibition. IFN-gamma and TNF combinations also showed significant antitumor 
effects against both tumor lines. We therefore conclude that cytokine combination 
treatment may provide a new approach in the treatment of hormone-escaped 
prostatic tumors. 
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INTRODUCTION 
Prostatic carcinoma is the most common tumor occurring among men (1). 
The tumor is found most frequently in men of 50 years or older, with the incidence 
rising with each decade. Furthermore, the incidence and mortality will most likely 
increase due to the aging of the population (2). 
The disease is frequently at an advanced stage at the time of presentation: 
more than 60% (range 21-80%) of the patients have disease extended beyond the 
prostate (3). The management of both regional and metastatic prostatic cancer 
remains a major clinical problem. Since Huggins and Hodges' report on the 
androgen dependency of prostatic carcinoma in 1941, androgen ablation has been 
the front-line therapy for prostatic cancer (4). Approximately 60-70% of the patients 
will initially respond to androgen ablation (5). Unfortunately, however, essentially all 
of these patients will relapse to a state unresponsive to further antiandrogenic 
therapy. To date, chemotherapy has not prolonged survival of patients with 
metastatic prostatic carcinoma (6,7). Therefore, new approaches to the treatment of, 
especially the androgen-independently growing, prostatic tumors must be developed. 
Next to surgery, chemotherapy and radiation therapy, immunotherapy is the 
fourth cancer treatment modality. Cytokines, like Interferons (IFN), show promising 
results in experimental model systems as well as in phase I and II clinical studies 
(8,9). Three main groups of IFN can be defined, IFN-alpha, IFN-beta and IFN-
gamma (10). Alpha-IFNs are a group of closely related proteins with approximately 
75% homology in their amino acid sequences. They are produced mainly by 
leukocytes upon exposure of viruses, bacteria, and double-stranded RNA, and share 
the same cell membrane receptor with IFN-beta. IFN-gamma is the product of 
activated T-lymphocytes, and is encoded by a unique gene which has little or no 
homology to the other two IFN-types (11). IFNs have direct antiproliferative effects 
against tumor cells and indirect immune modulating effects, e.g. they can induce or 
enhance the expression of cell surface antigens of the major histocompatibility 
complex (MHC) and stimulate cytotoxic T-cells, NK-cells and macrophages. In vitro 
studies with prostatic cancer cell lines showed direct antiproliferative effects of IFN-
alpha and -beta (12,13). Some clinical trials have already been conducted with 
different IFNs. The number of patients treated with IFN, however, is too small to 
draw firm conclusions about clinical activity of these drugs in prostate cancer (8). 
TNF is the cytokine in serum of mice treated sequentially with BCG and 
endotoxin that promotes tumor lysis (14). It is cytotoxic/cytostatic to some tumor 
lines in vitro (approximately 30% of the tested lines) and it can cause hemorrhagic 
necrosis in transplanted tumors in vivo (14,15). TNF is produced by activated 
macrophages and showed antiproliferative effects against prostatic tumor lines in 
vitro and in vivo (16,17). 
As shown for other solid tumors, combinations of alpha- and gamma-IFN 
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and TNF can result in the enhancement of their respective antitumor effects in vitro 
and in vivo (18,19,20). In the studies presented here we tested the antiproliferative 
effects of recombinant human IFN-alpha and -gamma and TNF alone or in 
combinations against two androgen-independently growing prostatic xenografts 
transplanted in nude mice. 
MATERIAL AND METHODS 
Animals 
Six weeks old male Balb/C nu/nu mice were obtained from Bornholt Gard, 
Rije, Denmark. Groups of five mice were kept in PAG type 2 cages covered with 
an iso cap (Iffa Credo, France) for sterile conditions and with a regimen of 12 
hours light per day. Sterilized sawdust (Iffa Credo Broekman BV, The Netherlands) 
was used as bedding material inside the cages. Mice were allowed access to gamma 
irradiated (0.9 MR) SRM-A MM food (Hope Farms, Woerden, The Netherlands) 
and water ad libitum. Drinking water was acidified with 0.7 ml concentrated HCl/l. 
Temperature was 220C, humidity in the experimental environment was not regulated. 
Mice were permitted two weeks to acclimatize before entry into an experiment. 
Cell lines 
Two established human prostatic carcinoma cell lines, PC3 and DU 145, 
were used in these studies. The tumor lines are derived from metastatic lesions in 
bone (PC3) (22) and brain (DU145) (23) from two different patients who suffered 
from prostatic cancer. Both lines were obtained from the American Type Culture 
Collection (ATCC No. 1435-CRL and 81-HTB). Cells were maintained in complete 
medium consisting of RPMI 1640 culture medium supplemented with 10% foetal 
calf serum, 2 mM L-glutamine, 100 lU/ml penicillin, 100 ßg/ml streptomycin, 250 nM 
dexamethasone, and 20 mM HEPES (GIBCO Ltd., Paisley, Scotland). Stock cultures 
of the cells were maintained in monolayer culture at 370C in 6% CO2 in air with 
100% humidity. 
Drugs 
Human IFN-alpha, IFN-gamma and TNF, kindly supplied by Boehringer 
Ingelheim, Alkmaar, The Netherlands, were produced in Escherichia coli. The 
specific activities of IFN-alpha and IFN-gamma were 3.2 χ 10* units/mg protein and 
2 χ IO7 units/mg protein, respectively. Specific activity was measured by inhibition of 
encephalomyocarditis (EMC) virus replication in A549 cells (human lung myeloma 
cell line) with reference to the National Institute of Health (NIH) IFN-alpha 
standard Go 23-901-527 and the NIH IFN-gamma standard Gg 23-901-530. The 
purity of both IFN's was > 98% as determined by SDS Polyacrylamide gel 
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electrophoresis and the amount of endotoxin was less than 1.0 ng/mg protein for 
IFN-alpha and less or equal to 0.5 ng/mg protein for IFN-gamma as based on the 
limulus amoebocyte lysate assay. The specific activity of TNF determined in the 
presence of Actinomycin D was 6 χ 10 Units/mg protein ^ 9 2 9 cytotoxicity assay). 
The purity was > 99% as determined by SDS Polyacrylamide gel electrophoresis 
and it contained 1.0 ng or less endotoxin/mg protein based on the limulus 
amoebocyte lysate assay. The drugs were dissolved in the accessory dissolvent and 
diluted with unsupplemented RPMI medium. After dilution, drugs were divided in 
aliquots of 1.2 ml and stored at -80oC until use. 
In vivo drug testing and monitoring 
In order to propagate tumors in vivo, 106 cells of in vitro passage 20 for the 
PC3 and 4 χ 106 cells of passage 64 for DU145 were injected subcutaneously (s.c.) 
in five mice per line; both lines showed a tumor take of 100%. Tumors were 
maintained by serial transplantation. After excision from a tumor-bearing animals, 
and removal of normal and necrotic tissue, tumor tissue was cut into pieces of 1-2 
mm cubes and implanted s.c. in the right flank of recipient animals. For the in vivo 
treatment protocols we used the fourth to seventh transplant generation for the PC3 
and the second to fifth transplant generation of the DU145. IFNs and TNF were 
administered s.c, peritumorally, three and five times per week respectively, in a 
total injection volume of 200 μΐ. Combinations of IFNs or IFN and TNF were given 
as a single injection. Control mice received unsupplemented RPMI medium three 
times per week. Treatment started 24 hours after tumor implantation. Five mice 
were included in each group; experiments were carried out at least twice. 
Tumor growth was followed by measurements of tumor size according to the 
method of Janik et al. (24) by the same technician throughout each experiment. 
Two times per week length (1), width (w), and height (h) were measured by using a 
slide caliper. No correction was made for skin thickness. The tumor volume (V) was 
calculated from the formula 
V = 0.5236 χ 1 χ w χ h. 
Statistical analysis 
For each mouse, the tumor volume was estimated 57 days after tumor 
implantation by linear regression on the logarithms of the tumor volumes throughout 
this period. For each tumor line, the influence on the estimated tumor volumes by 
the different treatment regimens was measured by analysis of variance. Duplo 
experiments gave similar results (p = 0.89 for the PC3 and ρ = 0.62 for the 
DU145). The p-values in this paper were obtained by two-side t-tests (F-tests). 
Results were considered significant if they gave rise to a family-wise error of less 
than 0.05 according to Hochberg's modification of the Bonferroni inequality (25). 
The effect of treatment A is defined as EA = ^contro^A
 a n <
* the effect of 
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treatment В as Е
в
 =
 с о п / г о // д , where ^, д, and Vcontro¡ are the estimates for 
the tumor volumes of treatment A, treatment В or control group respectively. 
Additivity is defined (26) as Έ.
Α
+
Β
 = Έ.
Α
 χ E B (i.e. log л + в = log E^ + log Е д ) . 
A combination of two treatments is synergistic when the effect of the combination 
(Έ.
Α+Β) is significantly greater than the product of the effects of the separate 
treatments. 
RESULTS 
In order to test the effects of cytokines against hormone refractory prostatic 
cancer a dose finding study was performed with РСЗ-bearing mice. From these 
studies we concluded that a dose range of 150 - 1,500 IU for each IFN is the most 
appropriate for combination drug testing. These doses are equivalent to 0.5 - 5 ng 
IFN-alpha and 8 - 80 ng IFN-gamma per gram body weight. Treatment with the 
highest dose of IFN-alpha (25 ng/g) resulted in a complete growth inhibition of all 
treated mice, whereas the highest dose of IFN-gamma (400 ng/g) could not inhibit 
tumor growth completely (Table I). 
For initial studies with TNF we choose the dose used by Sherwood et al. 
(16) and a ten times higher dose; 50 and 500 ng/g five times per week. No cachexia 
was observed during TNF treatment. However, tumors developed in all mice in 
these preliminary studies. Both doses were used for further studies. 
Effect of cytokine monotherapy on prostatic xenograft growth 
The antitumor effects of IFN-alpha against the PC3 tumor are depicted in 
figure 1A. IFN-alpha 0.5 and 5 ng/g body weight have significant antitumor effects; 
5 ng/g gives rise to a complete growth inhibition in 11 out of 15 mice (Table I). 
IFN-alpha has, in contrast to the very effective growth inhibition in the PC3 tumor, 
no significant effects against the DU 145 tumor (fig. 2A). 
IFN-gamma monotherapy is less effective than IFN-alpha and could not 
significantly suppress DU145 tumor growth (fig. 2B, Table I). Likewise, PC3 tumor 
growth was not inhibited by 8 ng/g bodyweight IFN-gamma. Application of 80 ng/g, 
however, had significant antitumor activity (fig. IB). 
On basis of units per gram body weight administered it is possible to 
compare the effectivity of the two different IFNs. Comparison of IFN 
monotherapies against the PC3 tumor showed that IFN-alpha 0.5 ng/g had a 
significantly stronger antitumor effect than IFN-gamma 8 ng/g (p < 0.001). The 
higher IFN-alpha dose was also more effective than 80 ng/g IFN-gamma (p < 
0.001). 
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Table I 
Cytokine mono- and combination therapy against PC3 and DU145 tumors. 
Statistical analyses and number of tumors growing per treatment group. 
Treatment· 
PC-3 
p-valueb tumor growth0 
DU145 
p-value tumor growth 
control 
alpha-IFN 0.5 
alpha-IFN 5 
alpha-IFN 25 
gamma-lFN 8 
gamma-IFN 80 
gamma-lFN 400 
TNF 50 
TNF 500 
alpha 0.5/gamma 8 
alpha O.S/gamma 80 
alpha 5/gamma 8 
alpha 5/gamma 80 
alpha 0.5/ΓΝΡ 50 
alpha 0.5/TNF 500 
alpha 5/TNF 50 
alpha 5/TNF 500 
gamma 8/TNF 50 
gamma 8/TNF 500 
gamma 80/ΓΝΡ 50 
gamma 80/TNF 500 
. 
<0.0001· 
<0.000И 
ND 
0.11 
<0.0001· 
ND 
0.0001* 
<0.0001* 
<0.000l* 
<0.0001· 
<0.0001· 
<0.0001· 
<0.0001· 
<0.0001* 
< 0 . 0 0 0 I · 
<0.0001* 
0.016 
•eO.OOOl* 
<0.0001· 
<0.0001· 
17/17 
10/14 
4/15 
0/5 
13/15 
12/14 
5/5 
11/15 
12/15 
2/10 
0/10 
0/10 
2/10 
3/10 
3/10 
0/10 
0/10 
10/10 
7/10 
8/10 
5/10 
. 
0.088 
0.077 
0.046 
0.017 
0.04 
"COOOOl· 
0.019 
0.041 
0.022 
0.13 
0.002 
0.0003* 
<0.0001* 
<0.0001* 
0.044 
•eO.OOOl* 
<0.0001* 
0.0003* 
10/10 
9/10 
10/10 
ND d 
8/9 
8/10 
ND 
9/10 
6/10 
9/10 
9/10 
9/10 
10/10 
8/10 
8/10 
7/10 
6/10 
9/10 
8/10 
7/10 
6/9 
a
 treatment in ng/g body weight 
b
 t-test comparing treatment vs. control 
c
 number of mice with tumor/total number of mice 
d
 not determined 
* significant according to Hochberg's modification of the Bonferroni inequality 
TNF monotherapy with 50 ng/g, five times per week, was effective 
againstthe PC3 tumor (fig. 1С), but not against the DU145 tumor (fig. 2C). The 
highest TNF dose, however, had a clear growth inhibiting effect against both 
xenografts. Furthennore, it should be noted that TNF 500 ng/g is the only 
monotherapy tested against the DU 145 tumor, which resulted in a growth inhibition 
significantly different from the untreated growth control. None of the mice died due 
to the TNF treatment. 
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Figure 1 
Figure 1. Antitumor effects of cytokine monotherapy against the PC3 tumor. Drugs were 
administered s.c, peritumorally; treatment started 24 hours after tumor implantation. Ten mice were 
included in each treatment group. Bars indicate standard error of the mean (SEM). A: IFN-alpha 
monotherapy, 0.5 or 5 ng/g body weight, 3 times per week. B: IFN-gamma monotherapy, 8 or 80 
ng/g body weight, 3 times per week. C: TNF monotherapy, 50 or 500 ng/g body weight, 5 times per 
week. 
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Figure 2 
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Figure 2. Antitumor effects of cytokine monotherapy against the DU145 tumor. Drugs were 
administered s.c, peritumorally; treatment started 24 hours after tumor implantation. Ten mice were 
included in each treatment group. Bars indicate SEM. A: IFN-alpha monotherapy, 0.5 or S ng/g body 
weight, 3 times per week. B: IFN-gamma monotherapy, 8 or 80 ng/g body weight, 3 times per week. 
C: TNF monotherapy, 50 or 500 ng/g body weight, 5 times per week. 
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IFN-alpha and -gamma combination therapy 
The pronounced antitumor effect of IFN-alpha alone against the PC3 tumor 
makes it difficult to prove synergism in combination with another cytokine. All 
combination regimens of both low- and high-dose IFN-alpha and IFN-gamma were 
very effective against PC3 tumor growth (p < 0.0001); only four out of 40 mice 
developed a tumor during the treatment period (fig. ЗА, Table I). In one of the 
duplo experiments mice were not sacrificed at the end of the treatment period, but 
were kept alive. After 8 weeks in 13 out of 20 mice a tumor started to grow, 
whereas in the IFN-alpha monotherapy regimens all mice developed a tumor (data 
not shown). 
Unlike the PC3 tumor, combinations of IFN-alpha and IFN-gamma have 
very limited effects in the treatment of the DU 145 tumor. Effects of none of these 
combinations could reach the level of significance (fig. 3B). 
Figure 3 
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Figure 3. Antitumor effects of IFN-alpha and -gamma combination therapy. Drugs were administered 
S.C, pentumorally, 3 times per week; treatment started 24 hours after tumor implantation. Ten mice 
were included in each treatment group. Bars indicate SEM. A: IFN-alpha 0.5 or 5 ng/g body weight 
and IFN-gamma 8 or 80 ng/g combination therapy against the PC3 tumor. B: IFN-alpha 0.5 or 5 
ng/g and IFN-gamma 8 or 80 ng/g combination therapy against the DU145 tumor. 
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IFN-alpha and TNF combination therapy 
Treatment of РСЗ-bearing mice with combinations of IFN-alpha 5 ng/g plus 
both doses of TNF resulted in complete growth inhibition (fig. 4A). After cessation 
of treatment, these mice were kept alive and no tumors developed after a period of 
at least 8 weeks. These combinations of IFN-alpha with TNF are, therefore, more 
effective than the combinations with IFN-gamma in which tumors did develop after 
the treatment period. In the combinations with IFN-alpha 0.5 ng/g plus TNF 50 or 
500 ng/g, eight out of ten mice developed a tumor 8 weeks after cessation of 
treatment. IFN-alpha 0.5 ng/g plus TNF 500 ng/g and both combinations with IFN-
alpha 5 ng/g showed significant growth inhibitions of the DU 145 tumor compared to 
the control group (fig. 4B). Complete growth inhibition, however, could not be 
achieved with any of these combinations. The best effect was found with the 
combination of IFN-alpha 5 ng/g and TNF 500 ng/g. Due to the great effect of TNF 
500 ng/g monotherapy this combination was not synergistic. 
Figure 4 
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Figure 4. Antitumor effects of IFN-alpha and TNF combination therapy. Drugs were administered 
Sx., peritumorally, IFN-alpha 3 times and TNF S times per week; treatment started 24 hours after 
tumor implantation. Ten mice were included in each treatment group. A: IFN-alpha 0.5 or 5 ng/g 
body weight and TNF 50 or 500 ng/g combination therapy against the PC3 tumor. B: IFN-alpha 0.5 
or 5 ng/g and TNF 50 or 500 ng/g combination therapy against the DU145 tumor. 
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Gamma-IFN and TNF combination therapy 
In the treatment of the PC3 tumor, all combinations of gamma-IFN and 
TNF, except for the combination of both lowest doses, had significantly growth 
inhibiting effects compared to the growth control (fig. 5A). Synergistic effects, 
however, were not observed. The combination of gamma-IFN 8 ng/g and TNF 500 
ng/g, for example, is significantly more effective than IFN-gamma monotherapy, but 
not more effective than TNF 500 ng/g alone. Against the DU 145 tumor three out of 
four gamma-IFN and TNF combinations produced significant growth-inhibiting 
effects, synergistic effects, however, were not observed (fig. 5B). 
Figure 5 
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Figure 5. Antitumor effects of IFN-gamma and TNF combination therapy. Drugs were administered 
S.C, pentumorally, IFN-gamma 3 times per week and TNF 5 times per week, treatment started 24 
hours after tumor implantation. Ten mice were included in each treatment group. Bars indicate 
SEM. A: IFN-gamma 8 or 80 ng/g body weight and TNF 50 or 500 ng/g combination therapy against 
the PC3 tumor. B: IFN-gamma 8 or 80 ng/g and TNF 50 or 500 ng/g combination therapy against 
the DU145 tumor (combination IFN-gamma 80 ng/g and TNF 500 ng/g, η = 9). 
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DISCUSSION 
Prostatic cancer is frequently in a locally advanced stage at presentation, 
making radical treatment such as surgery or radiotherapy ineffective (3). For almost 
50 years, since the pioneering efforts of Huggins and Hodges, hormonal therapy has 
been the major treatment modality for metastatic prostatic cancer (4). After initial 
response, the patient will inevitably develop a tumor which is hormonally 
unresponsive and resistant to current therapeutic modalities. Therefore, it would be 
useful to develop new ways to treat hormone-resistant tumors. 
In vitro studies with IFN-alpha and -beta showed antiproliferative efficacy of 
both drugs against the PC-3 and DU145 cell lines (12,13), IFN-beta being more 
effective than IFN-alpha (12). The androgen-dependent LNCaP cell line, however, 
was resistant to IFN-beta treatment (27). In vitro studies with TNF revealed 
controversial results. Sherwood et al. reported cytotoxicity toward all three prostatic 
cell lines (16), Fruehauf et al. also found sensitivity of the LNCaP cell toward TNF; 
PC3 cells, however, were resistant (17). 
We have investigated the in vivo antitumor effects of IFN-alpha and -
gamma and TNF against hormone-independent prostatic tumor lines. IFN-alpha 
monotherapy was very effective against the PC-3 tumor; no significant differences 
were found between the effects of 0.5 and 5 ng/g body weight. Alpha-IFN 25 ng/g, 
however, inhibited tumor growth completely. Gamma-IFN 80 ng/g had significant 
antitumor effects, whereas 8 ng/g could not reduce tumor growth. Also, the highest 
dose IFN-alpha appeared to be more effective against the DU 145 tumor although 
this was not significant. Both gamma-IFN doses mediated similar, not significant, 
growth-inhibiting effects. The antitumor effects of the IFNs can best be described as 
dose-dependent in the dose range tested. This in contrast to the so called bell-
shaped response curves we have found for alpha- and gamma-IFN against some of 
eight different renal tumor xenografts (28). Clinical trials with IFN-gamma in renal 
cell carcinoma also revealed an optimal treatment dose for these tumors. Aulitzky 
and co-workers showed that a relatively low dose of gamma-IFN, 100 μg (2 χ 10o 
lU) once weekly is biologically more active than higher doses. The low dose resulted 
in a nearly maximum rise of neopterin and ß2-microglobulin levels in the serum with 
minimal side effects, whereby the increments in these markers were predictive for 
response (29). 
TNF 500 ng/g was the only monotherapy which had significant antitumor 
effects in the DU145 tumor. Growth of the PC3 tumor was significantly inhibited by 
both TNF doses, which is in contrast to the in vitro data of Fruehauf et al. (17). 
Sherwood et al. also showed in vivo growth inhibition of the PC3 by intravenous 
administered TNF in a dose of 50-100 /ig/kg every other day (16). 
In our studies we administered the cytokines peritumorally. In clinical trials, 
however, treatment is usually given systemically, which will result in lower local drug 
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levels. Unlimited increase of cytokine administration is not possible due to toxicity, 
especially of TNF (30). In the studies presented here, we have shown that 
combinations of cytokines can produce significant antitumor effects with lower 
cytokine concentrations; e.g., low TNF doses in combination with IFN-alpha are 
more effective than high dose TNF monotherapy against the PC3 tumor. Another 
possibility to overcome the significant host toxicity of cytokines could be the use of 
liposome-encapsulated cytokines. TNF administered in this way retains its 
immunomodulatory activity, but has significantly lower toxic inflammatory effects 
when compared to free TNF in vivo (31). Liposome-encapsulated IFN-alpha 
retained its antitumor effects against bladder tumor cell lines in vitro (32). 
Furthermore, small changes in the TNF molecule can make it much less toxic (33). 
Heterotransplantation of human tumors into nude mice provides a model in 
which to study the antitumor activity of new drugs on human tumors in vivo (34). 
Due to the congenital absence of the thymus, cell-mediated immune functions in 
nude mice are severely impaired. The animals lack one of the important effector 
cells, the (cytotoxic) T-cell, and therefore, only the direct effects of the cytokines 
can be studied. Moreover, both the antiproliferative and immunomodulatory effects 
of IFNs are species-specific. Human IFN-alpha and IFN-gamma have no effects on 
the mouse immune system as measured by NK cell or macrophage activity (35,36). 
This makes it more unlikely that indirect effects contribute to the antitumor effects. 
A possibility in studying the complete spectrum of cytokine-mediated effects, 
i.e., direct and indirect host-mediated effects, could be the use of severely combined 
immunodeficiency (SCID) mice in which the human immune system can be partly 
reconstituted (37,38). Another possibility is the use of animal tumors in syngeneic 
animals. We have investigated the antitumor effects of rat gamma-IFN and human 
TNF in Dunning rat prostatic tumors and found limited activity of cytokine 
monotherapy but synergistic effects of the different combination treatments (39). 
Conclusion 
Most combination treatments resulted in significant growth inhibitions of the 
DU145 tumor. Combinations were also very effective against the PC3 tumor, e.g. 
combinations with IFN-alpha give rise to tumor growth in 10 out of 80 treated mice. 
We, therefore, conclude from our data that cytokine combination treatment can 
provide a new approach in the treatment of hormone-escaped prostatic tumors. 
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ABSTRACT 
A cohort of 300 ACI rats was kept under standard laboratory conditions. 
After 30 months or upon natural death complete autopsy was performed. In the 
genitourinary tract 4 kidney and 5 bladder tumors were found. Two of these bladder 
tumors, RBT323 and RBT157, are serially transplantable. In the 5th transplant 
generation the RBT323 tumor becomes metastatic to the lungs in more than 90% of 
the animals. The metastatic ability of the RBT157 tumor changed from low to 
intermediate (50% of the rats have lungmetastases) in the 4th passage. 
Histologically, the initial passages of the RBT323 and 157 tumors are grade II 
transitional cell carcinoma. The histological pattern of the RBT157 tumor remains 
essentially unchanged, whereas the RBT323 tumor changes into a grade III tumor in 
the third passage. Electronmicroscopical studies revealed oblong elliptical and round 
vesicles lined by an asymmetrical unit membrane in the tumor cells, which stresses 
the urothelial origin of the tumors. Immunohistochemically both tumors show 
expression of cytokeratin 5,7,8 and 18. The progression of the tumors to a 
metastatic phenotype, however, was not associated with a specific change in the 
morphological characteristics. Cytogenetic analysis of different passages showed that 
both tumors are peridiploid with few marker chromosomes. In subsequent passages 
an accumulation of marker chromosomes was found. Furthermore, in both tumors a 
loss of chromosomes was found which maintained during tumor progression. Flow 
cytometric analysis showed an aneuploid DNA content in the initial passages of the 
RBT323 tumor, the DNA content of subsequent transplant generations, however, 
was diploid, which is similar to the RBT157 tumor. 
Two independently arisen rat tumor lines that represent the progression of 
bladder cancer are described. This model system may be helpful in the identification 
of specific markers associated with the progression of bladder cancer. 
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INTRODUCTION 
Estimates of new cancer cases in the United States show that cancer of the 
bladder is the fourth most prevalent cancer in men and the ninth among female 
patients. Bladder cancer is about three times as common in men as in women. The 
estimates for 1990 are 36,000 new cases in males and 13,000 new cases in females 
in the USA. Bladder cancer death rates have been fairly constant the last 60 years 
(1,2). Recurrence rates vary from 30 per cent of a solitary papillary tumor to more 
than 90 per cent in some cases of multiple tumors. S to 30 per cent of all cases 
exhibit progression of disease (3). In general tumor progression is associated with 
large tumor size, high stage, high grade, multiplicity of tumors, vascular or lymphoid 
invasion and concurrent carcinoma in situ (3,4). More importantly, recent studies 
indicated involvement of specific chromosomal changes in tumor progression of 
TCC. In low-grade, non-invasive TCC trisomies for chromosome 1,7 and 11 and 
monosomy for chromosome 9 were found, with progression of the tumors the 
number of chromosomal aberrations increased (5). Allelic losses were found for 
chromosome 9, 11 and 17 (6). The greatest frequency was seen for chromosome 9q 
(67% of the informative cases) and 17p (63% of the informative cases). The authors 
concluded, after having investigated a greater number of cases, that the loss of 
chromosome 17 is a late event in tumor progression and can distinguish between 
low and high grade TCC (7). 
An important restriction in the study of human bladder cancer is the lack of 
available tumor tissue for experimental purposes. Especially tumor material, truly 
representative for the progression from low to high stage TCC is very difficult to 
obtain. The tumor volumes obtained from routine biopsies and cystectomies are 
often small and damaged due to intra-operative or prior treatment. Many important 
factors, not specific for bladder cancer, cannot be controlled with clinical material, 
including genetic differences, age, time of initial onset of the disease and 
distribution, variability of cell types etc. To overcome these problems a variety of 
animal models for bladder cancer have been developed (8,9). 
After heterotransplantation of human bladder cancer tissue into immune-
deprived and nude mice some short term and serially transplantable xenograft lines 
have been established. No correlation has been found between the success of 
xenografting and the grade of the 'donor' tissue (9,10). Russell et al demonstrated 
substantial heterogeneity within and between different TCC xenografts. Studies with 
these lines may help to explain the diverse natural history of bladder cancer (12). 
Animal tumor models can be divided in carcinogen-induced and spontaneous 
tumor models. A number of potent carcinogens can produce bladder neoplasms in 
laboratory animals (8,9,13). In most induced tumors concurrent squamous metaplasia 
occurs and most tumors consist of both poorly differentiated transitional cell 
carcinoma (TCC) and squamous cell carcinoma (SCC) (13,14). Few spontaneous 
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bladder tumor models are available up to now. The Brown Norway rat has a high 
incidence of spontaneously occurring urothelial tumors of the bladder and ureter, 
35% of the male and 3% of the female rats developed bladder tumors, which are 
transplantable in syngeneic rats (15). The invasive tumors consisted of transitional 
epithelium, but also areas of squamous metaplasia were observed, SCC, however, 
was not common. In the Nb rat a single transplantable transitional cell tumor has 
been described (16). In DA/Han rats 54% of male and 14.4% of female rats 
develop spontaneous urinary bladder tumors (17). The incidence increases with age 
of the rats, also for induced carcinomas an increased risk of urinary bladder 
carcinogenesis with age has been reported (18). The most frequent tumors found in 
the DA/Han rats were solid type transitional cell carcinomas; 0.3% of the male and 
9.6% of the female rats had SCC (17). 
ACI rats are known for their spontaneous genito-urinary carcinomas, 
especially prostatic carcinomas, but TCC has been described also (18,19). In this 
paper we present the characterization of two new transplantable TCC in ACI rats. 
Furthermore, these lines are evaluated for phenotypic and genetic changes occurring 
in the progression of the lines during serial transplantation. 
MATERIALS AND METHODS 
Animals 
For the initial tumor-finding study, 300 male ACI/SegHSD (Harlan Sprague, 
Inc., Indianapolis, IN) were housed in an environmentally controlled room and were 
provided with RMH-TM food (Hope Farms BV., Woerden, The Netherlands) and 
water ad libitum. Upon natural death complete autopsy was performed. The urinary 
bladder and prostate were excised in toto and fixed for at least 24 hours and 
embedded in paraffin. Sections were cut transversely through the midportion of the 
bladder, and four 5 д т sections were taken from each half to adequately sample 
the entire bladder and prostate; these sections were stained with hematoxylin and 
eosin. 
Tumor Transplantation 
Primary tumors and tumors from subsequent passages were excised from 
tumor-bearing animals, after removal of normal and necrotic tissue, the tumor tissue 
was cut into pieces of 20 mg. An 0.5 cm incision was made in the right flank of 
recipient animals, and after separating the subcutaneous tissue by blunt dissection, 
the tumor fragment was placed subcutaneously (s.c). The incision was closed using 
skin clips (7.5 χ 1.75 mm, Aesculap, Germany). In this way a tumor take of 100% 
was achieved. Per passage at least 6 rats were implanted. Tumor growth was 
followed by measurements of tumor size according to the method of Janik et al. 
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(21) by the same measurer throughout each experiment. At least once per week 
length (1), width (w) and height (h) were measured using a slide caliper. No 
correction was made for skin thickness. The tumor volume (V) was calculated from 
the formula V = 0.5236 χ 1 χ w χ h. Per animal, the paired serial measurements of 
days post-tumor inoculation (x-axis) and log tumor volume (y-axis) were plotted to 
reveal the time period of exponential growth. By means of linear regression the best 
lines were fitted. The slopes of the regression lines represent the growth rate, the 
inverse of the slopes represent the tumor doubling times. 
Light and Electron microscopy 
When the subcutaneously growing tumors reached a size of 5-10 cnv*, rats 
were sacrificed with an ether overdose and complete necropsy was performed. Both 
lungs and representative pieces of the tumor were routinely fixed in 4% buffered 
formalin for at least 24 hours and embedded in paraffin. Others organs were grossly 
inspected for metastases and if suspicious also fixed in formalin. To adequately 
sample the tumors and the lungs four 5 μιη sections were taken and stained with 
hematoxylin and eosin. Tumors were assessed according to Squire (22) and Koss et 
al. (23). 
For electron microscopy representative parts of the tumors were cut into 
small pieces and prefixed with 2% glutaraldehyde in 0.1 M phosphate buffer (pH 
7.4) at 4 C, and postfixed in 0.1 M paladebuffer. After washing in the same buffer 
and degradation in graded ethanols, the specimens were embedded in Epon 812. 
Thin sections were double-contrasted with uranyl acetate/lead citrate and examined 
in a Philips EM 300 (24). 
Immunohistochemistry 
For immunohistochemical studies we used the indirect immunofluorescence 
technique as described before (25). Frozen sections of the tissues (6 μιη) were cut 
on a cryostat and air-dried before fixation in methanol (5 min., -20 "С) and acetone 
(3 times 5 sec). After being washed in phosphate-buffered saline (PBS) for 10 min, 
the sections were incubated with 20% normal rat serum (NRS) in PBS at room 
temperature (30 min), and subsequently with the primary antiserum for 60 min. 
After repeated washing in PBS (3 times 10 min) the rabbit anti-mouse conjugated to 
peroxidase (DAKOpatts, Denmark) diluted 1:100 (v/v) in PBS with 20% NRS was 
applied for 30-45 min. After repeated washings in PBS (3 times 10 min), peroxidase 
activity was detected with 3-3'diaminobenzidine (DAB; 6 mg/10 ml, 0.65% imidazole 
in PBS) and hydrogen peroxide to a final concentration of 0.01%. After incubation 
for 5 min. and extensive washing with tap water, the slides were counterstained with 
hematoxylin, and mounted with permount (Fisher Scientific, New, Jersey, USA). 
The following antibodies directed against intermediate filament proteins 
were used in this study: 
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1. The mouse monoclonal antibody RCK 102, directed against keratins 5 and 8 
(nomenclature according to Moll (26)). This antibody stains virtually all 
epithelial tissues, but not nonepithelial tissues (27). 
2. The mouse monoclonal antibody RCK 10S, directed against keratin 7 and 
reactive with a subgroup of glandular epithelial tissues (27). 
3. The mouse monoclonal antibody RGE S3 directed against keratin 18, which 
specifically recognizes columnar epithelial cells from digestive, respiratory, 
and urogenital tracts, endocrine and exocrine tissues, and mesothelial cells. 
No significant reaction is normally found in squamous epithelial or 
nonepithelial tissues (28). 
4. The mouse monoclonal antibody RKSE 60, directed against human skin 
keratin 10 and specific for keratinizing stratified squamous cells. No reaction 
is found with this antibody in columnar epithelial cells, nonkeratinizing 
squamous cells, or nonepithelial cells (28). 
5. The mouse monoclonal antibody RV 203 is specific for vimentin (29). 
6. The mouse monoclonal antibody RD 301 is specific for desmin (30). 
Preparation of single cell suspensions 
When tumors reached a size of 5-10 спт* the rats were sacrificed and tumor 
material was suspended in RPMI 1640 tissue culture medium (Gibco, Paisley, UK). 
After careful removal of normal tissue and areas of tumor necrosis, tumors were cut 
into pieces and minced with scissors into a 300 д т metal sieve and continuously 
washed with RPMI 1640 solution into a petri dish. The minced tumor tissue was 
passed through a 40-70 μνη nylon filter (Ortho Diagnostics, Beerse, Belgium) to 
obtain a single cell suspension. This cell suspension was used for flowcytometric 
analysis and/or growth in the colony forming assay. 
Flow Cytometry 
The single cell suspension was centrifuged at room temperature at 400g for 
S min, after which the supernatant was discarded but fluid sticking to the wall of the 
tubes was allowed to cover the pellet, as described before (31). The pellet was 
vortexed vigorously and 70% ethanol (-ICPC) was added rapidly under constant 
vortexing. The final concentration was about 3 χ IO6 cells/ml. At this stage the cells 
could be stored at -2(rC. For DNA measurements 1 χ IO6 cells were resuspended in 
1 ml of a propidium iodide (PI) solution (20 mg/1 A grade in 150 mM sodium 
phosphate buffer, pH 7.4, Calbiochem-Boehringer, La Jolla, CA). To 1 ml of this 
cell suspension, 0.1 ml of a stock solution of RNAse ( 1% type A in sodium 
phosphate buffer, Sigma) was added and subsequently incubated for exactly 10 min 
at ЗТ^С. Then the cell suspension was filtered through a 49 βία filter (Ortho). Cells 
were kept in the dark prior to FCM analysis. 
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DNA measurements were performed using a Cytofluorograph 50H (Ortho 
Instruments, Westwood, MA). PI was excited at 488 nm with a argon ion laser 
(Spectra physics, Mountain View, CA). Fluorescence was measured using a 630 nm 
longpass filter. All data were recorded as 2048 channel histograms and stored in a 
PDP 11/34 computer (Digital Equipment Corporation, Marlboro, MA) for 
subsequent data analysis. For ploidy measurements chicken red blood cells (CRBC) 
were used as internal standard. A mixture of CRBC and rat lymphocytes served as 
an external standard. The degree of DNA content aberration is expressed by the 
DNA index (DI), which is the ratio of the mean of the relative DNA content of the 
G0/G1 cells of the tumor divided by the mean of the relative DNA measurements 
of the diploid G0/G1 rat lymphocytes (32). Diploid cells have, by definition, a DNA 
index of 1.0. Tumors were qualified FCM (near)-diploid (DI = 0.9-1.1), FCM 
aneuploid (DI = 1.2-1.7; > 2.2) or FCM tetraploid (DI = 1.8-2.2). The coefficient 
of variation of the Go/Gl peaks analyzed was between 2 and 6% (mean 4%). 
Soft-agar culture 
The single cell suspension was centrifuged at room temperature at 400g for 
5 min after which the supernatant was discarded. Upon resuspension of the cell 
pellet in double enriched CMRL 1066 (Gibco, Paisley, UK), cell density and viability 
were determined by adding 15 μΙ trypan blue solution (25 mg in 5 ml 3% acetic 
acid) to 15 μΙ cell suspension and simultaneously counting colored and not colored 
cells using a Biirker Turk haemocytometer. For the detection of the in vitro growth 
potential a modified double layer soft agar culture method as originally described by 
Salmon and Hamburger (33) was used (34). Tumor cell suspensions were plated in 
the upper layer of the two-layer culture system in a range of 10,000 - 500,000 cells 
per dish. Cells were cultured immediately after preparation of the single cell 
suspension, growth potential was quantified using an Omnicon Fas II automated 
colony counter (Milton Roy Inc., Rochester, New York (35)). 
Chromosomal Analysis 
Single cell suspensions were made by mincing tumors with scissors in RPMI 
1640 culture medium containing 10% fetal bovine serum (FBS) and colcemide (0.02 
μg/ml). After incubation at 37 0C for 10 minutes the medium was replaced with 
0.075 M KCl hypotonic solution containing colcemide (0.02 μg/ml) which was 
prewarmed to 37 0C. The suspension was incubated at 37 ^C for 25 minutes and 
fixed with methanohacetic acid (3:1). Chromosomal slides were prepared by 
dropping the cell suspension onto clean slides in a humid box. Thirty to 50 
metaphases were counted for each tumor. Chromosomes were banded using the 
trypsin-Giemsa technique (36) and arranged according to the scheme of Satoh et al. 
(37). At least five G-banded metaphases were karyotyped for each tumor. 
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RESULTS 
Etiolopv and growth characteristics 
300 male ACI rats were kept under standard laboratory conditions, without 
influence of any known carcinogen. Approximately 150 animals died within 24 
months, the remaining animals were sacrificed at 30 months. In the genitourinary 
tract 4 kidney tumors and 5 bladder tumors were found. In contrasts to other 
studies, no prostate tumors developed in these rats (18). All 5 bladder tumors were 
transplanted s.c. in syngeneic rats, 2 tumors appeared to grow under these 
conditions. These tumors were designated Rat Bladder Tumor 323 and 157 
(RBT323 and RBT157). Both tumors were slowly growing (Table 1). Initially both 
tumors typically grew as a cyst, with papillary tumors inside this cyst. Due to this 
growth pattern the tumor doubling times of the first passages should be considered 
inaccurate. Upon further passaging the tumor acquired a more solid growth pattern. 
The tumor doubling time of the RBT323 tumor decreased from 13 days in second 
passage to 3.5-4 days in passage eight and subsequent passages (at time of 
submission RBT323 tumor is in transplant generation #20). The tumor doubling 
time of the RBT157 tumor, however, was almost not changed. In the first passage 
the doubling time is 11 days, subsequent passages have doubling times of 8-9 days 
(tumor presently in pass. #7). 
The metastatic capacity of both tumors is low in the initial passages (i.e. less 
than 5% of the animals have microscopic lung metastases) (Table I). However, in 
passage 5 for the RBT323 tumor and passage 4 for the RBT157 tumor, both tumors 
acquire a higher metastatic potential especially to the lungs. More than 90% of the 
RBT323-bearing animals have microscopic and/or macroscopic lung metastases, 
occasionally an axillary or retroperitoneal lymphnode metastasis was found. No liver 
metastases were found. About 50% of RBT157-bearing animals show metastases to 
the lungs. 
Cells of transplant generation 1, 12 and 13 of the RBT323 tumor and 
generation 1 and 4 for the RBT 157 tumor were tested for their in vitro growth 
potential. The trypan blue exclusion test usually showed a viability of 20%. 14 days 
after plating 500,000 RBT323 cells 250-300 colonies were formed in the dishes, i.e. a 
plating-efficiency of 0.06%. Cells of RBT157 passage 1 form 20 colonies, while cells 
of transplant generation 4 form 70 colonies after 14 days of culture (plating 
efficiency from 0.004 - 0.014%). 
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Table I 
Tumor passage* DNA-index* Tumor doubling timeb metastases0 
RBT323 
RBT323.pl 
RBT323.p2 
RBT323.p3 
RBT323.p4 
RBT323.p5 
RBT323.p6 
RBT323.p8 
RBT323.plO 
RBT323.pl2 
RBT323.pl3 
RBT323.pl5 
RBT323.p6 (meta) 
RHUS? 
RBT157.pl 
RBT157.p2 
RBT157.p3 
RB1157.p4 
RBT157.p6 
1.759 
1.645 
0.916 
0.999 
0.976 
1.110 
1.017 
0.999 
0.970 
1.101 
1.024 
1.002 
0.946 
1.151 
1.016 
1.061 
1.017 
1.067 
1.049 
ND 
ND 
13.43 
11.81 
5.95 
5.69 
4.35 
3.84 
3.68 
4.16 
3.26 
4.29 
ND 
ND 
11.15 
ND 
10.50 
8.19 
9.46 
(1.40) 
(1.23) 
(1.02) 
(0.25) 
(0.10) 
(0.15) 
(0.22) 
(0.27) 
(0.25) 
(0.34) 
(0.82) 
(1.12) 
(0.32) 
(1.80) 
0/1 
0/6 
0/8 
1/10 
0/9 
ъп 11/13 
15/15 
9/9 
19/22 
6/6 
5/6 
0/1 
0/4 
1/7 
2/9 
5/8 
2/6 
• FCM (near)-diploid: DI - 0.9-1.1, FCM aneuploid: DI = 1.2-1.7; > 2.2) or FCM tetraploid: DI = 1.8-2.2 
ь
 Tumor doubling time in days, standard error of the mean in brackets 
c
 Number of rats with lungmetastasesAotal number of rats implanted with respective tumor passage 
Table I. Growth characteristics of rat bladder tumor lines 
a: RBT323, original tumor (x 125), b: RBT323, first passage (x 125) 
c: RBT323, passage #14 (x 250), d: RBT157, original tumor (x 125) 
e: RBT157, first passage (x 250), f: RBT157, passage #4 (x 250) 
Histology 
The original RBT323 tumor shows a multicystic growth pattern with solid, 
trabecular and papillary regions (fig. 1). The cells are slightly disorderly arranged 
and the nuclei are moderately atypic. There is an increased mitotic activity, 0-2 
mitoses per high power field (40x, HPF); grade II transitional cell carcinoma. The 
primary tumor exhibits no invasive growth. The wall of the cyst is lined by a 3-7 cell 
layers thick transitional epithelium with a superficial layer of umbrella cells. These 
cells are generally similar to the tumor cells. 
The tumor of the first transplant generation has a similar growth pattern as 
the original RBT323 tumor, however, invasive growth into the subcutaneous tissues 
was found. In the subsequent transplant generations the anisokaryosis of the nuclei 
increases, nuclei become bigger and are more disorderly arranged, i.e. a grade III 
transitional tumor. This grade III growth pattern remains the same for all further 
transplant generations (upto generation 20 at the time). The RBT157 tumor has 
generally the same growth pattern as the RBT323 tumor, but has larger cells due to 
a larger cytoplasm (fig. 1). The nuclei are moderately atypical. In subsequent 
transplant generations the tumor remains a grade II transitional cell carcinoma. The 
mitotic index, however, increases to 0-3 per HPF. No squamous differentiation was 
found in both tumors. 
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Electron Microscopy 
Generally the tumor cells of all passages demonstrate well developed nuclei 
and nucleoli, abundant organelles as well as distinct junctional complexes (fig. 2). 
The basal compartment cells of the first passage of the RBT323 tumor are 
surrounded by an intact basal lamina. In the intermediate layers many cells show 
additionally particles and clusters of glycogen, while other cells contain characteristic 
electron-dense membrane bound granules. In some foci well developed 
intermediated-sized filaments are present in the tumor cells. Numerous cells contain 
flattened discoid-like or fusiform membrane-bound vesicles, predominantly located in 
the juxtanuclear and the apico-luminal part of the cytoplasm. Close contact with the 
cell boundary is present. An adenomatous growth pattern of tumor cells can be 
observed and inter- as well as intracellular luminal formations are present. In the 
superficial cell layers several cells also demonstrate many flattened vesicles in the 
apical side of the cell. At higher magnifications the membranes of these vesicles are 
asymmetric with a thicker fuzzy luminal layer. Upon passaging of the RBT323 tumor 
the amount of junctional complexes apparently decreases with local absence of the 
basal laminae. The intracellular flattened vesicles change to more rounder shapes, 
some of them are obviously attached to the luminal cell membrane. Generally the 
first passages of the RBT157 tumor show the same growth pattern as the early 
passage of the RBT323 tumor. In contrast to the latter, the growth pattern shows 
no distinct changes in the later passages. 
Immunohistochemistrv 
The normal rat bladder, the original tumors, and tumor tissues of the 
transplant generations 1 to 11 for the RBT323 tumor and 1 to 5 for the RBT157 
were examined for their intermediate filament expression pattern by using 
monoclonal antibodies against keratins, vimentin and desmin. 
The broadly cross-reacting keratin monoclonal antibody RCK 102 stains all 
urothelial cell layers of the normal bladder and the RBT157 tumors. In the RBT323 
tumor, however, only the superficial "luminal" cell layer and the directly underlying 
cell layer are stained. Antibody RCK 105 also stains all cell layers of the normal rat 
bladder and the RBT157 tumors (fig. 3). In the primary RBT323 tumor this 
antibody stains all cell layers except most basal cells (only 10% of the basal cells 
stain) (fig. 3). In tumors of further transplant generations only the superficial cells 
and the directly underlying cell layer stain. Antibody RGE 53 reacts with the 
superficial and intermediate cell layers of the normal bladder and with 20% of the 
basal cells. In the primary RBT157 tumor all superficial and intermediate cell layers 
and about 30% of the basal cells are stained by RGE 53, in further transplant 
generations only the superficial and adjacent cells stain (fig. 3). In the primary 
RBT323 tumor all superficial and most intermediate cell cells react with RGE 53 
(fig. 3). Upon transplantation of the tumor generally only superficial cells stain with 
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Figure 2 
Figure 2. Electron micrographs of RBT323 tumor. 
a: First passage (5,000 χ), superficial tumor cells with abundant organelles are junctioncd and exhibit 
lateral interdigitations, b: First passage (40,000 x), detail of a superficial cell with microvilli and 
profiles of flattened elliptical vesicles, c: First passage (7,000 x), strongly interdigitatcd, junctioncd 
tumor cells, one tumor cell contains numerous endocrine granules, d: Passage # 9 (120,000 x), high 
magnification of the apical part of a superficial cell, distinctly demonstrating the unit membrane of 
the vesicles lined by an inner fuzzy coating; arrow indicates attachment of a vesicle to the luminal 
membrane, e: Passage # 9 (55,000 x), detail of a Golgi area showing early vesicle formation 
(asterisks); different stages of vesicular profiles are present. 
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RGE 53. From passage 1 to 6 the number of positive superficial cells decreases 
from 60% to 10%. This number increases, however, to 50% in the 11th passage, 
while in passage 9 all superficial cells are positive. 
RKSE 60, an antibody recognizing markers for keratinization, is negative in 
the normal rat bladder and in the RBT157 tumors. In the RBT323 tumor 
occasionally cells in the superficial cell layer stain, the number of positive cells is 
usually only 1% or less. RV203 detects normal and tumor stroma, but never stained 
normal rat urothelium or tumor tissue of both tumors. Both normal rat bladder and 
tumor tissues did not stain with RD 301. 
Figure 3. Immunoperoxida.se staining pattern of frozen sections from RBT323 (a-c) and RBT157 (d-
f) tumors, a: RBT323, original tumor, stained with anti-cytokeratin MoAb RCK102 (x 125), 
b: RBT323, passage #11, RCK102 (x 125), c: RBT323, first passage, RGE53 (x 125), 
d: RBT157, original tumor, RCK102 (x 125), e: RBT157, passage #4, RCK102 (x 125), 
f: RBT157, passage #4, RGE53 (x 125) 
DNA measurements by Flow Cytometry 
The DNA flow cytometric profiles of the original tumors and their 
subsequent serial passages are summarized in Table I. The original tumor and the 
initial passage of the RBT323 tumor (pi) show DNA aneuploidy, later passages 
demonstrate pure diploid DNA content (fig. 4). Lungmetastases of passage 6 have a 
diploid DNA content also. The DNA content of the original RBT157 tumor is near 
the 10% interval of diploidy and is, therefore, peridiploid. Subsequent passages of 
this tumor are diploid. 
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Figure 4 
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Figure 4. Row cytometrical DNA profiles of RBT323 and RBT157 tumors 
a: RBT323, first passage, b: RBT323, passage #2 
c: RBT323, passage #14, d: RBT157, original tumor 
Chromosomal Analysis 
For cytogenetic studies the tumors were transplanted in female rats, the 
existence of the Y-chromosome could serve, therefore, as marker for karyotyping of 
tumor cells. Four RBT323 tumors and two RBT157 tumors were studied (Table II). 
All six tumors had a near diploid chromosome number with numerical and structural 
aberrations. RBT157 passage 2 had 4p+, l lp+, and a marker chromosome (Ml) 
consistently. These structurally aberrations were conserved in RBT157 passage 4. All 
the RBT323 tumors had t(?::lq22->lqter) consistently. RBT323 pass. 4 and 7 had 
t(?::lpll->q54) and del(2) (q43) which were not observed in RBT323 pass 1 nor 2, 
resulting in structural abnormalities involving the short arm of both chromosome 1 
in RBT323 pass. 4 and 7. There were no common structurally abnormal 
chromosomes between RBT157 and RBT323, while monosomies of 5 and 20 were 
observed consistently in RBT157 and RBT323. 
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Table II 
Modal Range3 
chromosomal 
number 
Specific Chromosomal Aberration 
Numerical Structural 
RBT157p2 
RBT157p4 
41 
42 
39-42 
41-43 
+4.-5.-12.-12e.-20 
+3>+4)-5,-12,-20 
3p+.4p+.llpH-.Mlc. 
2 mars 
iso(3q),4p+ )llp+,Mlc, 
1-3 mars 
RBT323 pi 
RBT323 p2 
RBT323p4 
RBT323p7 
42 
41 
43 
40 
41-43 
39-42 
40-44 
40 
-5,-8>;15,-19,-20 
-5,-8,113,-15,-19,-20 
Υ,-5,-8,-10,-19,-20 
-Y,-5,-8,-10,-19,-20 
tC lq22->lqter), 
4 6 mars 
t( ' lq22->lqter), 
3-6 mars 
tC lq22->lqter), 
t(' lpl l->lq54) 
del(2)(q43),7mars 
t(» lq22->lqter), 
t( ' lpl l->lq54) 
del(2)(q43),8p+^mars 
* Range of chromosomal number in which 85% of counts were observed 
ь
 Specific changes underlined are not consistent Other changes are observed consistently (> 
e
 Ml is distinguished from the other markers, but origin of Ml is unknown 
Table II Cytogenetic analyses of rat bladder tumor lines 
DISCUSSION 
In an autopsy series on 300 ACI rats we found five TCC. Two appeared to 
be serially transplantable (RBT 323 and- 157). Upon transplantation tumor 
biological characteristics changed. The tumor doubling time of the RBT323 tumor 
increased from 13 to 3.5 days. The RBT157 tumor has a lower doubling time, which 
is stable at 8 days. The most important phenotypic change is the metastatic ability. 
The RBT323 tumor changed in the 5th passage from low metastatic, less than 5% 
of the animals have metastases, to high metastatic ability, more than 90% of the 
animals show lung metastases and occasionally lymphnode metastases. This way of 
metastasizing suggests a haematogenic pathway. The metastatic ability of the 
RBT157 tumor changed in the 4th passage from low to intermediate, about 50% of 
the animals have microscopic lungmetastases. We sought to identify markers that are 
associated with the metastatic phenotype of the rat bladder tumors. 
Light microscopy showed an invasive grade II TCC in the initial passages of 
the RBT323 tumor, which changed in the 3rd passage to grade III. The histological 
findings, therefore, do not correlate with the phenotypic changes. Even more, the 
histology of RBT 157 remained essentially unchanged, despite its progression to a 
moderate metastatic phenotype. 
Electron microscopically superficial cells of the mammalian bladder are 
typically lined by an asymmetrical unit membrane (AUM). Within these cells 
numerous oblong elliptical vesicles derived from the Golgi area are found (38-40). 
The fact that we could demonstrate these vesicles, although in an aberrant form, 
stresses the urothelial origin of the bladder tumors. Some cells in the intermediate 
layer contain electron-dense membrane-bound granules, resembling (neuro)-
endocrine granules, these cells have been described in human TCC also (41,42). 
Intermediate filament proteins are expressed in a tissue type specific fashion 
and are therefore useful in tumor diagnosis (43). RBT 323 and-157 express 
cytokeratins and can therefore be considered of epithelial origin. So far 20 different 
cytokeratins have been characterized and their expression pattern is characteristic 
for the differentiation stage (25,26,44). Transitional cell epithelium typically shows 
expression of CK 5,7,8,18 and 19 (45,46). The synthesis of CK is usually maintained 
during malignant transformation and can, therefore be exploited in specific tumor 
diagnosis. With the panel of monoclonal antibodies used in this study we could not 
detect changes in the ratio RGE 53 positive cells/ keratin positive cells: enrichment 
of RGE53 positive cells which marks high grade human TCC was not evident in this 
model system (31). Since, this can be due to an "epitope" masking effect, it may in 
fact not be actual in rats. The basal cells of the RBT323 tumors, however, were not 
detected by RCK102 and the number of positive cells with RCK105 was less, when 
compared to the normal bladder and the RBT157 tumor, which were both 
completely positive with both antibodies. Currently studies with an extended panel of 
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monoclonal antibodies to greater number of CK are ongoing. Differences in 
expression patterns of CK 13 and 14 also have been suggested to be involved in 
bladder tumor progression (46). It should be noted that RKSE 60, recognizing 
keratin 10, which is found in keratinizing epithelium, was negative. This indicates 
that no squamous cell carcinoma components are represented in these tumors (29). 
Clearly, the progression of tumor lines to a more aggressive phenotype (ie 
metastatic) is not marked by obvious histological changes. In an attempt to define 
the genetic changes associated with tumor progression, DNA content analysis by 
Flow Cytometry is usually helpful to establish gross genetic instability (47,48). The 
presence of an aneuploid cell population is considered a bad prognostic indicator, 
with limited usefulness for prognosis, since also diploid aggressive tumors are known 
to exist. We found that in the initial passages of RBT323, an aneuploid peak is 
present, and indeed this tumor line is the more aggressive one. In subsequent 
transplant generations, however, the aneuploid peak was not found, indicating that 
the genetic basis for the progression was expressed in the diploid tumor cell 
subpopulation. Aneuploidy, evident in the first transplant generations, may therefore 
have been an utterance of genetic instability but not per se being the subpopulation 
that progressed. This phenomenon may in fact explain the limited value of DNA 
measurements. The fact that we established a cell line from the first passage from 
this tumor line that was aneuploid, and non-tumorigenic (data not shown) further 
underlines the importance of the diploid cell population for tumor progression. 
Tumor line RBT157 was peridiploid in the first passage and remained so for the 
subsequent transplant generations. 
Evidently, the progression to a metastatic phenotype is not associated with 
gross genetic changes. Cytogenetic studies, were therefore performed to establish 
whether more subtle genetic changes occurred during the progression of RBT323 
and-157. Both the loss of genetic information, as well as, gain of function provoked 
by structural and/or numerical chromosomal changes are thought to be important. 
These analyses showed that both tumors were peridiploid with only few marker 
chromosomes. Moreover, in subsequent passages of each individual tumor line an 
accumulation of marker chromosomes was found, rather than selection for a 
subpopulation with a specific karyotype. In both rat tumors loss of chromosomes is 
found and maintained during tumor progression. One copy of chromosome 5,12 and 
20 is consistently lost in the RBT157 tumor, likewise one copy of chromosome 
5,8,19 and 20 is always absent in RBT323. Hence, chromosomes 5 and 20 are both 
lost in the independently arisen tumors, and this loss is maintained in all passages. 
No common structural changes, however, were found in the RBT323 and -157 
series. 
Thus we have characterized a panel of tumor lines derived from two 
independent superficial bladder tumors that represent the progression of bladder 
cancer. The progression is not characterized by gross phenotypic changes, yet is 
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associated with the accumulation of specific genetic changes. It is tempting to 
speculate that the model represents the more aggressive subgroup of superficial 
transitional cell carcinoma that progress to metastatic disease. We, therefore, think, 
that an important model system has been established that may be helpful in the 
identification of specific molecular steps associated with the progression of bladder 
cancer 
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ABSTRACT 
The antiproliferative activities of recombinant rat gamma-interferon and 
recombinant human tumor necrosis factor alpha were evaluated in a new rat 
bladder tumor model, RBT323. The RBT323 is a spontaneously arisen, serially 
transplantable, bladder tumor in ACI rats. Histologically and ultrastructurally this 
tumor is a grade 2-3 transitional tumor without squamous cells. The RBT323 
appears to be non-immunogenic in tumor excision and rechallenge experiments. 
The tumor was transplanted subcutaneously and the drugs were 
administered peritumorally. Gamma-interferon and tumor necrosis factor 
monotherapy starting two days after tumor implantation showed dose-dependent 
growth inhibiting effects. Combination treatment with gamma-interferon and the 
highest dose of tumor necrosis factor resulted in synergistic antiproliferative effects. 
After cessation of the combination treatment all tumors resumed growth, initially 
with a low doubling time, but finally with their original growth rate. Gamma-
interferon treatment initiated at a tumor volume of 0.2-0.5 cm had no antitumor 
effects, whereas treatment with 100 μg tumor necrosis factor per rat inhibited tumor 
growth significantly. Different combinations of the cytokines had synergistic effects 
against established tumors. 
These studies demonstrate antitumor effects of gamma-interferon and tumor 
necrosis factor in a rat bladder tumor model system. Combination therapy has 
synergistic effects and prolongs the time to tumor recurrence. 
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INTRODUCTION 
In 1990 approximately 49,000 new cases of bladder cancer were diagnosed 
in the USA, of which 75 to 80% present as superficial tumors^'2. Bladder cancer, 
therefore, is the fourth most prevalent malignant disease among male and the ninth 
among female patients in the United States. It is now well established that 30 
percent of the solitary papillary tumors, and more than 70 per cent of multiple 
tumors will recur after initial treatment^. 5 to 30 percent of all patients exhibit 
tumor progression to more invasive stages and eventually metastases2, . The current 
therapy for patients presenting with recurrent superficial bladder tumors is 
endoscopic resection followed by adjuvant intravesical chemo- or immunotherapy, 
with e.g. thiotepa, doxorubicin, mitomycin C, or Bacillus Calmette Guerin (BCG). 
Although properly selected patients benefit from intravesical therapy, these agents 
do not consistently eradicate existing disease or prevent tumor recurrences4. 
Furthermore, each of the agents has been associated with local and/or systemic 
toxicities4. 
The mechanism of action of intravesical immunotherapy with BCG is largely 
unknown. Histopathological examinations before and after BCG application revealed 
an increase in cellular infiltrate in the bladder wall5. Another indication of the 
involvement of the immune system in the antitumor effects of BCG is the elevation 
of cytokines such as Interleukin-1 and -2, and Tumor Necrosis Factor (TNF) in the 
urine of BCG-treated patients. The local concentrations of TNF should be high 
enough to provide an antitumor effect6. 
TNF is a cytokine that can mediate the necrosis of subcutaneously 
implanted tumors. The neovasculature of transplanted and spontaneous tumors in 
mice is specifically affected by a single dose of TNF (5-20 μg/mouse), but there is 
no effect on the vascularization of normal tissue transplants . TNF is synthesized by 
various activated phagocytic and non-phagocytic cells, including macrophages and 
monocytes, and has direct and indirect anticellular effects, mediated via the host 
immune system . Growth of various tumors, e.g. renal and breast tumors, can be 
inhibited in animal model systems, although the antitumor effects against 
experimental bladder tumors are limited9'^. Recently, clinical trials with intravesical 
TNF instillations have been initiated' . 
Several preclinical and clinical studies have suggested that another cytokine, 
Interferon (IFN), can inhibit bladder tumor growth76"75. The IFNs are a family of 
naturally occurring glycoproteins, which share antiviral, immunomodulatory, and 
antiproliferative effects. Three major classes of IFNs (alpha, beta, and gamma) are 
deñned on the basis of chemical, antigenic, and biological differences79. IFNs exhibit 
direct antitumor effects and can augment the effectiveness of immune effector cells, 
such as cytotoxic T-cells, natural killer cells, and monocytes. Moreover, the 
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expression of surface antigens, including HLA class I and II antigens on both tumor 
and effector cells and several oncogenes can be regulated by WNs19,20. 
Combinations of cytokines can have synergistic antitumor effects. In previous 
studies we showed synergistic antiproliferative effects of gamma-IFN and TNF in a 
rat renal cell carcinoma model system9. In this study we report the antitumor effects 
of rat-gamma-IFN and human TNF in mono- and combination therapy in a new rat 
bladder tumor model system. Due to the species specificity of IFN we had to use 
the rat IFN9. In contrast to IFN, TNF has little species-specificity9. 
The RBT323 tumor is a spontaneously arisen bladder tumor in ACI rats2 ' 
(manuscript submitted). Histologically and ultrastructurally it is a grade 2-3 
transitional cell tumor with no squamous cells. Intermediate Filament Protein 
expression pattern analysis also revealed no squamous cell characteristics, i.e. 
expression of Cytokeratin 10 was not detected. Tumor cells were positive for 
Cytokeratins 7 and 18, which are specific for transitional cells. 
MATERIALS AND METHODS 
Animals 
Adult male ACI/SegHSD rats (Harlan Sprague, Inc., Indianapolis, IN) were 
kept 3 rats per cage with a regimen of 12 hours light per day. The animals were 
allowed access to RMH-TM food (Hope Farms BV., Woerden, The Netherlands) 
and water ad libitum. 
Tumor Line 
For the experiments, transplant generation 8 to 13 of the RBT323 tumor 
were excised from a tumor-bearing animal, and after removal of normal and 
necrotic tissue, the tumor tissue was cut into pieces of 20 mg (18-23 mg). The 
precise weight of each tumor piece was measured on preweighed sterile gauzes on a 
laboratory scale (Mettler). An 0.5 cm incision was made in the right flank of 
recipient animals, and after separating the subcutaneous tissue by blunt dissection, 
the tumor fragment was placed subcutaneously (s.c). The incision was closed using 
skin clips (7.5 χ 1.75 mm, Aesculap, Germany). In this way a tumor take of more 
than 95% was achieved. 
To test the immunogenicity of the rat bladder tumor, RBT323 tumors of 
passage 6 were completely removed together with the overlying skin and underlying 
subcutaneous tissues. The skin defect was closed with skin clips. Immediately after 
removal of this tumor, a tumor piece of 20 mg was implanted s.c. in the 
contralateral, left, flank. 
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Drugs 
Recombinant human TNF alpha was kindly provided by Boehringer 
Ingelheim (Alkmaar, The Netherlands). The specific activity of TNF determined in 
the presence of Actinomycin D was 6 χ IO7 Units/mg protein as determined in the 
L-929 cytotoxicity assay. The purity was >99% as determined by SDS 
Polyacrylamide gel electrophoresis and it contained less than 1.0 ng endotoxin per 
mg protein based on the limulus amoebocyte assay. The original TNF solution was 
diluted with RPMI 1640 culture medium (Gibco, Paisley, UK) to a final 
concentration of 2, 20, or 200 μg per ml, divided in aliquots and stored at -20o С. 
Recombinant rat gamma-IFN was produced by a chinese hamster ovary 
(CHO) cell line transformed with a plasmid carrying the chromosomal gene for rat 
gamma-IFN and purified as described previously22. The cytopathic effect reduction 
assay was used for estimating gamma-IFN activity. Ratee cells (a continuous rat 
embryonic cell line) were incubated with gamma-IFN for 18 hours before they were 
challenged with vesicular stomatitis virus to determine the cytopathic effect. Because 
no internationally accepted reference standard for rat interferon is available, all 
titers were determined by comparison with a laboratory standard preparation of 
gamma-IFN (1 mg pure rat gamma-IFN corresponds to 7 χ 106 Units). After 
purification by monoclonal antibody affinity chromatography gamma-IFN was freeze-
dried for long-term storage. It was reconstituted with Milli-Q to a final concentration 
of 16,000 or 160,000 Units per ml, divided in aliquots and stored at -80° С until use. 
Treatments and monitoring 
Gamma-IFN and TNF were administered s.c, peritumorally, 3 and 5 times 
per week respectively, in a 0.5 ml injection volume. Phosphate buffered saline (PBS) 
was used for the control group. Treatment started two days after tumor implantation 
or at a tumor volume of 0.2-0.5 cm^ and was continued until the tumors in the 
control group reached a volume of 5 cm*. Tumor growth was followed by 
measurements of tumor size according to the method of Janik et al.25 by the same 
measurer throughout each experiment. Three times per week length (1), width (w) 
and height (h) were measured using a slide caliper. No correction was made for 
skin thickness. The tumor volume (V) was calculated from the formula 
V = 0.5236 χ 1 χ w χ h. 
Statistical analysis 
For each rat, the tumor volume was estimated 5 weeks after tumor 
implantation, i.e. time when the control group reaches the volume of 5 cm*, by 
linear regression on the logarithms of the tumor volumes throughout this period. 
Two-sided t-tests were used to compare the final volumes of the treatment versus 
the control groups and to test for additive effects in the combination treatments. Ρ 
< 0.05 is considered as statistically significant. 6 animals were included in each 
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group. The effect of treatment A is defined as EA = VC()n(r<>;/V4 and the effect of 
treatment В as EB = VCWIÄo//V£, where ^, д, and Vcontrol are the estimates for 
the tumor volumes of treatment А, В or control group respectively. Additivity is 
defined9 as Έ.
Α+Β = Έ.Α χ Е в (i.e. log А+В = log Έ.Α + log E f i). A combination 
of two treatments is considered synergistic when the effect of the combination 
(EA+B) is significantly greater than the product of the effects of the separate 
treatments. 
RESULTS 
To study the antitumor effects of human recombinant TNF-alpha and 
recombinant rat-IFN-gamma against bladder cancer, we have used a new, 
spontaneously arisen rat bladder tumor model. According to Hewitt, tumor models 
representative for human tumors should be spontaneously arisen and non-
immunogenic2"'. We, therefore, first tested the immunogenicity of the tumor line. 
Immunogenicity of RBT323 tumor line 
After complete removal of RBT323 tumors with a volume of 5 cm , and 
subsequent reimplantation of a tumor piece in the contralateral flank of 8 rats, a 
tumor started to grow with the same growth rate and no lag-phase compared to 
tumors implanted in naive rats, suggesting that the tumor is non-immunogenic. 
Cytokine monotherapy 
In previous studies with a rat renal cell carcinoma model system we 
evaluated the influence of the administration route on antitumor effects of 
cytokines9. Comparison of intravenous (¡.v.), intraperitoneal (i.p.) and subcutaneous 
(s.c.) routes showed that i.p. and i.v. injected cytokines were less effective than s.c. 
injections. We therefore administered gamma-IFN and TNF s.c, peritumorally. 
Figures 1A and IB depict the results of different dosages of gamma-IFN 
and TNF monotherapy. Gamma-IFN and TNF were administered three and five 
times per week respectively. Treatment started 2 days after tumor implantation and 
was continued for 5 weeks, i.e. the time taken for the control group tumors to reach 
a volume of 5 cm*. 80,000 U gamma-IFN had a stronger antiproliferative effect than 
8,000 U, suggesting a dose-dependent response (fig. 1A). Treatment with TNF also 
showed dose-dependent effects, 100 Mg TNF per rat was more effective than the 
lower dose of 10 ¿ig TNF (fig. IB). The highest doses of both cytokines provoked a 
statistically significant growth inhibition. 
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Figure 1 
control 
IFN 8,000 
IFN 80,000 
Figure 1: Effect of single agent therapy started 48 hours after tumor implantation. Bars indicate 
standard deviation. A: Gamma-IFN monotherapy administered s.c peritumorally, 3 times per week; 
8,000 U (n.s.) or 80,000 U (p < 0.01) per rat. B: TNF monotherapy, s.c. peritumorally, 5 times per 
week; 10 ßg (ρ - 0.02) or 100 μg (ρ = 0.0003) per rat. n.s. = not significant 
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IFN and TNF combination therapy 
As shown in figure 2 combinations of gamma-IFN and TNF can be more 
effective than their respective monotherapies. The combination of 8,000 U gamma-
IFN and 10 μg TNF had no additive growth inhibiting effects, whereas a tenfold 
increase of the TNF dose produced a clear synergistic effect (p = 0.008). 2 out of 
six rats did not develop a tumor during the treatment period. However, after 
cessation of treatment all tumors started to grow again, finally with the same growth 
rate as the untreated control group. 
Figure 2 
control 
IFN 8,000/TNF 10 
IFN 8,000/TNF 100 
8 
7 | -
6 
5 
4 
3 
2 
О 5 10 15 20 
days 
Figure 2. Combination therapy with gamma-IFN and TNF, 3 times and 5 times per week 
respectively. Treatment started 48 hours after tumor implantation. 8,000 U gamma-IFN and 10 μg 
TNF (n.s.) or 8,000 U IFN and 100 μg TNF (ρ = 0.0007) per rat. 
In a separate experiment (fig. ЗА) we tested the combination of 80,000 U 
gamma-IFN and 100 μg TNF. Rats receiving combination treatment lost 38 grams of 
their initial body weight during three weeks of treatment, whereas the rats in the 
other groups gained 15 grams in this period. For this reason, combination treatment 
was ceased earlier, i.e. time when control group reached a volume of 1 cc, and rats 
were evaluated for tumor recurrence. In the rats treated with the combination no 
tumors developed in the three weeks treatment period, whereas tumor growth was 
observed in the other three groups. Thus a synergistic antitumor effect of the 
combination was found (p = 0.01). At day 42 after tumor implantation the gamma-
IFN/TNF treated rats were at their initial body weight. However, tumors were now 
also found in these rats, initially growing with a low doubling time, but the tumors 
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Figure 3 
-•- control 
-b- IFN 80.000 
-•- TNF 100 
- В - combination 
В 
-•- control 
4- IFN ΘΟ,ΟΟΟ 
- · - TNF 100 
- - combination 
Figure 3. A: Effects of 80,000 U Gamma-IFN 3 times per week (p < 0.01) or 100 ßg TNF 5 times 
per week (p = 0.0001) and their combination (p < 0.0001). Treatment started 48 hours after tumor 
implantation. B: Tumor growth after cessation of therapy at day 35 (monotherapies) or day 21 
(combination treatment) after tumor implantation. 
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regained their original growth rate 64 days after tumor implantation (flg. 3B). The 
time to reach a tumor volume of 2 cm*, however, was longer than in the 
monotherapies. The time to tumor recurrence was, therefore, prolonged by the 
combination treatment. 
Influence of initial tumor volume 
To assess the antiproliferative efficacy of gamma-IFN and TNF mono- and 
combination therapy on higher tumor volumes, therapy was started at 0.2-0.5 cm3, 
i.e. 17-19 days after tumor implantation. 
Gamma-IFN monotherapy at doses of 8,000 (fig. 4A) or 80,000 U per rat 
(fig. 5) did not significantly inhibit tumor growth. Also TNF monotherapy with the 
lowest dose of 10 ßg per rat did not inhibit tumor growth. A tenfold higher dose, 
however, had significant antiproliferative effects (figs. 4A and 5). 
The combination of 8,000 U gamma-IFN and 10 μg TNF revealed no 
potentiating effects (fig. 4B), but the combination of 8,000 U gamma-IFN and 100 
μg TNF showed significant synergistic antiproliferative effects (p = 0.006). 2 out of 
six rats showed stabilization of tumor volume during the treatment period. 
Treatment with the combination of 80,000 U gamma-IFN and 100 μg TNF also had 
synergistic antitumor effects (p = 0.04, fig. 5). 2 tumors showed regression, 1 tumor 
showed stabilization, whereas the remaining three tumors had a very strong 
reduction of their volume doubling time. Interestingly, these rats did not show any 
sign of toxicity. 
Rats receiving combination therapy which included 100 μg TNF, showed 
tumor growth after cessation of treatment with a growth pattern similar to that 
shown in fig. 3B. The initial growth rate of the tumors was low, but finally all 
tumors regained their original growth rate. 
DISCUSSION 
According to Hewitt the ideal tumor models to use for immunotherapeutical 
studies should be spontaneously arisen and non-immunogenicr . Since most 
carcinogen- or virus-induced tumors carry tumor-associated antigens on their cell 
surface, these tumors will be immunogenic25. Up to now most immunotherapeutical 
studies in experimental bladder cancer are carried out in the immunogenic murine 
FANFT-induced MBT-2 tumor model7 7"7 3 ' '6 , 2 6. It is possible to elicit an immune 
reaction against MBT-2 tumor vaccines with whole tumor cells or cell extracts, but 
these mechanisms are not likely to contribute significantly to the host immune 
defense in human transitional cell carcinoma27. To gain further insight in the 
efficacy of immunotherapy with cytokines against bladder carcinoma it is necessary 
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Figure 4 
-•"· Control 
- θ - IFN 8,000 
-»• TNF IO 
- θ - TNF 100 
10 
в 
-•- Control 
- S - IFN β,ΟΟΟ/TNF 10 
" · - IFN β,ΟΟΟ/TNF 100 
10 
Figure 4. Start of treatment at tumor volume of 0.2-0.5 cm3. Gamma-IFN 3 times and TNF 5 times 
per week, s.c, peritumorally. A: Monotherapies: Gamma-IFN 8,000 U (n.s.), TNF 10 ßg (n.s.) or 
TNF 100 ßg (ρ = 0.0003) per rat. В: Combination therapy with combination of 8,000 U Gamma-
IFN and 10 Mg TNF (ρ < 0.05) or 8,000 U Gamma-IFN and 100 Mg TNF (ρ = 0.0003) per rat. 
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Figure 5 
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10 
Figure 5. Effects of 80,000 U Gamma-IFN 3 times per week (p = 0.005) or 100 ßg TNF 5 times per 
week (p = 0.0002) and their combination (p = 0.003). Treatment started at tumor volume of 0.2-0.5 
cm3. 
to use more tumor models in different animals. We, therefore, examined the 
antitumor effects of rat-gamma-IFN and TNF in the spontaneously arisen and non-
immunogenic rat bladder tumor model system, RBT3232i. 
The antitumor effect of TNF has now been established in various animal 
model systems7,9''0. The activity against the MBT-2 tumor, however, is limited. 
Studies with TNF derived from supernatants of the endotoxin stimulated J774.1 
macrophage cell line showed in vitro cytotoxicity, this crude TNF also significantly 
suppressed growth of subcutaneous tumors'2. Recombinant TNF alone, or in 
combination with a low dose Actinomycin D had no cytotoxic effects in vitro, 
furthermore, intravesical treatment with 10 μg TNF did not reduce the outgrowth of 
bladder tumors in vivo'·'. In contrast to these results, Lee et al. observed a 
significant reduction in MBT-2 tumor weight with intravesical crude and recombinant 
TNF treatment in a dose-dependent fashion". The tumor incidence was lower with 
crude TNF, which was not the case with the recombinant TNF. The differences in 
antitumor activity may be explained by admixture of other cytokines or endotoxins in 
the crude TNF preparations or by differences between human and murine TNF. In 
the KK-47 bladder tumor xenograft model, intravenously or intratumorally 
administered recombinant TNF did not inhibit the growth of subcutaneously 
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implanted tumors7*. In our model we showed a dose-dependent tumor growth 
inhibition by TNF injected peritumorally, 5 times per week. TNF 10 ng per rat was 
not effective, whereas TNF 100 Mg per rat induced clear antitumor effects, this dose 
also inhibited growth of established tumors (0.2-0.5 cnr). 
In vitro studies using human cell lines showed antiproliferative effects of all 
three IFN types20. Mouse IFN-alpha,beta inhibited the in vitro proliferation of 
MBT-2 cells70, however, in vivo treatment with this IFN type was not effective. 
Combination treatment with Adriamycin or DFMO, did not increase the effects of 
IFN-alpha,beta in vivo70. In our studies start of rat gamma-IFN treatment 48 hours 
after RBT323 tumor implantation resulted in a dose-dependent antiproliferative 
effect, however, treatment initiated at a higher tumor volume was not effective. The 
same relation of IFN effectiveness to tumor mass was found for beta-IFN in the 
treatment of the RT4 bladder tumor xenograft in nude mice and in previous 
experiments in a rat renal tumor model system ' . Multiple clinical trials have been 
carried out with different IFN-types. Horoscewicz reviewed nine clinical trials and 
found 41% objective responses among 100 patients with bladder cancer77. 
Furthermore, it is clear that the number of side effects is low77,7*. 
Different combinations of cytokines can result in the enhancement of their 
antiproliferative effects, e.g. the combination of TNF and rat gamma-IFN has 
synergistic antitumor effects in breast and renal tumor models * . MBT-2 cells 4 
hours pretreated with mouse-gamma-IFN were more sensitive to TNF in vitro7·5. 
However, 30,000 U mouse-gamma-IFN intravenously combined with 2.5 or 12.5 ^g 
TNF intravesically, did not show additional tumor suppression of the MBT-2 tumor 
in the dose range tested . In contrast to these results, combinations of both doses 
rat gamma-IFN and 100 Mg TNF showed synergistic effects against low and high 
tumor volumes of the RBT323 tumor, the latter being more representative for the 
clinical situation. 
In the experiments described we injected the drugs peritumorally, in order 
to get a direct contact of the drugs with the tumor, similar to intravesical drug 
administration. However, once the tumor becomes metastatic this local treatment is 
not effective anymore. Systemic administration of the doses used in our experiments 
will result in lower local drug levels and, therefore, lower antitumor effects. Due to 
the toxicity of TNF an unlimited increase of the administered dose is not possible. 
Small changes in the TNF molecule made it less toxic, this TNF-s has already shown 
to have antitumor effects in experimental bladder tumors·*0. Encapsulation of 
cytokines in liposomes also lowers their cytotoxic effects*7. Specific targeting of 
cytokines to metastases would rise local drug levels with subsequent improved 
antitumor effects. A possibility could be the use of cytokines coupled to a 
monoclonal antibody directed to a bladder carcinoma cell surface-expressed antigen. 
In conclusion: cytokine treatment with TNF and gamma-IFN monotherapy 
showed antitumor effects in the rat bladder tumor model system. Combinations of 
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the cytokines had synergistic effects, also against established tumors. Treatment of 
low tumor volumes with the combination of 80,000 U gamma-IFN and 100 /ig TNF 
showed no tumor growth during the treatment and a clear growth delay after 
cessation of treatment. Unfortunately, finally all tumors started to grow with the 
original doubling time. More research is needed to investigate other cytokine 
combinations and to elucidate the mechanism of action of the cytokines. The 
RBT323 tumor can be instrumental for both purposes. 
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SUMMARY AND PROSPECTS 
Summary 
In chapter I, part 1, an overview is given of the available animal model 
systems for renal, prostatic and bladder cancer. Generally, tumor models can be 
divided into four categories: drug induced tumors, virus induced tumors, spontaneous 
tumors and heterotransplanted human tumors in immune-deprived animals. The best 
tumor models for performing immunotherapeutical studies are the spontaneously 
arisen tumors. Part 2 of the general introduction gives an overview of the current 
knowledge of interferon (IFN) and tumor necrosis factor (TNF) and their use in the 
treatment of urologica! cancers. The antiproliferative effects of the cytokines can be 
divided into direct effects on the tumor cells, and indirect effects, mediated by the 
immune system. Although a great number of studies have been performed to 
elucidate the mechanism of action of these cytokines, current knowledge is still 
fragmentary and many questions regarding the optimal doses, the best route of 
administration, the best cytokine combination and the intracellular effects of IFN 
and TNF remain hitherto unanswered. 
IFN is the most widely used cytokine in immunotherapy of renal cell 
carcinoma (RCC). All preclinical studies using IFN and/or TNF are performed in 
cell lines or xenografts transplanted into nude mice. In 1987 we, therefore, started 
our studies with the syngeneic rat renal cell tumor model system, as described in 
chapter II. Pilot-studies showed that intraperitoneally or intravenously injected 
cytokines were less effective than subcutaneous (s.c.) injections. Therefore we 
injected IFN and TNF s.c, peritumorally in all in vivo experiments described in this 
thesis. Rat-gamma-interferon had dose-dependent antitumor effects, whereas TNF 
was only effective at the highest dose level. Different combinations of IFN and TNF 
had additive or synergistic effects. The combination of both highest doses completely 
inhibited tumor growth. The antitumor effects of the cytokines appeared to be 
dependent on the tumor volume at the start of therapy. Cytokine monotherapy 
could not inhibit growth of tumors with a volume of 0.2-0.5 cm^. The combination 
of both highest doses significantly inhibited tumor growth, but did not provoke 
tumor regression. These studies clearly show that cytokine combination treatment is 
more effective than monotherapy. Furthermore, treatment should be started as soon 
as possible, i.e. at low tumor burden. 
In chapter ΙΠ we describe the antitumor effects of TNF and/or radiotherapy 
against rat renal cell tumor spheroids. TNF monotherapy had a dose-dependent 
growth inhibiting effect. Single-dose irradiation also had dose-dependent antitumor 
effects, although this was not a linear dose-dependency. In combination treatments, 
TNF was added 4 hours prior to irradiation. TNF did not induce a potentiation of 
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the lowest dose of radiation. However, the combinations with the higher doses 
induced additive or synergistic antitumor effects. This study, and studies done by 
others (1-4) indicate that the combination of TNF and radiotherapy may be useful 
in clinical cancer therapy. 
The combination of cytokines with chemotherapeutical agent seems very 
promising (5). In vitro studies showed marked enhancement of the cytotoxicity of 
TNF in combination with chemotherapeutical agents directed against DNA-
topoisomerase II (6). In vivo studies using RCC xenografts also showed synergism 
between VP16 and TNF (7,8). We have investigated the in vitro and in vivo 
antitumor effects of TNF and Adriamycin or VP 16 (chapter IV). Adriamycin 
monotherapy was already very active in vitro, therefore only the lowest dose 
produced synergistic effects in combination with TNF. Different combinations of 
VP16 and TNF produced significant antitumor effects, but none of these 
combinations had synergistic effects. The highest dose of Adriamycin in vivo (1 
mg/kg bodyweight) administered for three consecutive days every two weeks, had 
significant antitumor effects, and induced synergistic effects in combination with 
TNF. The same dose given for three consecutive days every three weeks showed 
neither significant, nor synergistic effects in combination with TNF. Similar to the 
studies presented in chapter II, TNF and Adriamycin monotherapy were not 
effective when treatment started at a tumor volume of 0.2-0.5 cm*. But, TNF and 
Adriamycin combination therapy was not effective either. VP16 monotherapy did not 
induce significant antitumor effects, and VP16 in combination with TNF did not 
show substantial potentiation of the therapeutic efficacy. In conclusion: TNF and 
IFN-gamma combination therapy is more effective than the combination of TNF 
with chemotherapeutical agents directed against DNA-topoisomerase II in the 
syngeneic model system studied. 
In chapter V we studied the antitumor effects of rat-gamma-IFN and TNF 
in the syngeneic Dunning R3327 rat prostatic tumor model system. In vitro studies 
with three different androgen-independently growing cell lines showed very limited 
antiproliferative effects of IFN and TNF mono- and combination therapy. For in 
vivo studies androgen-dependent and -independent tumor lines were used. Except 
for IFN monotherapy against the MatLyLu line, cytokine monotherapy was not 
effective. Combination therapy, however, had synergistic antitumor effects against all 
four cell lines tested. Survival studies showed a significant increase in survival of 
MatLyLu tumor-bearing rats. Chapter VI describes the in vivo antitumor effects of 
human IFN-alpha and -gamma and TNF against two androgen-independently 
growing prostatic tumor xenografts, PC3 and DU145. TNF 500 ng/gram bodyweight 
was the only monotherapy effective against both xenografts. Combinations of both 
IFNs were effective against the PC3 tumor, but not against the DU 145 tumor. 
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Combinations of IFN-alpha and TNF were very effective against both xenografts. 
IFN-gamma and TNF combinations also showed significant antitumor effects against 
both lines. The data presented in chapter V and VI indicate that cytokines can have 
antiproliferative effects against hormone-dependent and -independent prostatic 
tumors. This may open a way to a new therapeutic modality in the treatment of 
prostatic cancer. 
The number of spontaneous bladder tumor model systems is very limited. In 
chapter П we present the characterization of two new transplantable transitional 
cell carcinoma (TCC) lines in ACI rats, rat bladder tumor (RBT) 323 and RBT157. 
The metastatic ability of the RBT323 tumor changed from low (<5% of the rats 
have lungmetastases) to high (more than 90%) in the 5th passage. In the 4th 
transplant generation the RBT157 tumor became metastatic to the lungs in about 
50% of the animals. Histological, electronmicroscopical and immunohistochemical 
studies showed that the tumors have the typical characteristics of TCC. The 
progression of the tumors to a metastatic phenotype, however, was not associated 
with a specific change in morphology. Cytogenetic analysis of different passages 
showed that both tumors are peridiploid with few marker chromosomes in the initial 
passages. In subsequent passages an accumulation of marker chromosomes was 
found. Furthermore, in both tumors a loss of chromosomes was found which 
maintained during tumor progression. Thus, we have characterized a panel of tumor 
lines derived from two independently arisen superficial bladder tumors that 
represent the progression of bladder cancer and that may be helpful in the 
identification of specific molecular steps associated with the progression of bladder 
cancer. 
Chapter VIII presents the data obtained with rat-gamma-IFN and TNF 
treatment of the RBT323 tumor. IFN and TNF monotherapy had dose-dependent 
growth inhibiting effects. Combination therapy resulted in synergistic effects. IFN 
had no antitumor effects against tumors of 0.2-0.5 cm*, whereas TNF monotherapy 
inhibited tumor growth significantly. Different combinations of both cytokines had 
synergistic effects against established tumors. 
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Prospects 
In the studies presented here we have administered the cytokines 
subcutaneously, peritumorally. In clinical trials, however, cytokines will be 
administered subcutaneously, intramuscularly or intravenously, inevitably resulting in 
lower local cytokine levels. Bartsch et al. tried to overcome this problem by 
intralesional application of TNF (9). In five out of 14 patients with different 
advanced solid tumors local tumor regression occurred. The duration of the 
response was short, suggesting a rapid development of resistance to TNF. Another 
route of administration resulting in high local drug levels is selective direct arterial 
infusion of TNF (10). 
Clinical trials have shown that cytokines, especially TNF, can have major 
dose-limiting side-effects, such as hypotension. Other common side-effects include 
fever, rigors, nausea and vomiting at relatively low doses. Different approaches can 
overcome this toxicity; a single injection of indomethacin or ibuprofen 2 hours 
before TNF administration or bismuth subnitrate (50 mg/kg/day) 5 days before TNF 
administration, reduces the toxic effects of TNF, without preventing its anti-
neoplastic actions in animal model systems (11,12). In clinical trials, Fossa et al. and 
Creagan et al. showed similar results with the combination of IFN-alpha with 
corticosteroids or aspirin (13,14). Another possibility to overcome side-effects is the 
use of liposome-encapsulated cytokines (15,16). Gatanaga et al. constructed novel 
TNF molecules (TNF-s) and showed reduced toxicity of these molecules without loss 
of antitumor activity (17). 
Clinical experience with cytokines indicate that a subset of patients is 
sensitive to this therapy. However, it has been impossible to predict which patients 
will respond to cytokine therapy. In an interesting paper, Nanus et al. found that 
the expression of a kidney-associated differentiation glycoprotein, gpl60, correlated 
with resistance to IFN-alpha therapy, and, conversely, that lack of expression 
correlated with sensitivity to IFN-alpha in vitro and in vivo (18). It has been shown 
that molecules of the major histocompatibility complex (MHC) can be upregulated 
by cytokines. The inducibility of both MHC class I and II antigens appeared to be a 
predictive marker for response to IFN and TNF therapy in nude mice (19). 
However, class I and II expression of untreated tumors were not related to the 
antitumor effects of both cytokines (19). A retrospective study is ongoing in which 
we test the hypothesis whether the pretreatment MHC expression of primary and 
metastatic RCC specimens is related to the effectivity of IFN-alpha and -gamma 
combination treatment. 
More studies are needed to elucidate the mechanism of action of cytokines. 
In the rat renal cell model system we are currently investigating the lymphocyte-
infiltration in tumors before and after cytokine treatment. Preliminary data indicate 
an increase of macrophages after TNF treatment. In all rat models used in this 
thesis, human TNF was not toxic to rats, although TNF was given in high doses. 
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This phenomenon could be due to the development of TNF-neutralizing antibodies 
in rats. However, in a preliminary study with serum of 12 rats, performed at the 
TNO REP-institutes, Rijswijk, no TNF-neutralizing antibodies were found. 
In the near future, the use of recombinant DNA-technology will provide 
new cytokines, such as IFN-alphas (20) and hybrid combination molecules, such as 
IFN-gamma plus TNF-beta (21). For testing of new immunological approaches, the 
availability of a valid pre-clinical screen is very important (22). The animal models 
used in this thesis seem to provide such a preclinical screen. Furthermore, new 
immunotherapeutical modalities, such as monoclonal antibodies (23) and new 
cytokine combinations can be tested in these models. 
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SAMENVATTING EN TOEKOMSTVERWACHTINGEN 
Samenvatting 
In hoofdstuk I, deel 1 wordt een overzicht gegeven van de beschikbare 
diermodellen voor nier-, prostaat- en blaaskanker. In het algemeen kunnen deze 
modellen worden ingedeeld in 4 categorieën: tumoren geïnduceerd door carcinogene 
stoffen, viraal-geïnduceerde tumoren, spontaan ontstane tumoren en humane 
tumoren getransplanteerd in dieren met een gestoorde afweer (heterotransplantatie). 
De beste tumormodellen voor het uitvoeren van immunotherapeutische studies zijn 
de spontaan ontstane tumoren. Deel 2 van de algemene introductie geeft een 
overzicht van de huidige kennis betreffende interferon (IFN) en tumor necrosis 
factor (TNF) en het gebruik van deze cytokines in de behandeling van urologische 
tumoren. De antiproliferatieve effecten kunnen verdeeld worden in effecten direct 
aangrijpend op de tumorcellen en indirecte effecten, gemedieerd door het 
immuunsysteem. Hoewel er reeds een groot aantal studies zijn uitgevoerd om het 
werkingsmechanisme van deze cytokines te bestuderen, blijft de huidige kennis 
fragmentarisch. Vele vragen betreffende de optimale dosering, de beste 
toedieningsroute, de beste combinatietherapie en de intracellulaire effecten van IFN 
en TNF blijven tot nu toe onbeantwoord. 
IFN is de meest toegepaste cytokine bij de immunothérapie van 
niertumoren. Alle preklinische studies met IFN en TNF hebben gebruik gemaakt 
van cellijnen of xenografts. Daarom zijn wij in 1987 gestart met onze studies in het 
ratten-niertumormodelsysteem, zoals beschreven in hoofdstuk II. Pilot-studies lieten 
zien dat intraperitoneaal of intraveneus toegediende cytokines minder effectief 
waren dan subcutane injecties. Daarom zijn in alle hieropvolgende experimenten 
IFN en TNF subcutaan, peritumoraal gespoten. Rat-gamma-IFN had dosis-
afhankelijke antitumor effecten, terwijl TNF alleen effectief was in de hoogste 
dosering. Verschillende combinaties van IFN en TNF hadden additieve of 
synergistische effecten. De combinatie van de beide hoogste doseringen resulteerde 
in complete groeiremming van de tumoren. De antitumor effecten bleken 
afhankelijk te zijn van het tumorvolume bij aanvang van de therapie. Cytokine 
monotherapie kon niet de groei remmen van tumoren met een volume van 0,2-0,5 
mr'. De combinatie van beide hoogste doseringen gaf een significante groeiremming, 
maar veroorzaakte geen tumorregressie. Deze studies tonen duidelijk aan dat 
cytokine combinatietherapie effectiever is dan monotherapie. Bovendien moet de 
behandeling zo snel mogelijk gestart worden, dat wil zeggen, bij een klein 
tumorvolume. 
In hoofdstuk Ш beschrijven we de antitumor effecten van TNF en/of 
radiotherapie tegen ratten-niertumor spheroiden. TNF monotherapie had een 
193 
dosisafhankelijk groeiremmend effect. Éénmalige bestraling had ook een 
dosisafhankelijk effect, hoewel dit geen lineaire dosisafhankelijkheid was. Bij de 
combinatiebehandeling werd TNF vier uur voorafgaande aan de bestraling 
toegediend. TNF veroorzaakte geen versterking van het effect van de laagste 
bestralingsdosis. Echter de combinaties met de hogere doses induceerden additieve 
of synergistische effecten. Onze en andere studies (1-4) laten zien dat de combinatie 
van TNF en radiotherapie bruikbaar kan zijn in de behandeling van kanker. 
De combinatie van cytokines met chemotherapeutica lijkt veelbelovend (5). 
In vitro studies lieten een duidelijke versterking van de cytotoxiciteit van TNF zien 
in combinatie met chemotherapeutica gericht tegen DNA-topoisomerase-II (6). In 
vivo studies met niertumor xenografts toonden ook synergisme tussen VP16 en TNF 
(7,8). Wij hebben de antitumor effecten van TNF en Adriamycine of VP16 in vitro 
en in vivo onderzocht in het syngene ratten-niertumormodelsysteem (hoofdstuk IV). 
Adriamycine monotherapie bleek in vitro reeds zeer effectief te zijn en daarom 
resulteerde alleen de combinatie van de laagste dosis met TNF in een synergistische 
remming van de kolonievorming. Verschillende combinaties van VP16 en TNF 
resulteerden in significante groeiremming in vitro, maar geen van deze combinaties 
vertoonde synergisme. De hoogste dosering van Adriamycine (1 mg/kg 
lichaamsgewicht), toegediend op drie opeenvolgende dagen iedere twee weken, gaf 
significante antitumor effecten en induceerde in combinatie met TNF synergistische 
effecten. Dezelfde dosis gegeven op drie opeenvolgende dagen iedere drie weken 
toonde noch significante noch synergistische effecten in combinatie met TNF. TNF 
en Adriamycine monotherapie waren niet effectief tegen tumoren van 0,2-0,5 cnr*, 
dit is in overeenstemming met de studies gepresenteerd in hoofdstuk II. Echter TNF 
en Adriamycine combinatietherapie was ook niet werkzaam op gevestigde tumoren. 
VP16 monotherapie induceerde geen significante antitumor effecten en bovendien 
resulteerde VP16 in combinatie met TNF niet in een wezenlijke versterking van 
effectiviteit. Concluderend blijkt TNF in combinatie met IFN-gamma effectiever te 
zijn in het syngene ratten-niertumormodel dan TNF in combinatie met chemo-
therapeutica gericht tegen DNA-topoisomerase-II. 
In hoofdstuk V onderzochten we de antitumor effecten van rat-gamma-IFN 
en TNF in het syngene Dunning R3327 ratten-prostaattumor modelsysteem. In vitro 
studies met drie androgeen-onafhankelijk groeiende cellijnen lieten zeer beperkte 
antiproliferatieve effecten van IFN en TNF mono- en combinatietherapie zien. Voor 
de in vivo studies werden androgeen-afhankelijke en -onafhankelijke tumorlijnen 
gebruikt. Cytokine monotherapie was niet werkzaam, met uitzondering van IFN 
tegen de MatLyLu lijn. Combinatietherapie had echter synergistische effecten op 
alle vier geteste tumorlijnen. Overlevingstudies toonden een significante 
levensverlenging aan van de ratten met de MatLyLu-tumor. Hoofdstuk VI beschrijft 
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in vivo experimenten met humaan IFN-alpha en -gamma en TNF tegen twee 
androgeen-onafhankelijk groeiende prostaattumor xenografts, PC3 en DU 145. TNF 
in een dosering van 500 ng/gram lichaamsgewicht was de enige monotherapie die 
werkzaam was tegen beide xenografts. Combinaties van beide types IFN waren 
alleen effectief tegen de PC3 tumor, maar niet tegen de DU145 tumor. Combinaties 
van IFN-alpha en TNF waren zeer effectief tegen beide xenografts. Ook de 
combinatie van IFN-gamma en TNF resulteerde in significante antitumor effecten 
tegen beide tumorlijnen. De in hoofdstuk V en VI gepresenteerde gegevens laten 
zien dat cytokines antiproliferatieve effecten hebben tegen hormoon-afhankelijke 
en -onafhankelijke prostaattumoren. Dit kan misschien leiden tot een nieuwe 
therapievorm in de behandeling van prostaattumoren. 
Het aantal spontaan ontstane blaastumor-modelsystemen is zeer beperkt. In 
hoofdstuk П wordt de karakterisatie van twee nieuwe, transplanteerbare 
overgangscelcarcinoom (TCC) lijnen in ACI ratten, de ratten-blaastumor (RBT) 323 
en RBT157, beschreven. De metastaserende capaciteit van de RBT323 tumor 
veranderde in de vijfde transplantatie generatie van laag (minder dan 5%) naar 
hoog (meer dan 90% van de ratten hebben longmetastasen). In de vierde passage 
veranderde de neiging tot metastasering van de RBT157 tumor van laag naar 
intermediair (longmetastasen in ongeveer 50% van de dieren). Histologisch, 
electronenmicroscopisch en immuunhistochemisch onderzoek toonde aan dat de 
tumoren de typische karakteristieken van TCC hebben. De progressie van de 
tumoren tot een metastaserend phenotype was echter niet geassocieerd met een 
specifieke verandering in de morfologische kenmerken. Cytogenetische analyse van 
verschillende passages toonde aan dat beide tumoren peridiploid zijn met weinig 
markerchromosomen in de eerste passages. In de daaropvolgende passages werd een 
accumulatie van markerchromosomen gevonden. Bovendien werd in beide tumoren 
een verlies van chromosomen gevonden, wat bleef bestaan gedurende verdere 
tumorprogressie. Hiermee hebben wij een panel van tumorlijnen gekarakteriseerd, 
afgeleid van twee onafhankelijk ontstane oppervlakkige blaastumoren, dat de 
tumorprogressie van blaaskanker representeert. Deze lijnen kunnen van nut zijn bij 
het onderzoek naar specifieke moleculaire veranderingen geassocieerd met de 
progressie van blaaskanker. 
Hoofdstuk Ш beschrijft de experimenten met rat-gamma-IFN en/of TNF 
tegen de RBT323 tumor. IFN en TNF monotherapie hadden een dosisafhankelijk 
groeiremmend effect. Combinatietherapie resulteerde in synergistische effecten. IFN 
monotherapie had geen groeiremmend effect op tumoren van 0,2-0,5 cnr*, terwijl 
TNF monotherapie bij dit tumorvolume de groei wel significant remde. 
Verschillende combinaties van beide cytokines lieten synergistische antitumor 
effecten tegen gevestigde tumoren zien. 
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Toekomstverwachtingen 
In de hier beschreven studies werden de cytokines subcutaan, rond de tumor 
gespoten. In klinische trials zullen de cytokines echter subcutaan, intramusculair of 
intraveneus toegediend worden, hetgeen onvermijdelijk resulteert in lagere lokale 
cytokine concentraties. Bartsch et al. probeerden dit probleem op te lossen door 
TNF intratumoraal toe te dienen (9). In vijf van de veertien patiënten met tumoren 
in een vergevorderd stadium trad lokale tumorregressie op. De duur van de respons 
was kort wat zou kunnen wijzen op een snel ontstaan van resistentie tegen TNF. 
Een andere mogelijkheid om hogere lokale cytokine concentraties te krijgen is 
selectieve intra-arteriële toediening (10). 
Klinische trials hebben laten zien dat cytokines, met name TNF, belangrijke 
dosisbeperkende bijwerkingen kunnen hebben, zoals hypotensie. Andere veel 
voorkomende bijwerkingen die reeds bij lagere doseringen optreden zijn: koorts, 
krampen, misselijkheid en braken. Er zijn verschillende methoden om deze toxiciteit 
tegen te gaan; een eenmalige injectie van indomethacine of Ibuprofen twee uur voor 
toediening of bismuth subnitrate (50 mg/kg/dag) 5 dagen voor toediening van TNF 
vermindert de toxische effecten van TNF in diermodellen zonder dat de antitumor 
werking teniet gedaan wordt (11,12). Fossa et al. and Creagan et al. lieten in 
klinische trials gelijksoortige effecten zien bij de combinatie van IFN-alpha met 
corticosteroiden of aspirine (13,14). Een andere manier om bijwerkingen te 
voorkomen is het gebruik van cytokine-bevattende liposomen (15,16). Gatanaga et 
al. construeerden nieuwe TNF-moleculen (TNF-s) en vonden een verminderde 
toxiciteit van deze moleculen zonder verlaging van de antitumor activiteit (17). 
Klinische resultaten met cytokines laten zien dat een subgroep van de 
patiënten reageert op deze therapie. Het is echter tot nu toe onmogelijk te 
voorspellen welke patiënten zullen reageren. In een interessante studie beschrijven 
Nanus et al. dat de expressie van een nier-geassocieerd glycoproteïne, gpl60, 
correleerde met resistentie tegen IFN-alpha therapie en omgekeerd, dat afwezigheid 
van gplóO-expressie correleerde met gevoeligheid voor IFN-alpha in vitro en in vivo 
(18). Cytokines kunnen de expressie van moleculen van het major 
histocompatibiliteitscomplex (MHC) verhogen. De induceerbaarheid van MHC klasse 
I en II antigenen bleek een voorspellende waarde te hebben voor de respons op 
cytokine therapie in naakte muizen (19). Echter, klasse I en II expressie van 
onbehandelde tumoren was niet gerelateerd met antitumor effecten van beide 
cytokines (19). Momenteel is een retrospectieve klinische studie gaande waarin 
onderzocht wordt of de MHC expressie van tumoren bij aanvang van behandeling 
met IFN-alpha en -gamma gerelateerd is aan de effectiviteit van de behandeling en 
als marker met voorspellende waarde voor respons kan dienen. 
Meer studies zijn nodig om het werkingsmechanisme van de cytokines te 
ontrafelen. In het ratten-niertumormodel wordt momenteel de lymphocyten-infiltratie 
voor en na cytokine therapie onderzocht. Voorlopige data laten een toename van 
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macrophagen zien na TNF toediening. Humaan TNF bleek niet toxisch te zijn voor 
de ratten gebruikt in dit proefschrift, hoewel TNF in hoge doseringen is toegediend. 
Dit fenomeen zou kunnen duiden op de ontwikkeling van neutraliserende 
antilichamen door de ratten tegen TNF. In een studie met het serum van 12 ratten, 
uitgevoerd door TNO REP-instituten te Rijswijk, konden deze antilichamen niet 
worden aangetoond. 
In de nabije toekomst zullen door middel van recombinant DNA-technologie 
nieuwe cytokines gemaakt worden, zoals IFN-alphas (20) en hybride combinatie-
moleculen, zoals IFN-gamma en TNF-beta (21). Voor het testen van nieuwe 
immunotherapieën is de beschikbaarheid van goede preklinische testsystemen zeer 
belangrijk (22). De diermodellen gebruikt in dit proefschnft lijken hiervoor zeer 
geschikt. Nieuwe immunotherapeutische modaliteiten, zoals monoclonale antistoffen 
(23) en nieuwe cytokine combinaties kunnen ook in deze modellen getest worden. 
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STELLINGEN 
behorende bij het proefschrift 
CYTOKINE THERAPY IN 
EXPERIMENTAL UROLOGICAL CANCER 
R.J.A. van Moorselaar 
Nijmegen, 12 september 1991 
I De beste tumormodellen voor het uitvoeren van immunotherapeutische 
studies bestaan uit spontaan ontstane, syngeen transplanteerbare tumoren. 
II Cytokme-therapie is het meest effectief in combinaties en gestart bij een 
klein tumorvolume. 
III De combinatie van tumor necrosis factor en bestraling kan bruikbaar zijn in 
de behandeling van kanker 
IV De antitumor effecten van Adnamycine of VP 16 in combinatie met tumor 
necrosis factor kunnen niet verklaard worden door hun werking op het 
DNA-topoisomerase-II. 
De antiproliferatieve effecten van cytokines tegen hormoon-afhankelijke en 
hormoon-onafhankelijke prostaattumoren kunnen leiden tot een nieuwe 
behandelingsmethode voor deze tumoren 
VI De RBT tumorlijnen zijn geschikt voor het onderzoek naar specifieke 
moleculaire veranderingen geassocieerd met de progressie van blaaskanker. 
VII The mouse doctor is a disturbing force to clinicians, because he keeps 
asking them explanations for their decisions and often such questions cannot 
be answered rationally. 
DW van Bckkum in "Some mouse doctors cure people", IKR-bulletin, april 1991, biz. 4-17 
Vili New therapies for advanced renal cell carcinoma should always be based on 
experimental data rather than just on the availability of new drugs. 
R Heicappcll and R Ackermann, Urol Res, 18, 357-372, 1990 
IX The mouse is an animal which, if killed m sufficient numbers under carefully 
controlled conditions, will produce a PhD thesis. 
Journal of Irrcproducible Results 
Zolang de ziekenhuisdirecties werkdagen van meer dan 8 uur accepteren 
voor arts-assistenten dienen de openingstijden van ziekenhuiscrèches hieraan 
aangepast te worden. 
XI Amateurwielrenners schatten hun intelligentie hoger in dan de professionals 
gezien de in de eerste groep veel gedragen helm die in de tweede groep zo 
verguisd is. 
XII De kunst is geen reproductie van het zichtbare, zij maakt zichtbaar. 
Paul Klee 
XIII Gevestigde specialisten zouden zich hun eigen solicitatie-gesprek in 
herinnering moeten roepen bij het interviewen van aankomende collega's. 



